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ABSTRACT
Through the process of drug development, a molecule goes through discovery screening;
lead selection and optimization, ADME testing, toxicity profiling, dosage form determination,
preclinical testing in an in vitro and in vivo setup, followed by clinical research, FDA review and
approval until eventually it is manufactured in the determined dosage form and reaches the patient.
At every point through this process, scientists actively work towards a smoother transition and a
quick and safe approval of the molecule towards the next step. The different chapters in this
research would cover various phases of drug development; from discovery stage to fill-finish and
primary container compatibility.
Cannabidiol (CBD), has therapeutic potential in the management of diabetic retinopathy
induced pain and inflammation, however, being a lipophilic molecule, is challenged by delivery
to the back of the eye through the topical route. This work aims at improving ocular penetration
of CBD by means of drug design and analog derivatization. Another cannabinoid, Δ9Tetrahydrocannabinol-Valine-Hemisuccinate,

a

relatively

hydrophilic

prodrug

of

Δ 9-

Tetrahydrocannabinol, synthesized with the aim of improving ocular bioavailability of the parent
molecule. This work brings forth importance of combination of prodrug strategy with ophthalmic
formulation development. Triamcinolone Acetonide (TA) is a corticosteroid administered
intravitreally for the management of ocular inflammatory conditions such as diabetic retinopathy.
Currently, there is a need for the development of a topical formulation of TA, designed to achieve
drug levels at the back of the eye. Nanostructured lipid carriers (NLCs) are lipid-based
nanoparticles made up of a combination of solid and liquid lipids. This project aims at the
ii

development of TA-NLC formulations. Voriconazole (VRC) has emerged as a promising
candidate for the treatment of fungal keratitis. Antifungal drugs such as VRC have been reported
to have a synergistic effect with fluoroquinolones such as Ciprofloxacin (CIP). The goal of this
project is use of statistical techniques for the development of a dual drug, VRC and CIP, loaded
NLC carrier for the treatment of fungal keratitis. The final chapter focuses on development of a
capping mechanism that would enable a vial-stopper combination to maintain integrity and product
quality at storage temperatures of -55ºC and below.
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CHAPTER 1
INTRODUCTION AND SPECIFIC AIMS
Introduction
The number of compounds which can be classified as “drug-like” are few, these
compounds possess acceptable ADME properties and a toxicity profile, enabling them to survive
through Phase 1 clinical trials. 1 Lipinski et al. proposed few guidelines for an orally absorbable
molecule, the Lipinski’s rule of 5 (RO5) which determines limitations for drug design for an oral
targeted molecule to be successful through all the stages of drug development (molecular weight
500, log P 5, H-bond donors 5, H-bond acceptors 10). With a few modifications, we can utilize
the Lipinski’s RO5 in designing molecules for non-oral routes of delivery.

2-3

Investigational

studies conducted have tried to determine the applicability of RO5 to non-oral routes of delivery,
such as ophthalmic delivery. 2-3 Taking into consideration the ocular barriers, designing a molecule
permeating across the cornea is more challenging than targeting intestinal permeation. However,
as the dosage requirements of most of ophthalmic molecules for local treatment is low in
comparison to oral molecules, the reduction in the overall bioavailability is balanced, allowing us
to follow RO5 guidelines in drug design. 2-3
Chemical derivatization strategies such as prodrug derivatization, have been employed to
improve trans-membrane permeation. The prodrug approach provides a strategy to modulate the
lipophilicity, solubility, ionization and stability of the drug candidate and, thus, improve ocular
penetration.4 Hussain et al. introduced the prodrug concept was introduced to the field of
1

ophthalmology in 19765 to enhance the absorption of a highly polar molecule, epinephrine, through
lipid membranes.6 Since then, various prodrugs have been designed to improve physicochemical
properties of therapeutic agents. This strategy involves modification of the active moiety into
various derivatives in a fashion that imparts some advantage, such as membrane permeability, site
specificity, transporter targeting and improved aqueous solubility, over the parent compound. The
application of prodrug strategies to ocular drug delivery provides an option of enhancing drug
penetration into the ocular tissues, and overall ocular bioavailability, with minimum disruption of
the ocular diffusion barriers. A prodrug/analog strategy has been, and is being, employed to
overcome barriers in ocular delivery for some drug molecules, utilizing a chemical modification
approach rather than a formulation-based approach. Although success of the prodrug strategy is
contingent on various factors, such as the chemical structure of the parent molecule, aqueous
solubility and solution stability, capacity of targeted transporters and bioreversion characteristics,
this approach has been successfully utilized, commercially and therapeutically, in several cases.
Ocular bioavailability cannabinoids such as Δ9- Tetrahydrocannabinol (THC) and Cannabidiol
(CBD) can be enhanced by employing this strategy.
The other strategy, that can be employed to improve bioavailability, is a formulation-based
approach. Retention of the formulation on the ocular surface and penetration of the active
ingredient into the ocular tissues are critical parameters governing the effectiveness of topical
application. Conventional formulation strategies involve the use of viscosity enhancers such as
hydroxyethyl cellulose and hydroxypropyl methyl cellulose, or penetration enhancers such as
cyclodextrins, benzalkonium chloride or surfactants, in solution and suspension formulations.7 The
formulator may also opt for gels, ointments and other viscous formulations to improve residence
time on the surface.8-9

2

Improving the viscosity improves the contact time of the active ingredient with the corneal
surface and improves flux but does not improve the corneal membrane permeation characteristics
of the molecules. Nanocarriers, such as liposomes, niosomes, lipid nanoparticles and
nanoemulsions, are a few of the innovative strategies that can encapsulate a wide range of drugs.
Vesicular carriers such as liposomes have an added advantage in that they can load both
hydrophilic as well as lipophilic molecules and provide an option for surface modification. The
use of a vesicular system is, however, associated with problems such as limited drug loading, shortterm stability, unwanted side effects and difficulty with sterilization.10-11 Lipid-based
nanoparticulate systems have recently gained interest for ocular delivery. Solid lipid nanoparticles
(SLN) and nanostructured lipid carriers (NLC) show promise because of better biocompatibility,
enhanced corneal retention and permeation of the nanoparticles.12-13 The formulation approaches,
however, do not change the ability of the compounds themselves to diffuse across membranes.
Ocular drug delivery remains a major challenge for formulators because of the unique
structural organization of the eye. To understand the fate of the drug in the ocular tissues and
overcome the barriers to drug absorption, it is necessary to study the anatomy of the eye (Figure
1.), organized into an anterior segment and a posterior segment. Therapeutic agents may need to
be targeted to one or both segments of the eye.
Anatomical and physiological considerations for drug delivery
Ocular drug delivery remains a major challenge for formulators because of the unique
structural organization of the eye.14-16 To understand the fate of the drug in the ocular tissues and
overcome the barriers to drug absorption, it is necessary to study the anatomy of the eye (Figure
1.), which is organized into an anterior segment and a posterior segment.17 Therapeutic agents may
need to be targeted to one or both segments of the eye. The anterior segment is composed of the
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crystalline lens suspended from the ciliary body, and the structures anterior to it; namely, the
cornea, the iris and the two chambers containing aqueous humor: the anterior and the posterior
chambers. The anterior chamber contains approximately 0.25 mL of aqueous humor and is bound
anteriorly by the back of the cornea and posteriorly by the iris and a part of the ciliary body. The
posterior chamber consists of approximately 0.06 mL of aqueous humor and is bound anteriorly
by the iris and a part of the ciliary body and posteriorly by the crystalline lens.18-19 The aqueous
humor is a clear, colorless fluid, secreted by non-pigmented epithelial cells of the ciliary body,
with a chemical composition similar to that of blood plasma, but with a low protein content.20 The
sclera, retina-choroid, vitreous humor and optic nerve make up the posterior segment, of which the
vitreous humor, a hydrophilic gel matrix, makes up 80% of the volume of the eye.14, 18, 21-24

Figure 1. Physiological barriers to ocular drug delivery (diffusional barriers are indicated in red,
elimination route is indicated in green). A major pathway for ocular penetration of topically
administered therapeutic agents is via the cornea (1). Some large and hydrophilic drugs prefer
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the conjunctival and scleral route, and then diffuse into the ciliary body (2). After systemic
administration small compounds can diffuse from the iris blood vessels into the anterior segment
(posterior chamber) (3). From the anterior segment the drugs are eliminated either by aqueous
humor outflow (4) or by venous blood flow - diffusion across the iris surface (5). Systemically
administered therapeutics agents must pass across the retinal pigment epithelium or the retinal
capillary endothelium to reach the retina and vitreous humor (6). Alternatively, drugs can be
administered by intravitreal injection (7). Drugs are eliminated from the vitreous via the blood–
retinal barrier (8) or via diffusion into the anterior chamber (9).

Topical delivery is the preferred and patient-friendly technique for treating diseases of the
anterior segment and involves instillation of the eye drops into the conjunctival cul-de-sac. A
topically applied formulation, however, has to overcome multiple pre-corneal barrier mechanisms,
such as dilution, overflow, tear-fluid enabled lacrimal drainage and conjunctival absorption
resulting in elimination from the pre-corneal area.17, 25-26 The ocular tissues maintain a highly
regulated environment for visual cells and transparent tissues. Ocular barriers, namely the BloodAqueous Barrier (BAB) and the Blood-Retinal Barrier (BRB), play a vital role in the protection of
the eye and the maintenance of ocular functions by restricting the entry of xenobiotics,
consequently challenging the passage of therapeutic drug molecules into the ocular tissues.27
The cornea is the outermost tissue in the anterior ocular segment and consists of five layers:
the epithelium, Bowman’s membrane, the stroma, Descemet’s membrane, and the endothelium.2829

The corneal epithelial cells are connected to each other via desmosomes and express tight-

junctions that act as a rate-limiting barrier for hydrophilic molecules.30-31 Lipophilic drugs,
depending on biopharmaceutical characteristics such as solubility, partition coefficient, ionization
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and charge and polar surface area, demonstrate better transcellular permeation compared to
hydrophilic molecules.32-33 The stroma underlying the corneal epithelium, however, is hydrophilic
in nature.34 Additionally, efflux pumps present on the corneal and conjunctival membranes restrict
the entry of substrates (mostly lipophilic in nature) into the deeper ocular tissues.29, 35-37 Thus,
therapeutic agents must possess optimal physicochemical and biopharmaceutical characteristics to
permeate efficiently across the total corneal membrane. The non-corneal route of absorption
encompasses conjunctival pathways, and favors hydrophilic and large polar molecules.14, 38-39 The
BAB and the BRB also limit the passage of both hydrophilic and lipophilic molecules by virtue of
the tight-junctions and efflux mechanisms present.14, 36, 40-43 Both systemic and periocular delivery
are affected by the presence of the BAB and BRB.
Designing a stable formulation delivering effective amounts of API to the desired site of
action involved several steps, such as preformulation screening, stability and solubility of the API,
determination of the route of delivery and an appropriate formulation strategy, excipient selection
and compatibility, process parameters and scale up44. The drug product development process for
any molecule is a multi-variate process and these variables could be interdependent, affecting the
efficacy of the optimized formulation. In this situation, instead of running random trials, by
changing single variable, using Quality by Design (QbD) principles for formulation and process
development a more cost effective and time efficient technique. This process involves setting up a
target product profile for the product, within its safety and efficacy limitations, identifying critical
quality attributes (CQAs) that affect the final drug product properties, coming up with a
manufacturing process that meets the CQAs for the final drug product, identifying the main effects
or the critical process parameters (CPPs) that control the critical material attributes of the final
product. The different tools utilized by QbD are Design of Experiment (DOE), process analytical
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technologies (PAT) and risk assessment. Using DOE for formulation optimization is a systematic
way of analyzing effects of independent variables and interactions on the final formulation
properties (response variables). Constructing a robust model using these variables results in
establishing a predictive design space, helping us design an optimum formulation as also establish
the edge of failure.
QbD principles can also be applied to optimization of pharmaceutical manufacturing
processes such as tableting or homogenization or even filling. A process optimization DOE would
help establish equipment limits and optimum conditions for processing the material, in turn
increasing process efficiency. Applying QbD principles to developing processes involves similar
steps, keeping in mind a target product profile, identifying the CQAs for the product and
establishing the CPPs for the process in concern. The design space constructed facilitates
understanding of the relationship between CPPs and CQAs of the product in question. A
pharmaceutical capping process is a critical process that ensures the optimized drug product is
protected from external stresses. Depending on the equipment in use, there are various CPPs (main
effects) that affect the CQA, which in this case would be an acceptable crimp ensuring container
closure integrity through the product cycle. The final chapter would discuss one such process
optimization for a stopper-vial combination for storage and shipping at frozen conditions.
The work described herewith would employ prodrug/analog strategy, formulation strategy
and both to enhance ocular bioavailability of the target molecule. In entirety, the research chapters
described henceforth would talk about various aspects of the path followed by a small molecule
ophthalmic from the bench to the final product. The initial chapters would discuss work on the
cannabinoids in early discovery phase: THC and CBD, their prodrugs and analogs respectively.
The THC chapter aims at improving the ocular bioavailability of the molecule by means of
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optimizing a novel formulation of its prodrug, THC-VHS. The therapeutic potential of this novel
formulation was evaluated in a set of preclinical pharmacokinetic-pharmacodynamic (PK-PD)
studies in a small animal model. The primary goal of the CBD chapter was to screen CBD analogs
in an in vitro setup. Furthermore, the efficacy of a few lead candidates was evaluated in a small
animal model. Apart from Cannabinoids, formulation optimization of anti-inflammatory agents
(Triamcinolone Acetonide), antifungals (Voriconazole) and antimicrobial agents (Ciprofloxacin)
was undertaken by statistical DOE. The final chapter discusses pharmaceutical capping process
optimization for drug products meant for cold storage. This work tries to unify pharmaceutical unit
operations such as capping and filling at a laboratory scale and a manufacturing scale by modeling
a predictive design space for that operation.
Specific Aims
1. To evaluate ocular bioavailability of CBD analogs with a range of physicochemical properties
and establish in vitro-in vivo correlation.
2. To evaluate the intra-ocular pressure (IOP) lowering efficacy and ocular tissue disposition of
THC and its prodrug, THC-VHS in nanoemulsion and solid lipid nanoparticulate formulation.
3. To study the effect of surface modification of Triamcinolone Acetonide Nanostructured Lipid
carriers with Chitosan and Chitosan derivatives on the permeation profile of the same
4. Anti-fungal & Anti-bacterial PEGylated-NLCs for ocular applications: Formulation
Development, Characterization and In vitro Efficacy Testing
5. Optimization of Capping Parameters for Low Temperature Storage of a Plastic Vial-Rubber
Stopper Combination
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CHAPTER 2
ANALOG DERIVATIZATION OF CANNABIDIOL FOR IMPROVED
OCULAR PERMEATION
Introduction
Non-inflammatory disorders such as diabetic retinopathy (DR) might occur as a result of
inflammatory mediators, needing anti-inflammatory agents as a part of clinical therapy. 45 DR is
one of the leading causes of vision loss in working age adults and the fifth most common cause of
moderate to severe vision impairment.

46-47

Studies testing the global prevalence of DR reported

285 million people with diabetes, one third of whom show symptoms of DR.

48

DR involves

leakage of the retinal blood vessels leading to distorted vision. Breakdown of the blood-retinal
barrier leads to further vision loss through macular edema and retinal neovascularization.

49-50

Degeneration of the retinal cells may be caused by a mechanism involving tyrosine nitration and
may include a vascular endothelial growth factor (VEGF) triggered breakdown component.51-52
Diabetic retinas have shown an increase in the vascular permeability which can be associated with
increase in VEGF and tumor necrosis factor alpha (TNFα) pointing towards pro-inflammatory
roots of this disease.53 High glucose conditions in diabetic retinas stimulates endothelial apoptosis
by activation of p38 MAP kinase.54
Current treatment options for DR include laser photocoagulation, vitreoretinal surgery and
intravitreal injections of anti-VEGF and steroids. Laser photocoagulation is the recommended
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therapy for DR; however, laser photocoagulation is associated with neural tissue death raising the
need for the development of non-invasive therapies for DR.

55

Intravitreal steroid therapy often

leads to unwanted side effects such as elevated intra-ocular pressure, cataracts and advent of
opportunistic infections.

56-57

Ophthalmic surgical procedures such as vitreoretinal surgeries are

often accompanied by post-surgical complications such as elevated intra-ocular pressure,
endopthalmitis and cataract formation.58
Discoveries pertaining to the involvement of the endocannabinoid system in modulation of
ocular pain and inflammation open new avenues for targeting the cannabinoid receptor system
(CB1 and CB2) for the management of ocular inflammatory conditions. 59-60 CB1 are Gi/o-proteincoupled receptors expressed in the central nervous system (CNS) especially in the basal ganglia,
cerebellum and hippocampus. They are also located in the periphery, including the retina, sperm
cells, testis, colonic tissues and peripheral neurons.

61-63

While CB2 receptors are located in the

immune system; there have also been reports of localization of CB2 receptors in the retinal cells.
61, 64-67

CBD is a major cannabinoid of the plant Cannabis sativa, free of cannabimimetic CNS
activity, possessing neuroprotective, anti-emetic and anti-inflammatory properties

68

. Possible

explanations for the anti-inflammatory activity of CBD could be its ability to interact with CB2
receptors and inhibiting immune cell migration.69 Moreover, CBD acts as an effective anti-oxidant
by scavenging reactive oxygen species (ROS) and blocking NADPH oxidase

50

. CBD has been

shown to decrease retinal inflammation by blocking ROS and TNFα formation and by p38 MAP
kinase activation.50 It has also been reported to exert anti-inflammatory activity by inhibiting
adenosine re-uptake in rat retinal microglial cells. 70 Thus, CBD, by virtue of its anti-inflammatory
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properties, might be a treatment option for DR induced pain and inflammation, by modulating the
formation of TNFα and scavenging ROS.
El-Remessy et al. demonstrated neuroprotection in NMDA-induced retinal neurotoxicity
in rats via the anti-oxidant effect of CBD 50. They also determined the effect of blocking oxidative
stress on the BRB preservation in diabetic rats 50. The benefits of CBD, i.e. blocking oxidative
stress and inhibiting adenosine reuptake to enhance a self-defense mechanism against retinal
inflammation, potentially represents a novel therapeutic approach for the inflammatory
complications of the eye. 70
CBD (Figure 2A) is a lipophilic molecule with a Clog P of 5.91 making its topical delivery
to treat retinal inflammation extremely challenging. In order for CBD to produce a therapeutic
effect, the molecule has to transverse across the static ocular layers and the dynamic blood-ocular
barriers to reach the back of the eye 71. This work aims at improving ocular penetration of CBD
by means of bio-engineered analog derivatization. Through structural modifications in the
molecule, inherent molecular properties such as molecular size, structural conformation,
lipophilicity, solubility etc. were optimized to increase the “druglikeness” of the molecule.
CBD-amino acid ester (CBD-AA) analogs are prepared by linking one or both of its
hydroxyl groups to an amino acid such as L-Valine, via an ester linkage, to form CBDmonovalinate (CBD-Mono-Val) and CBD-divalinate (CBD-Di-Val), respectively (Figures 2B &
C). L-Valine has previously been reported to improve the transport of the molecule acyclovir and
ganciclovir 72. The electron releasing-electron withdrawing properties of the side chain determine
the stability of the bond. The parent molecule, as a virtue of its steric bulk is lipophilic and
incorporation of an ionizable group in this structure attempts to increase its aqueous solubility.
Hemi-esters of dicarboxylic acids have been known to enhance the solubility of
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methylprednisolone, chloramphenicol, propranolol and a few other drugs 73-76. CBD-dicarboxylic
acid (CBD-DCA) analogs were synthesized (Figure 2D) by attaching a dicarboxylic acid, such as
succinic acid to both hydroxyl groups of CBD (CBD-HS). Another derivatization approach
employed synthesis of CBD-amino acid- dicarboxylic acid ester (CBD-AA-DCA) analogs by
linking a dicarboxylic acid such as succinic acid to the free amino group of the CBD-AA to form
CBD-monovalinate-monohemisuccinate (CBD-Mono-VHS) (Figure 2E) and CBD-divalinatedihemisuccinate (CBD-Di-VHS) (Figure 2F), respectively. The rationale behind this modification
was to impart the stability in biological matrix as achieved by the AA analogs and solubilize the
molecule at physiological pH by including an ionizable group. Moreover, addition of an ester bond
after the amide bond increases the stability of the amide bond. The physicochemical properties of
the synthesized analogs are mentioned in Figure 2.
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Figure 2. Structures, chemical formulae and physicochemical parameters of CBD and biologically
active CBD-analogs
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Materials
CBD analogs were synthesized by ElSohly Labs Inc. 77. Tocrisolve™ was purchased from Tocris®
Bioscience, Bristol, UK. High performance liquid chromatography (HPLC) - grade solvents, and
other chemicals (analytical grade) were obtained from Fisher Scientific (Hampton, NH, USA).
Animals
Male New Zealand White rabbits (2-2.5 kg), obtained from Harlan laboratories® (Indianapolis, IN)
were used in all studies. All animal experiments conformed to the tenets of the Association for
Research in Vision and Ophthalmology statement on the use of animals in ophthalmic and vision
research. All experiments followed the University of Mississippi Institutional Animal Care and
Use Committee approved protocols.
Methods
Stability of CBD and Analogs in Ocular Tissue Homogenates
Tissue Preparation
The degradation of CBD analogs was determined in aqueous humor (AH), vitreous humor (VH),
iris-ciliary bodies (IC), and retina-choroid (RC). The tissues were shipped on dry ice from PelFreez Biologicals; AR. Ice-cold isotonic phosphate buffer (IPBS) was used to homogenize the
solid tissues, RC and IC, in an ice bath using a TISSUEMISER (Fisher Scientific). The
homogenates were then centrifuged at 13,000 rpm at 4°C for 15 minutes. The protein contents of
the supernatants were determined according to the method of Bradford and were adjusted to
approximately 1 mg/mL. 78
Hydrolysis Procedure
Enzymatic degradation of CBD and analogs was studied at 37°C in a shaking water bath. The
tissue homogenates were equilibrated for 30 minutes at 37°C to activate the enzymes. To 1.9 mL
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of the supernatant, 100 µL of the CBD/analog stock solution were added to make the final CBD/
analog concentration as 25 µg/mL (analog concentration spiked for CBD-di-Val was 50 µg/mL).
At predetermined time-points, 100 µL aliquots of the sample were withdrawn up to 6 hours post
initiation. An equal volume of ice-cold acetonitrile was added to each sample to arrest the
enzymatic degradation. The samples were centrifuged at 13,000 rpm for 15 minutes and the
supernatant was analyzed for analog/CBD content using HPLC-UV.
Chromatography methods
Analytical method for in vitro samples
The in vitro samples were analyzed for CBD and analogs using an HPLC-UV system comprising
a Waters 717 plus Auto sampler, Waters 600E pump controller, Waters 2487 dual λ Absorbance
detector and an Agilent 3395 integrator. Stock solutions of CBD and analogs were prepared in
acetonitrile. A gradient method (Table 1.) was used for elution of CBD and analogs with the mobile
phase consisting of Acetonitrile and 5 mM Phosphate buffer (pH 2.5). A Phenomenex® C18 (4.6
x 150 mm) column was used at a flow rate of 1 mL/min. Detection was carried out at 222 nm.

Table 1. HPLC gradient method for separation and quantification of CBD and analogs
Time
(min)
0
3-6
7-15

Flow (mL/min)

% Acetonitrile

% Buffer

1
1
1

75
95
75

25
5
25

15

Preparation of topical ophthalmic nanoemulsion of CBD/analogs
CBD and the associated analogs were formulated into a soybean-oil based nanoemulsion
composed of a 1:4 ratio of soya oil/water that was emulsified with the block co-polymer Pluronic
F68 (Tocrisolve™). The formulations were prepared by adding the drug/analog to the blank
emulsion. This mixture was vortexed for five minutes followed by sonication for ten minutes. For
quantification of CBD and analogs in the nanoemulsion, the formulations were centrifuged at 9000
rpm for 5 min at 25°C. The solubility of CBD and the analogs is listed in Figure 2.
Distribution of CBD and analogs in ocular tissues after topical administration
In vivo bioavailability of CBD and analogs was determined in Male New Zealand White Albino
(NZW) rabbits, weighing between 2 and 2.5 kg, procured from Charles River Labs. CBD and its
analogs, namely CBD-Di-VHS, CBD-Di-Val, CBD-Mono-Val, CBD-Mono-VHS and CBD-HS
were formulated in Tocrisolve™ emulsion. These formulations were evaluated in vivo in a
conscious rabbit model, at least in triplicates (n = 3). The initial study compared ocular penetration
of CBD-Di-VHS and CBD-Di-Val to that of CBD. The second study compared the ocular
bioavailability of CBD-Mono-Val, CBD-Mono-VHS, CBD-HS and CBD. Concentration of the
CBD analog as well as CBD were determined in the AH, VH, RC and IC. Fifty microliters of the
above formulations were dosed topically (Dose: 250 μg CBD equivalent) - instilled in the
conjunctival sac of the NZW rabbits. Ninety minutes after dosing the rabbits were anesthetized
using a combination of ketamine (35 mg/kg) and xylazine (3.5 mg/kg) injected intramuscularly.
The rabbits were euthanized with an overdose of pentobarbital injected through the marginal ear
vein. The eyes of the rabbits were then enucleated and washed thoroughly with IPBS and the
intraocular tissues such as IC, AH and VH were separated.
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Tissue sample preparation and extractions
A protein precipitation technique was employed to determine the amount of CBD and analogs in
the ocular tissue homogenates. The solid tissues, namely IC (50 mg) and RC (30 mg) were cut into
small pieces and homogenized with ice-cold IPBS in an ice bath using a TISSUEMISER (Fisher
Scientific), whereas, the liquid tissues, AH (50 µL) and VH (100 µL) were taken as they were.
For the calibrators, standards were prepared by spiking the tissues with CBD and the analogs to
yield final concentrations of 2.5, 5, 10, 25, 50, and 100 ng/ml. Twenty-five microliters ice-cold
acetonitrile, precipitating proteins from individual tissues. Samples were vortexed and kept aside
for 10 minutes. The supernatant was collected after centrifuging for 30 minutes at 13,000 rpm and
analyzed using LC-MS/MS.
Bio-analytical quantification method
Analysis was performed on two LC-MS-MS systems consisting of a Shimadzu Prominence HPLC
with a dual pump, a vacuum solvent micro degasser, a controlled-temperature autosampler, and an
MS-MS detector (Applied Biosystems/MSD Sciex Qtrap 3200 and 4500 with a turbo-ion ESI
source operating the positive-ion multiple reaction monitoring, or MRM, mode). Specific MRM
transitions were monitored for each compound for maximum selectivity and sensitivity. Separation
was achieved on a Synergi Hydro-RP column (50 x 3.00 mm; 2.5 μm; 100 Å) from Phenomenex
(Torrance, CA, USA). Water with 0.1% Formic acid (Pump A) and Acetonitrile with 0.1% Formic
acid (Pump B) were used as the mobile phase with a gradient elution. Data acquisition and
processing were performed with Analyst™ 1.6.2 software (Applied Biosystems (AB Sciex), Foster
City, CA).
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Statistical analyses
Data is represented as the mean ± standard deviation, for a minimum of three independent
experimental runs. Statistical comparisons of the means were performed using one-way analysis
of variance (ANOVA) or Student’s t-test. The differences were considered significant when the pvalue was < 0.05.
Results and Discussion
Physicochemical characterization of analogs
To improve aqueous solubility and tissue permeability, the parent molecule was derivatized; the
aim of analog design was to modify molecular properties in the desired direction. Physicochemical
parameters such as molecular weight, log P, pKa, hydrogen bond donors and acceptors and polar
surface area, were estimated using the ChemDraw software (PerkinElmer®) to obtain a better
understanding of the membrane permeation characteristics of the molecule. Figure 1. lists the
computed physicochemical parameters for CBD and analogs. Optimum physicochemical
parameters would in turn prove to be efficient predictors of overall ocular bioavailability. The RO5
defined by Lipinski determines limitations for drug design for an oral targeted molecule to be
successful through all the stages of drug development (molecular weight 500, log P 5, H-bond
donors 5, H-bond acceptors 10). With a few modifications, we can utilize the Lipinski’s RO5 in
designing molecules for non-oral routes of delivery. 2-3
Stability of CBD and analogs in ocular tissue homogenates
Stability of CBD in ocular tissue homogenates
The stability of CBD in the biological matrix and its resistance to enzymatic attack is shown in
Table 2. CBD was stable in most of the ocular tissues tested. Some degradation is observed in
the iris-ciliary bodies.
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Table 2. Stability of Cannabidiol in ocular tissue/tissue homogenates.
Tissue

Time (min)

0

15

30

45

60

90

120

180

240

360

Aqueous
Humor

CBD
(µg/mL)

31.3

29.8

31.8

30.0

29.4

29.3

23.9

30.5

32.6

26.3

Vitreous
Humor

CBD
(µg/mL)

30.9

34.2

34.5

34.4

32.9

34.0

37.4

44.2

34.9

32.0

Retina
Choroid
Iris
Ciliary
bodies

CBD
(µg/mL)

30.0

19.9

34.3

34.2

31.9

34.5

36.2

28.4

34.1

32.0

CBD
(µg/mL)

16.6

12.5

15.1

11.2

10.9

14.8

13.8

12.5

10.9

7.3

Stability of CBD-Di-Val in ocular tissue homogenates
The results (Figure 3) suggest that CBD-Di-Val is enzymatically hydrolyzed in some of the ocular
tissues with detectable levels of CBD observed ninety minutes post initiation of the study. The half
life of CBD-Di-Val in AH and VH was 5.78 h and 2.89 h respectively, with apparent first order
degradation rate constants of 0.33x10-4 h-1 and 0.67x10-4 h-1. The delayed and restricted generation
of CBD could be explained by possible formation of intermediate degradation products such as
CBD-Mono-Val. AA derivatives synthesized with promoeties such as valine, isoleucine,
phenylalanine etc. have been reported to provide stability to hydrolytic attack in comparison to the
DCA analogs due to the presence of steric groups such as branched aliphatic amino acid (valine)
or aromatic amino acid (phenylalanine). 79-82 CBD-Di-Val is a lipophillic molecule with a clog P
of 6.45 (Figure 1.), and shows limited dissolution in the homogenized tissues. Figure 3. depicts
low initial concentrations of CBD-Di-Val followed by a slight increase and steady analog
concentrations through the duration of the study. This behaviour could be attributed to the drug
concentrations exceeding equilibrium solubility in the biological matrices, leading to possible
precipitation of the analog followed by continual dissolution of the same in the tissue matrix
leading to an equilbrium between the drug in solution and undissolved drug. In solid tissues, IC
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and RC, no CBD as a breakdown product was observed. However,a decline in the analog levels
were detected. This could again be attributed to generation of intermediate degradation products
and the resistance of the analog to hydrolytic attack.

Figure.3. In vitro enzymatic stability of CBD-Di-Val in ocular tissue homogenates;

Figure 3. In vitro enzymatic stability of CBD-Di-Val in ocular tissue homogenates; Aqueous
Humor, Vitreous Humor, Retina Choroid and Iris Ciliary Bodies. The blue bars represent CBDDi-Val concentrations (nM) and the red bars represent regenerated CBD (nM) concentrations.

Stability of CBD-HS in ocular tissue homogenates
CBD-HS, like CBD-Di-Val, is enzymatically hydrolyzed in some of the ocular tissues (Figure 4).
The half life of CBD-HS in AH and VH was 13.07 and 13.52 minutes, respectively, with apparent
first order degradation rate constants of 0.053 and 0.051 min-1 respectively. Furthermore, the AH,
VH and IC data shows constant CBD-HS levels initially with a sudden drop, below detection levels
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hinting towards solubility issues of the analog and the stability of ester bond governing the overall
rate of the reaction, with it changing from pseudo-zero to first-order degradation process. The
delayed generation of CBD suggest formation of an intermediate degradation product, like CBDMono-HS, before generating CBD or a different degradation pathway.

Figure.4. In vitro enzymatic stability of CBD-HS in ocular tissue homogenates; Aqueous Humor,
Vitreous Humor, Retina Choroid and Iris Ciliary Bodies. The blue bars represent CBD-HS
concentrations (nM) and the red bars represent regenerated CBD (nM) concentrations.

The half life of CBD-HS in IC was 16.5 minutes and the apparent first order degradation rate
constant was 0.042 min-1. The observed bioconversion in IC was similar to the results for
bioconversion of CBD-Di-Val in IC; CBD-HS failed to regenerate CBD through the duration of
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the study. We can attribute this phenomenon to secondary degradation products formed due to
precence of multiple sites for hydrolytic attack and presence of unexplored degradation pathways.
The results in RC point towards formation of an initial supersaturated solution followed by
precipitation and generation of an equilibrium between the solid state and solution state as
evidenced by CBD-HS levels remaining almost constant even though generation of CBD is
observed two hours post initiation. 76, 82.

Figure.5. In vitro enzymatic stability of CBD-Di-VHS in ocular tissue homogenates; Aqueous
Humor, Vitreous Humor, Retina Choroid and Iris Ciliary Bodies. The blue bars represent CBDDi-VHS concentrations (nM) and the red bars represent regenerated CBD (nM) concentrations.
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Stability of CBD-Di-VHS in ocular tissue homogenates
CBD-Di-VHS demonstrates excellent stability in the ocular tissues without any CBD generation
even after a 6 h exposure (Figure 5.). This is consistent with the results observed with CBD-DiVal and CBD-HS since the increased chain length leads to steric hindrance and provides greater
protection from enzyme attack. Moreover, the number of intermediates that can form are double
that with CBD-Di-Val and CBD-HS. Out of all the analogs tested, CBD-Di-VHS was observed to
be the most stable, with no degradation within the study duration, whereas, CBD-Di-Val and CBDHS regenerated CBD but at a slow rate.
The in vitro data points towards the solubility of the analogs, the stability of the ester bond,
involvement of different degradation pathways and formation of multiple degradation
intermediates as a possible explanation for the low rate of bioconversion observed in the biological
matrices of the analogs and generation of CBD.
Distribution of CBD and Analogs in ocular tissues after topical administration
First PK Study
Fifty microliters of three formulations were dosed in the first study, CBD, CBD-Di-Val and CBDDi-VHS (n=6) in Tocrisolve™ emulsion in NZW rabbits (n=3), with the dose being equivalent to
250 µg CBD (Figure 6). CBD, from CBD formulations, did not penetrate across the ocular tissues
following topical instillation, with CBD being detected only in the RC tissues (17.35 ± 4.57 ng/g).
This indicates that CBD, because of its physicochemical characteristics, is not suited for
penetration across the ocular membranes. CBD-Di-Val formulations displaying a similar pattern
- did not permeate significantly into the ocular tissues with about 9.11 ± 1.07 ng/g of the analog
(equivalent to

ng/g of CBD) being detected in the RC only. A potential explanation for this
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phenomenon could be that CBD-Di-Val, being slightly more hydrophobic than the other
analogs displays poor solubility in the tissue environment at physiological pH. In comparison
to CBD, CBD-Di-Val is more lipophilic (clog P 6.45) and is a bulkier molecule, resulting in
overall lower bioavailability in comparison to the parent molecule. Because of its lipophilic
nature and high solubility in the oily emulsion (Figure 2), its dissolution in the tissue
microenvironment serves as a rate-limiting step, preventing the molecule from partitioning
into the hydrophilic tear fluid.

Figure 6. Ocular tissue concentrations of CBD, CBD-Di-Val and CBD-Di-VHS 90 min post
topical application of CBD (0.47%), CBD-Di-Val (0.94%) or CBD-Di-VHS (1.2%) in Tocrisolve™
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emulsion (Dose: 250 µg CBD; 50 µL instilled volume) respectively. Data represented is Mean ±
SEM, the differences were considered significant when the p-value was < 0.05
CBD-Di-VHS, on the other hand, demonstrated significantly better ocular bioavailability.
CBD-Di-VHS concentration were 612.48 ± 187.11 ng/mL (detected in three of the six test
animals) in the VH and 279.77 ± 75.29 ng/g tissue weight in the RC. Concentrations in the
front of the eye tissues were lower with 12.32 ± 7.53 ng/ mL in the AH and 160.31 ng/ g tissue
weight in the IC (detected in IC of only one animal). The reason behind overall higher
bioavailability of this compound could be its improved solubility at physiological pH. CBDDi-VHS has a pKa of 3.93, and is charged at physiological pH, resulting in higher solubility of
the analog, in turn increasing its partitioning into the tear and permeation. CBD-Di-VHS was
not metabolized to CBD in the ocular tissues within the timeframe tested. This observation
was consistent with the in vitro stability data in the tissue homogenates. The analog
demonstrated surprisingly high penetration into the VH. The charge of the analog at
physiological pH and the route of ocular permeation could possibly explain penetration of the
analog from the RC into the VH. However, the overall tissue disposition profile of CBD and
the analogs, from the nanoemulsion formulations, suggests a non-corneal route of absorption,
with higher levels of the analogs present in the posterior tissues.
Second PK Study
Taking into consideration the in vitro and in vivo data of CBD, CBD-Di-Val and CBD-Di-VHS,
mono derivatized AA and AA-DCA analogs of CBD (CBD-Mono-VHS, CBD-Mono-Val) were
synthesized for in vivo evaluation, aiming to reduce the steric bulk of the molecule but retaining
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the overall permeation/stability profile offered by an AA and AA-DCA analog. CBD and the DCA
analog, CBD-HS, were also included in this set.
Fifty microliters of the four formulations were dosed in the second study: CBD, CBD-Mono-Val,
CBD-Mono-VHS (n=6), and CBD-HS in Tocrisolve™ emulsion in NZW rabbits (n=3), with the
dose being equivalent to 250 µg CBD (Figure 7). Following topical administration of CBD-HS,
the analog concentrations were below detection levels in all the ocular tissues tested at the end of
90 minutes; however, bio-reversed CBD, 263.15 ± 93.33 ng/ g tissue weight in RC and 266.69 ±
35.52 ng/g in IC, were observed, consistent with the in vitro stability profile. CBD-HS, being a
DCA analog has two ester bonds prone to hydrolysis rendering it susceptible to chemical and
enzymatic hydrolysis.
Comparing the data obtained in both sets, following CBD administration, lower levels of CBD
were observed in the RC in the first study, however the difference in the drug concentrations
detected were not statistically significant and this variation could be attributed to biological system
variability.
CBD-Mono-Val is a hydrophobic molecule with a clog P value of 6.18, (Figure 2). The lipophilic
nature as well as other physicochemical characteristics of the molecule along with restricted
solubility in the tissue microenvironment results in low ocular bioavailability (below detection
limit in all tissues tested) as observed in the in vivo study.
CBD-Mono-VHS, in contrast, showed significantly higher levels of the analog in AH (94.5 ± 7.83
ng/ml), IC (728.18 ± 152.62 ng/g) and RC (603.92 ± 160.42 ng/ g tissue weight), in comparison
to CBD-HS and CBD-Mono-Val (Figure 7).
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Figure 7. Ocular tissue concentrations of CBD- Mono-VHS, CBD-Mono-Val, CBD, CBD-HS 90
min post topical application in Tocrisolve™ emulsion (Dose: 250 µg; 50 µL instilled volume)
respectively. Data represented is Mean ± SEM, the differences were considered significant when
the p-value was < 0.05
*CBD-Mono-VHS > CBD, CBD-HS, CBD-Mono-Val
**CBD-HS > CBD & CBD-Mono-Val

The in vivo studies suggest that the mono derivatized form, CBD-Mono-VHS permeates more
effectively than CBD-Di-VHS, with higher concentrations of the analog detected in the tissues.
CBD-Mono-VHS levels are almost twice, four times and eight times higher in RC, IC and AH
(Figure 7), respectively in comparison to CBD-Di-VHS (Figure 6). Looking at the ocular
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bioavailability in relation to drug design, several features about the physicochemical properties of
the molecule stand out (Figure 2.); CBD-Mono-VHS is a smaller molecule (M.W 513.68) in
comparison to CBD-Di-VHS (M.W 712.88) and has one charged group at physiological pH,
balancing its hydrophilic and lipophilic nature. The transmembrane permeation of CBD-MonoVHS, which has a PSA of 112.93 A2, is comparatively more effective than that of CBD-Di-VHS, a
more polar molecule with a PSA of 185.4 A2. Looking at the total number of hydrogen bond donors
and acceptors (Figure 2), even though both molecules follow Lipinski’s RO5, CBD-Mono-VHS
displays a better profile due to a lower number of donors and acceptors, giving it a comparatively
better ADME profile. We also observe bio-converted CBD, following topical application of CBDmono-VHS formulations, in RC (348.37 ± 131.17 ng/g), IC (469.09 ± 62.78 ng/g) and AH (30.66
± 13.84 ng/ml) indicating that this analog was more prone to hydrolysis than CBD-Di-VHS.
Conclusion
The above results demonstrate that CBD displays poor ocular tissue permeation following
topical application. When analogs are designed with a natural AA modification (e.g. CBD-Di-Val)
or as a DCA ester (e.g. CBD-HS), penetration into the ocular tissues is not adequate. A
combination of an AA and DCA (e.g. CBD-Di-VHS) strikes an effective balance between the
hydrophilicity and lipophilicity and other physicochemical characteristics, effectively increasing
ocular bioavailability.
CBD-mono-AA analogs, wherein one of the hydroxy groups is derivatized as a valine ester
and the other hydroxyl group is unsubstituted, do not penetrate into the ocular tissues. On the other
hand, when one of the hydroxyl groups is derivatized with a valine-hemisuccinate moiety and the
other hydroxyl group is free (CBD-Mono-VHS), ocular bioavailability following topical
application is significantly enhanced. The results suggest that the free –COOH group and stability
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of the linkage plays an important role in the penetration across the ocular tissues. Amongst all the
derivatives studied, the AA-DCA analog possessed optimum physicochemical properties,
permeating effectively across ocular barriers.

Supporting data
Table 3. In vitro stability of CBD-Di-Val, CBD-Di-VHS and CBD-HS in ocular tissue
homogenates; AH, VH, RC and IC. Analog and CBD concentrations (nM) monitored over a period
of 6h.
Analog concentration (nM) CBD concentration (nM)
Formulation Type Tissue Time point Mean
Std. Dev
Mean
Std. Dev
0
34.9
1.15
0
0
15
31.5
0.5
0
0
30
29.1
0.25
0
0
45
28.4
0.31
0
0
60
27.6
0.17
1.19
0.23
AH
90
26.9
0.03
4.73
0.34
120
0
0
9.18
1.07
180
0
0
16.2
0.33
240
0
0
18.8
1.43
360
0
0
26.5
0.12
0
27
0.19
0
0
15
26.2
0.56
0
0
CBD-HS
30
25.9
0.08
0
0
45
25.8
0.1
0
0
60
25.5
0.04
0
0
VH
90
12.6
17.9
0
0
120
0
0
3.42
4.83
180
0
0
2.5
3.54
240
0
0
4.31
1.14
360
0
0
12
1.31
0
29.2
0.06
0
0
15
28.7
0.08
0
0
IC
30
28.4
0.02
0
0
45
28.3
0.03
0
0
60
28.2
0.02
0
0
29

RC

AH

CBD-Di-Val
VH

IC

90
120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90

0
0
0
0
0
32.2
31
30.6
30.4
30.2
29.9
30
30.3
30
29.9
66.4
117
121
111
116
101
84.5
77.4
62.2
45.7
26.1
25.5
35.4
27.9
23
20.3
16.5
15.9
11.7
7.7
27.7
16.9
17.8
13.8
9.62
7.66

0
0
0
0
0
0.12
0.74
0.08
0.05
0.04
0.01
0.1
0.49
0.02
0.01
13.3
7.76
0.66
11.3
3.8
0.9
4.77
4.12
7.15
3.28
1.93
2.8
16.5
7.34
1.3
2.94
3.74
3.44
0.72
1.63
0.96
2.69
0.14
4.43
0.29
1.1
30

0
0
0
0
0.5
0
0
0
0
0
0
2.29
7.14
11.2
18.2
0
0
0
0
0
13.9
4.93
11.1
13.2
7.31
0
0
0
0
0
2.44
0
5.34
8.36
5.95
0
0
0
0
0
0

0
0
0
0
0.7
0
0
0
0
0
0
0.23
3.09
3.48
4.85
0
0
0
0
0
11.1
3.58
2.54
0.92
0.2
0
0
0
0
0
3.45
0
7.56
11.8
4.55
0
0
0
0
0
0

RC

AH

CBD-Di-VHS
VH

IC

120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90
120
180
240
360
0
15
30
45
60
90
120

2.24
2.4
0
0
39.4
9.73
37.8
21.3
33.7
24.3
15.4
23.7
34.3
34.5
34
31.8
33
32
32.5
30.5
30.1
28.6
28.1
33.6
30.1
34.3
34.3
33.6
32.8
30.9
29.1
25.2
23.1
34.1
36.3
38.4
37.1
37.1
37.2
38.3
37.9

3.16
3.4
0
0
14.5
6.91
2.98
10.3
3.85
3.41
3.57
10.9
2.2
6.53
0.47
1.91
0.37
0.86
0.61
0.71
0.84
0.49
0.32
0.03
4.38
0.64
0.96
0.65
0.11
0.59
0.69
0.31
0.29
0.04
0.08
1.83
0.22
0.33
0.85
0.39
0.21
31

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

RC

180
240
360
0
15
30
45
60
90
120
180
240

36.8
37.8
32.7
35.8
33.8
32.9
33.5
30.4
30.8
29.5
26.6
28.7

0.1
0.56
0.34
1.49
1.3
1.45
0.41
0.22
2.5
1.3
0.25
0.34

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

Table 4. Ocular tissue concentrations of CBD, CBD-Di-Val, CBD-Di-VHS, CBD-HS, CBDMono-VHS compiling studies 1 and 2, 90 min post topical application of CBD (0.47%), CBDDi-Val (0.94%) or CBD-Di-VHS (1.2%) in Tocrisolve™ emulsion (Dose: 250 µg CBD; 50 µL
instilled volume) respectively. Data represented is Mean ± SEM
*Concentrations detected in only one animal
**Concentrations detected in three of the six test animals
Analog Conc (ng/g of
tissue)
Study
number
1

Formulation
dosed
CBD

CBD-Di-Val

CBD-Di-VHS

Tissue
Analyzed
AH
VH
IC
RC
AH
VH
IC
RC
AH
VH
IC
RC

Mean

Std Err

0.00
0.00
0.00
17.35
0.00
0.00
0.00
9.11
12.32
612.48**
160.31*
279.77

0.00
0.00
0.00
4.57
0.00
0.00
0.00
1.07
7.53
187.11
75.29
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CBD Conc (ng/g
of tissue)
Std
Mean
Err
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
8.35
8.35

2

CBD

CBD-HS

CBD-Mono-Val

CBD-Mono-VHS

AH
VH
IC
RC
AH
VH
IC
RC
AH
VH
IC
RC
AH
VH
IC
RC

0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
94.50
0.00
728.18
603.92
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0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
7.83
0.00
152.62
160.42

0.00
0.00
0.00
0.00
0.00
0.00
266.69
263.15
0.00
0.00
0.00
0.00
30.66
0.00
469.10
348.37

0.00
0.00
0.00
0.00
0.00
0.00
32.52
93.33
0.00
0.00
0.00
0.00
13.84
0.00
62.78
137.2

CHAPTER 3
Δ9-TETRAHYDROCANNABINOL DERIVATIVE LOADED NANOFORMULATION LOWERS IOP IN NORMOTENSIVE RABBITS
Introduction
Glaucoma is a neurodegenerative disorder characterized by progressive peripheral vision
loss due to structural and functional damage to the optic nerve head. 83-84 The latest statistics from
the World Health Organization ranks glaucoma as the second leading cause of blindness, after
cataracts, affecting almost 60 million people worldwide.85 The 2010 report by the National Eye
Institute stated that 2.72 million people in United States suffer from glaucoma, 23 percent higher
than the 2.22 million affected in the year 2000, and projects almost 6.3 million to be affected by
this illness by 2050. 85-88
Glaucomatous optic neuropathy is caused by several factors that result in death of retinal
ganglion cells (RGC) and their axons. The major risk factor for glaucoma is elevated intraocular
pressure (IOP), normally regulated by AH hydrodynamics in the anterior chamber.89 AH is a fluid
secreted by the IC.90 AH drains out via the trabecular meshwork (TM) through the Canal of
Schlemm into venous circulation. The ciliary muscles maintain the tension on the TM structure
and control the drainage of AH. The Goldmann equation can be used to describe AH
hydrodynamics,91
𝐼𝑂𝑃 = 𝑃𝑒 +

(𝐹−𝑈)

…...(1)

𝐶𝑡𝑟𝑎𝑏
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Wherein, Pe is the episcleral venous pressure (the pressure opposing the drainage of AH
through the trabecular meshwork), F is the AH flow, U is the uveoscleral outflow and Ctrab is the
AH outflow from the TM and Schlemm canal.89 The balance between AH production and drainage
determines IOP, wherein increased AH production or inadequate AH drainage might result in
increased pressure.89,

92-94

Glaucoma medications target IOP reduction by acting on the

aforementioned factors i.e. either decreasing the production of AH or increasing AH outflow
through TM and through the uveoscleral pathway or both.95-97
Currently, there are five families of treatment governing the market as anti-glaucoma
agents.98 Adrenergic agonists, beta blockers, prostaglandin F2-α analogs, carbonic anhydrase
inhibitors and cholinergic agents. The mechanism of action of each class and examples of some
FDA approved agents are listed in Table 5.

Table 5. Classification and mechanisms of action of the currently used anti-glaucoma medications
Anti-glaucoma
medications

Mechanism of Action

Prostaglandin analogs

Reduction in hydraulic resistance
to uveoscleral outflow, Increase in
trabecular outflow facility

Beta blockers

Reduce aqueous humor production
by acting on the β1 and β2
receptors

Adrenergic agonists

Carbonic anhydrase
inhibitors

Increases elimination by reducing
episcleral venous pressure,
increasing uveoscleral outflow by
increasing prostaglandin synthesis
Inhibit the enzyme carbonic
anhydrase, reduce production of
aqueous humor
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FDA approved therapy
Xalatan® (latanoprost),
Lumigan® (bimatoprost),
Travatan Z® (travoprost),
Zioptan™ (tafluprost)
Timoptic® (timolol maleate
ophthalmic solution),
Betagan® (levobunolol
hydrochloride ophthalmic
solution
Alphagan®P (brimonidine),
Iopidine® (apraclonidine
hydrochloride, ophthalmic
solution)
Trusopt® (dorzolamide),
Azopt® (brinzolamide)

Cholinergic agents

Increases aqueous humor outflow
by contracting longitudinal fibers
in of the ciliary muscles

Isopto® Carpine (pilocarpine
hydrochloride ophthalmic
solution)98-99

Current glaucoma research is directed towards finding new lines of treatment pursuing
novel mechanisms for lowering of the IOP. The recent FDA approvals on anti-glaucoma agents,
Rhopressa (Netarsudil 0.02%), a rho-kinase inhibitor and Latanoprostene Bunod 0.024% (made of
two components, Latanoprost and a nitrogen oxide donating component) are examples of drug
products harnessing novel mechanisms of action for IOP reduction.99 There are several
investigational treatments such as a sustained release bimatoprost implant and ocular punctal plugs
of travoprost and latanoprost, however all these approaches focus on a formulation-based
approach.99 A completely new class of agents would bring forth another perspective for antiglaucoma medications.
Cannabinoids have been investigated for the past few decades for their IOP lowering
capacity. Cannabinoids utilize several unique mechanisms for IOP reduction. There are reports
suggesting that IOP reduction occurs due to decreased AH production, a result of curtailed release
of noradrenaline in ocular tissues.100 Δ9-Tetrahydrocannabinol (THC) is an example of a
cannabinoid that favors the opening of the endothelial-lined Schlemm’ s channels draining the
AH.100-105 Another suggested mechanism involves the CB1 receptors in IOP reduction. Human
ciliary bodies are rich in CB1 mRNA, and functional protein, supporting the hypothesis that
cannabinoids such as THC, through their action on CB1 receptors, may act directly as vasodilators
of the efferent blood vessels of the anterior uvea, favoring AH efflux.63,

106

Taking into

consideration the pathophysiology of glaucoma, along with increased IOP, there is also a
neurodegenerative component to the disease. Increased IOP produces early injury in glaucomatous
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optic atrophy resulting in structural changes in the lamina cribrosa, a membrane through which the
RGC axons pass before condensing to form the optic nerve.107-109 Moreover, overproduction of
free radicals, such as nitric oxide, results in an excessive release of glutamate, which, by activating
NMDA receptors results in apoptotic ganglionic cell death.110-112 Findings suggest that THC can
inhibit glutamic acid release by increasing K+ and decreasing Ca2+ permeability.111, 113-114 It also
exhibits antioxidant properties and prevents neuronal cell death by reactive oxygen species (ROS)
scavenging action.104, 115 Reportedly, in an animal glaucoma model, treatment with THC for 20
weeks decreased IOP and reduces death of RGCs by approximately 75%. 116 The neuroprotective
effect of THC on the RGC makes it one of the very few agents tackling not only IOP reduction but
also halting progressive vision loss.104, 117
Hepler and Frank reported about 25-30% drop in IOP after smoking marijuana, in a small
number of subjects with a duration of action of 3-4 hours.118-119 Crawford and Merritt in the late
1970’s conducted clinical studies to determine a relationship between changes in heart rate, blood
pressure, IOP in normotensive (n=8) and hypertensive volunteers (n=8) and also patients
diagnosed with open- angle glaucoma (n=16) and they observed decreased IOP (6-21mm of Hg
lower than control) along with intense cardiovascular effects.120 Overall, it has been observed that
smoking of marijuana is accompanied with a drop in both systolic pressure as well as IOP;
however, cardiovascular effects such as tachycardia and postural hypotension outweighs the IOP
lowering effects, giving rise to the need of investigating the effect of topical application THC on
lowering of IOP.119-120 Several reports can be found on the topical administration of THC
formulated in various oily vehicles.121-124 However, for THC to show both an IOP reducing and a
neuroprotective effect, it is important for it to permeate through initial layers of the eye, to the
target tissues.63, 125 Previously, a prodrug approach was devised aiming to improve the ocular
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bioavailability of THC.126 Adelli et al. evaluated the pharmacokinetic and pharmacodynamic
efficacy of a hydrophilic prodrug of THC, Δ9-Tetrahydrocannabinol-Valine-Hemisuccinate (THCVHS) in an elevated IOP model (Figure 8.). THC-VHS demonstrated a better permeation profile
in comparison to THC, penetrating to the IC and RC, and a corresponding IOP drop for about 180
minutes. 76, 86
A

B

Figure 8. Chemical structures of (A) Δ9-Tetrahydrocannabinol and (B) Δ9-Tetrahydrocannabinol
Valine Hemisuccinate (THC-VHS).
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To understand the IOP lowering mechanisms of THC-VHS in an intact eye with all the
production and drainage mechanisms unimpaired, a normotensive IOP model was opted for in the
current set of studies. The goals of this project were to formulate a lipid-based vehicle, SLNs, to
improve the delivery of the prodrug, THC-VHS, to the target tissues. SLNs have been reported to
enhance ocular bioavailability by prolonging the residence time of the formulation in the cul-desac, forming a lipid-based drug reservoir interacting with the ocular mucosa.127
The formulation was characterized in terms of drug content (% w/v), particle size (d. nm),
polydispersity index and scanning transmission electron microscopy (STEM). Stability of the
formulations in terms of particle size growth under different storage conditions was investigated.
A comparative PK-PD profile of the THC-VHS-SLN formulations was established post single and
multiple topical applications in a normotensive rabbit model. The PK-PD profile of THC-VHSSLN was compared to that of THC-VHS formulated in a soybean oil-based emulsion and THCSLN to delineate the effect of prodrug derivatization and the effect of vehicle in improving ocular
bioavailability. IOP lowering efficacy (PD profile) of the formulations were also compared against
marketed ophthalmic formulations of pilocarpine and timolol maleate in the same model (single
dose).
Materials
THC-VHS was synthesized by ElSohly Laboratories, Inc. according to previously established
protocols.128 Compritol® 888 ATO (glyceryl behenate) was obtained as a gift sample from
Gattefossé (Paramus, NJ, USA), glycerin was purchased from Acros Organics (NJ, USA),
Pluronic® F68 (poloxamer 188) was purchased from Spectrum Pharmaceuticals (Henderson, NV),
Tween™ 80 was received as a gift sample from Croda Inc. (Mill Hall, PA), Tocrisolve™ 100 was
purchased from Tocris® biosciences (Bristol, UK). HPLC - grade solvents, and other chemicals
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(analytical grade) were obtained from Fisher Scientific (Hampton, NH, USA). Amicon® Ultra
centrifugal filter devices, regenerated cellulose membrane (MWCO 100 kDa) were purchased
from EMD Millipore (Billerica, MA). Formalin was purchased from Thermo Scientific™. Timolol
maleate eye drops (0.25 % w/v) and pilocarpine HCl eye drops (2 %w/v) are commercially
available formulations obtained from The University of Mississippi, Health Center.
Animals
Male New Zealand White rabbits (2-2.5 kg), obtained from Harlan laboratories® (Indianapolis, IN)
were used in all studies. All animal experiments conformed to the Association for Research in
Vision and Ophthalmology statement, “Use of Animals in Ophthalmic and Vision Research” and
followed the University of Mississippi Institutional Animal Care and Use Committee approved
protocols.
Development of SLNs and Emulsion
THC-VHS-SLNs and THC-SLNs
THC-VHS or THC loaded SLNs were prepared by the ultra-sonication technique. Compritol® 888
ATO constituted the lipid phase of the SLNs. THC-VHS (equivalent to 0.6% of THC) and 0.6%
of THC was mixed with Compritol® 888 ATO to obtain a clear lipid phase. The aqueous phase
comprising of Pluronic® F-68 (0.25% w/v), Tween™ 80 (0.75% w/v) and glycerin (2.25% w/v)
was simultaneously heated in bi-distilled water. The hot aqueous phase was added to the melted
lipid phase under constant stirring. A coarse emulsion from this pre-mix was formed by
emulsification at 11,000 rpm for 5 min using T 25 digital Ultra-Turrax™. This coarse emulsion
was subjected to ultrasonification using SONICS® Vibra-Cell™ Ultrasonic Liquid Processor using
previously optimized parameters (Amplitude: 40%; Pulse on: 10 seconds, Pulse off: 15 seconds;
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Time: 10 minutes). The temperature during this entire process was maintained at 70°C. The hot
emulsion was slowly cooled to room temperature to form THC-VHS or THC SLNs.
THC-VHS and THC emulsion
THC-VHS and THC emulsion were prepared by dispersing weighed amount of THC (0.6% w/v)
or THC-VHS (0.98% w/v, equivalent to 0.6% w/v THC) in the Tocrisolve™ emulsion vehicle
(THC-TOC and THC-VHS-TOC), a soya-bean oil emulsion composed of a 1:4 ratio of soya
oil/water, purchased from Tocris Bioscience. Tocrisolve™ is a water-soluble emulsion used for
formulating hydrophobic moieties such as cannabinoids. The soybean oil solubilizes the
cannabinoid molecule and the emulsion is stabilized by the block co-polymer, Pluronic-F68,
preventing the lipid droplets from coalescing in the dispersion. This mixture was vortexed for 5
minutes on Ultra Cylone™ and sonicated for 10 minutes.
Formulation Characterization
Drug content
To determine the drug content in the SLNs and the emulsion, the lipid/oil was precipitated using
ethanol. An accurately measured volume of the formulation was extracted in 1 mL ethanol and
this suspension was centrifuged at 13,000 rpm for 15 minutes. The drug content in the supernatant
was analyzed using the following HPLC-UV method.
In-vitro sample analysis
The samples were analyzed for THC and THC-VHS using an HPLC-UV system comprising a
Waters 717 plus Autosampler, Waters 600E pump controller, Waters 2487 dual λ Absorbance
detector and an Agilent 3395 integrator. Stock solutions of THC-VHS and THC were prepared in
acetonitrile and used immediately. A mobile phase consisting of 60: 40 Acetonitrile: Water with
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0.1% glacial acetic acid was used on a Phenomenex® C18 (4.6 x 250 mm) column at a flow rate
of 1 mL/min. Detection was carried out at 226 nm.
Particle size, Polydispersity Index (PDI), Zeta Potential
The mean particle size and the PDI of the THC-VHS-SLN, THC-SLN, and THC-VHS-TOC
formulations were determined by Dynamic Light Scattering (DLS) technique using the Zetasizer
Nano ZS Zen3600 (Malvern Instruments, Inc.) at 25°C and 173° detection optics using the NonInvasive-Back-Scatter technology. The cells used were disposable folded capillary clear cells. The
measurements were obtained using a helium-neon laser of 633 nm, and the particle-size analysis
data was evaluated using intensity distributions. Zeta potential was measured at 25°C in folded
capillary cells using the same instrument. To measure the particle size distribution, the samples
were diluted (1:500) with bidistilled water filtered using 0.2-micron filters.
Scanning transmission electron microscopy studies
A negative staining procedure was used to conduct the STEM studies. THC-VHS-SLNs were
characterized by scanning transmission electron microscope Zeiss Auriga®-40 dual beam using
1%w/v uranyl acetate as a stain. Twenty microliters of the sample was placed on a piece of
parafilm and a glow discharged 200 mesh copper grid with a thin carbon film was floated on top
of the sample (film side down) for 30 seconds. After taking the grid off the drop, excess sample
was blotted using a piece of filter paper. The grid was then floated on a drop of distilled water for
a couple of seconds. Once excess water was removed, the grid, sample side down was floated on
a drop of 1% uranyl acetate for 1 minute. After blotting and drying, the samples were imaged in a
Zeiss Libra operating at 30 kV and in STEM mode.
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Physical and Chemical Stability
THC-VHS-SLNs were evaluated for changes in % drug content, particle size and PDI on storage
at conditions of 40°C/60% RH, 25°C/75% RH and 4°C.
Corneal Histology
Six NZW rabbits were used for comparison of corneal histology after treatment with PlaceboSLNs or with IPBS as control (n=3). The placebo-SLNs were topically administered to the eye of
normotensive New Zealand White rabbits to observe the effect of the vehicle on the histological
characteristics of the cornea. Rabbit corneas dosed with IPBS, under similar experimental
conditions, were used as controls. The study was conducted for 120 minutes, after which the
animals were euthanized, and the corneas were excised. Extracted corneas were fixed in 10%
Neutral Buffered Formalin. Histological evaluation was carried out at Excalibur Pathology Inc.
(Oklahoma City, OK) as per previously reported protocols. Corneas embedded in paraffin were
sliced into 5μm cross sections using a microtome (American Optical® 820 Rotary Microtome).
These sections were placed on a slide and dried overnight in an oven at 68 °C. The slide was
washed with xylene to remove paraffin and washed with alcohol and water to hydrate the tissue.
This was then stained with nuclear dye Gill III hematoxylin (StatLab medical) for 10 min and
rinsed, and then counterstained with eosin. These slides were then washed in reverse manner
(running water, alcohol, and xylene), cover slipped and examined under microscope
(ChromaVision ACIS II).
Efficacy studies
Multiple Dose studies
The rabbits were acclimatized to the environment, personnel and IOP measurements using a TonoPen Vet™ (Reichert® Technologies) for a period of 2-3 weeks. The formulations THC-VHS-
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SLNs, THC-VHS-TOC, THC-SLNs were dosed topically, conforming to a predetermined multiple
dosing protocol in eighteen NZW rabbits (n=6). Fifty microliters of SLNs or nanoemulsion (in
Tocrisolve™), was instilled topically in the cul-de sac of the left eye of normotensive rabbits, twice
a day, for five consecutive days. The right eye served as the control. To avoid spillage, the eyelid
was closed for 10 seconds. On Day 1, for the single dose IOP-Time profiling, IOP was measured
before (baseline IOP), and, every 30 minutes after administration until IOP returned to 90 % of the
baseline. From Day 2 onwards the IOP was measured before (baseline) and 60-90 min after
administration of the dose. The IOP value displayed by the TONO-PEN VET™ (Reichert, Inc.)
was an average of five concurrent IOP measurements, and each time point was measured in
triplicates. The decrease in IOP was recorded as a function of single dose and multiple dosing, i.e.
an intra-day as well as an inter-day IOP trend was monitored. On Day 5, IOP-Time profiling was
done similar to Day 1. On Day 6, the animals were sacrificed at two time points, the first time
point, which showed the lowest drop in IOP on day 5, and the second time point right before the
IOP returned to 90% IOP from the baseline.
Eye Dissection and Tissue collection
At the time points mentioned before, the rabbits were administered Ketamine (35 mg/kg) and
Xylazine (3.5 mg/kg) intramuscularly and euthanized under anesthesia with an overdose of
pentobarbital administered through the marginal ear vein. The eyes were immediately enucleated
after washing with ice-cold IPBS. Enucleated eyeballs were then dissected and the AH, VH, IC
and RC tissues were collected. All samples were weighed and stored at −80°C until further
processing.
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Bioanalytical methods for quantification
An AB Sciex QTrap 4500 (Framingham, MA, USA) LC-MS/MS quadrupole interfaced with
Shimadzu Nexera HPLC (Kyoto, Japan) was used to analyze both the THC and THC-VHS content.
Calibration curves were prepared by spiking THC and THC-VHS into blank ocular tissues along
with the internal standard, D3-THC. The tissues analyzed were AH, VH, IC, RC and plasma (PL).
Protein precipitation took place after addition of ice-cold acetonitrile followed by extraction of
THC and THC-VHS. The samples were vortexed and then centrifuged at 13,000 rpm, for 30
minutes. The supernatant was filtered through a 0.2-µm filter, and the filtrate was analyzed for
THC and THC-VHS content. The calibration curves were prepared with both THC and THC-VHS
in AH (2.5–100 ng/ml), VH (2.5–100 ng/ml), IC (2.5–100 ng/ml), RC (2.5–100 ng/ml), and plasma
(2.5–100 ng/ml). Tissues collected from the multiple dosing studies were also prepared per this
protocol. A Phenomenex Synergi Hydro Reverse Phase, 100 A, 50 x 3 mm, 2.5-µm column was
used with a gradient elution method; the solvent phase was composed of water and acetonitrile
with 0.1% w/v formic acid.
Single Dose studies
Single dose IOP-lowering efficacy studies were conducted with the marketed ophthalmic
formulations of timolol maleate (0.25 % w/v) and pilocarpine HCl (2 %w/v) in NZW rabbits (n=4).
Fifty microliters of each test formulation were instilled into the lower cul de sac of the left eye of
the rabbits, while the right eye acted as the control. The eyelids were closed after the instillation
for 10 seconds to avoid spillage. IOP was measured before instillation (baseline IOP) and every
30 min post instillation until the IOP returned to 90% of baseline IOP. The drop in IOP was also
expressed as ΔIOP or percent baseline IOP (± SEM) i.e. (measured IOP/baseline IOP) x 100.
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Statistical Analysis
To assess the effect of formulation on change in IOP over time a repeated measures model was
used. Between and within group differences were modeled using the proc mixed procedure in SAS
with treatment, time and interaction of treatment and time as independent factors in the model. A
two-tailed p-value of ≤ 0.05 was considered statistically significant. Data analysis was conducted
using Statistical Analysis System 9.4 software (SAS Institute; Cary, NC). Furthermore, using
JMP® 12 (SAS Institute, NC, USA) data analyses software, a Standard Least Squares personality
was used to fit the time-based IOP-drop from the baseline IOP for each of the formulations to
study the comparative IOP trend across treated and untreated eyes. A p-value of less than 0.05 was
considered statistically significant.
Results
Formulation characterization
A detailed description of the compositions of these formulations has been listed in Table 6.
The homogenization-ultrasonification process yielded SLNs with hydrodynamic radii less than
300 d. nm and a narrow distribution range. However, their particle size was slightly greater than
that of Tocrisolve™ emulsion. Tocris Bioscience reports the mean droplet size of the emulsion as
182 nm and our investigated values for THC-VHS-TOC particle size fall along similar lines
(189.75 ± 22.7 d. nm). Physicochemical properties of the test formulations have been listed in
Table 7. A consistent negative zeta potential was observed in all the formulations. That, along with
a narrow PDI suggests no aggregation/ coalescence of the nano-colloidal formulations.
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Table 6. Optimized composition of THC-VHS-SLN, THC-VHS-TOC and THC-SLN
formulations
Content (% w/v)
Ingredients

THC-VHS-SLN

THC-VHS-TOC

THC-SLN

Compritol

3

-

3

Glycerin

2.25

-

2.25

Poloxamer 188

0.25

-

0.25

THC

-

-

0.6

0.98

0.98

-

Tocrisolve™ emulsion

-

Q.S

-

Tween 80

0.75

-

0.75

Water, HPLC grade

Q.S

-

Q.S

THC-VHS (0.6% THC equivalent)

Table 7. Particle size (d. nm), polydispersity index (PDI), zeta potential (mV) and drug content
(%w/v) of test formulations THC-VHS-SLN, THC-VHS-TOC and THC-SLN
Particle size (d. nm) Polydispersity Index (PDI) Drug content (% w/v)
Formulation
(± Std. deviation)

(± Std. deviation)

(± Std. deviation)

THC-VHS-SLN

287.80 ± 7.35

0.29 ± 0.01

93.57 ± 4.68

THC-VHS-TOC

189.75 ± 22.7

0.15 ± 0.06

87.74 ± 3.6

THC-SLN

269.2 ± 5.66

0.32 ± 0.15

96.84 ± 0.02
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Scanning transmission electron microscopy studies
Morphological characteristics of THC-VHS-SLNs were studied using STEM (Figure.9). STEM
technique images samples based on absorption of an electron beam as it passes through ultra-thin
layer of sample. The transmitted beam is then projected on a phosphorescent screen or detector,
providing us with information regarding the morphological characteristics of the particles as well
as the hydrodynamic radius. The electron microscopy pictures at different magnifications (Figure.
9) show the presence of spherical nanoparticles with a smooth well-defined periphery.
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Figure 9. STEM images of THC-VHSSLN at A. 92.29 KX and B. 209.82 KX magnification

49

Physical and Chemical Stability
The particle size and polydispersity index of THC-VHS-SLNs was observed for 6 months at
40°C/60% RH, 25°C/75% RH and 4°C. The formulations were stable over a period of six months
at both 4°C and 25°C with particle size remaining around 200 to 300 d.nm and a PDI of 0.3

129

(Figure 10.). However, after 1 month at 40°C, a 95% increase in particle size was observed from
the original diameter of 248.9 nm and a PDI of 0.4. In terms of drug content, the THC-VHS-SLN
was stable with a change in % drug content of ± 1.5% when stored at 4°C and 25°C over a period
of 23 days (the last timepoint checked).

Figure 10. Particle size and polydispersity index of THC-VHS-SLNs stored at conditions of
40°C/60% RH, 25°C/75% RH and 4°C over a period of six months.
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Corneal Histology
To observe the effect of formulation on the corneal histology, cross-sections of rabbit corneas
treated with placebo-SLNs (Figure 11. A, B, C) and IPBS (control) were studied (Figure 11. D, E,
F). The cornea is composed of five membranes; the corneal stratified squamous epithelium (1),
Bowman’s membrane (2), stroma consisting of collagen fibers and keratocytes (3), Descemet’s
membrane (4) and the endothelium (5), as marked in Figure 11. A. The corneal epithelium of all
the rabbits, treated with control or placebo-SLNs looked intact, and attached to the Bowman’s
membrane, without any signs of edema.

Figure 11. Histological sections of rabbit corneas (Magnification 10x) excised from NZW rabbits
(n=3) treated with placebo-SLNs (A, B, C) and IPBS (control) (D, E, F) 120 minutes after
application

51

Efficacy studies
Multiple dosing regimen for THC-VHS-SLN
It has been previously reported that THC fails to lower IOP of normotensive rabbits. The data
obtained on normotensive rabbits for studies with THC-VHS-SLN formulations show a significant
IOP lowering effect by THC-VHS when formulated in SLNs. Figure 12 depicts the 5-day mean
IOP vs Time profile for treated eye after dosing with THC-VHS-SLN over the five-day dosing
regimen in comparison to the contralateral eye IOP (untreated eye). IOP of the treated eye was
significantly lower than the untreated eye from the 30 minutes time-point, and this effect lasted
until 360 minutes.

Figure 12. Mean IOP vs time profile for treated (blue line) and untreated (red line) eyes in
normotensive rabbits (n=6) dosed with 50 µL of 0.98 % THC-VHS-SLN twice a day for five
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consecutive days. The line represents the mean of these data points at each time point (± SEM).
The IOP profile of the Treated vs contralateral rabbit eyes were compared using proc mixed
repeated measures model. The p-values for treated vs untreated eyes are also listed.

Multiple dosing regimen for THC-VHS-TOC
The THC-VHS-TOC emulsion formulation did not have a significant effect on the IOP of
normotensive rabbits. The 5-day mean IOP vs Time profile for the eye treated with THC-VHS
TOC in comparison to the contralateral eye is shown in Figure 13. The IOP drop in the treated eye
lasts for about 90 minutes with IOP significantly lower than the contalateral eye at the 30, 60 and
90 minute time points.
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Figure 13. Mean IOP vs time profile for treated (blue line) and untreated (red line) eyes in
normotensive rabbits (n=6) dosed with 50 µL of 0.98 % THC-VHS-TOC twice a day for five
consecutive days. The lines represent the mean of these data points at each time point (± SEM).
The IOP profile of the Treated vs contralateral rabbit eyes were compared using proc mixed
repeated measures model. The p-values for treated vs untreated eyes are listed in figure.

Multiple dosing regimen for THC-SLN
To elucidate the effect of prodrug derivatization, the efficacy of the THC-SLN formulations were
also tested. The mean 5-day IOP vs Time profile comparing the THC SLN treated and contralateral
eyes is shown in Figure. 14. The eyes receiving THC-SLNs did not show a significant drop in IOP
in comparison to the contralateral eye upto 90 minutes. However, at the 135 minute time-point the
IOP of the treated eye was significantly lower than the contralateral eye. After a period of 2.5
hours, at the 285 minute time-point, this effect was reversed and the contralateral eye showed
significantly lower IOP in comparison to the treated eye.
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Figure 14. Mean IOP vs time profile for treated (blue line) and contralateral (red line) eyes in
normotensive rabbits (n=6) dosed with 50 µL of 0.6% THC-SLNs twice a day for five consecutive
days. The line represents the mean of these data points at each time point (± SEM). The IOP
profiles of the Treated vs contralateral rabbit eyes were compared using proc mixed repeated
measures model. The p-values for treated vs untreated eyes are listed in the figure.

Figure 15. illustrates statistically significant within-group differences, comparing IOP for the same
treatment with baseline IOP (time-point 0), and between-group differences for different
formulations at various time points. The within-group differences for treatment THC-VHS-SLNs
the drop in IOP at time-points 60, 90, 120 and 180 minutes are significantly lower than baseline
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IOP (time-point 0 min) with p-values 0.011, <.0001, <.0001, 0.0021 respectively. A proc mixed
repeated measures model was used with a Tukey Kramer adjustment to assess these differences.
Other treatment formulations, THC-VHS-TOC and THC-SLNs do not show significantly lower
IOP in comparison to baseline IOP. Analyzing between group differences, THC-VHS-SLNs
demonstrated significantly lower IOP than THC-SLNs (p-value <.0001) and THC-VHS-TOC (pvalue 0.0019) at time-points 60 and 90 minutes and 90 minutes, respectively.

Figure 15. Comparative mean IOP vs time profiles for rabbits treated with 50 µL of 0.98 % THCVHS-SLN, 0.98 % THC-VHS-TOC or 0.6 % THC-SLNs (n=6) twice a day for five consecutive
days. The line represents the mean of these data points at each time point (± SEM). The rabbit eyes
receiving the different formulations were compared using proc mixed repeated measures model.
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Ocular Bioavailability
For THC-VHS-SLN, the maximum drop in the IOP from the baseline (ΔIOPmax) was 31% and
29.3 % on Day 1 and Day 5, respectively. The time to achieve ΔIOPmax, Tmax on Day 1 and Day 5
was 90 minutes and the duration of action for THC-VHS-SLN, or the time required for ΔIOP to
reach 90% of baseline IOP was 480 minutes on both Days 1 and 5. The two-sacrificial time-points,
determined based on the IOP data, were 90 and 360 minutes. Table 8. displays the concentration
of both THC-VHS and the parent molecule at the two-sacrificial time-points. At 90 minutes, THCVHS concentrations were 10.67 ± 2.28 ng/50 mg in AH and decreased to 3.84 ± 0.53 ng/50 mg at
360 minutes. In comparison to AH, higher levels of the prodrug were observed in the IC and RC
with 1466 ± 514.5 ng/50 mg and 902 ± 372 ng/50 mg observed at 90 minutes and 77.6 ± 69.5
ng/50 mg and 238.3 ± 143.3 ng/50 mg observed at the 360 minutes time points, respectively. At
360 minutes, 6.36 ± 3.83 ng/50 mg of bio-reversed THC was observed. Significant amounts of
drug permeated to the RC and IC tissues, both important from the point of view of neuroprotection
and IOP lowering and a corresponding IOP drop was observed as the pharmacodynamic response.
THC-VHS was not observed in the plasma even after multiple administration, which helps rule
out CNS involvement through systemic exposure.
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Table 8. Tissue concentrations (ng/50 mg) of THC-VHS and THC on Day 6, post instillation of
50 µL of 0.98 % THC-VHS-SLNs, at 90 minutes (n=3) & 360 minutes (n=3) in Aqueous Humor,
Vitreous Humor, Retina Choroid and Iris Ciliary Bodies. Dose equivalent to 300 µg THC.
ND: below limits of detection
ng / 50 mg

Formulation

THC
Standard
Mean
Error
ND
ND

Tissue
Analyzed

Time point
(min)

Aqueous Humor

90

10.7

2.3

360

3.8

0.5

ND

ND

90

ND

ND

ND

ND

360

ND

ND

ND

ND

90

1466

514.5

ND

ND

360

77.6

69.5

6.4

3.8

90

902

372

ND

ND

360

238.3

143.3

ND

ND

Vitreous Humor
THC-VHSSLN

THC-VHS
Standard
Mean
Error

Iris Ciliary
Bodies

Retina Choroid

For THC-VHS-TOC, the ΔIOPmax for Day 1 and Day 5 of dosing was 11.7 and 10.9% respectively
and the Tmax was 60 minutes. The sacrifice time-points thus determined for this formulation were
60 and 120 minutes. The ocular concentrations of THC-VHS obtained with the THC-VHS-TOC
formulation were significantly lower than those obtained with the THC-VHS SLN formulation
(Table 9).
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Table 9. Tissue concentrations (ng/ 50 mg) of THC-VHS and THC on Day 6, post administration
of 50 µL of 0.98 % THC-VHS-TOC, at 60 minutes (n=3) & 120 minutes (n=3) in Aqueous Humor,
Vitreous Humor, Retina Choroid and Iris Ciliary Bodies. Dose equivalent to 300 µg THC.
ND: below limits of detection
*Drug levels observed in a single animal only
ng / 50 mg

Formulation

THC-VHSTOC

THC-VHS
Standard
Mean
Error

THC
Standard
Mean
Error
ND
ND

Tissue
Analyzed

Time point
(min)

Aqueous Humor

60

91.2

1.85

120

ND

ND

ND

ND

60

ND

ND

ND

ND

120

ND

ND

ND

ND

60

24.2

5.06
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28.9

120

11.3

0.50

57.4

18.5

60

15.5

6.70

5.2

0.2

120

7.5*

NA

5.3^

NA

Vitreous Humor
Iris Ciliary
Bodies
Retina Choroid

Consistent with the previously reported data, THC did not produce as intense or as prolonged an
IOP drop from baseline IOP in comparison to the THC-VHS formulations 86. A 6.9% drop in IOP
in comparison to the baseline IOP was observed with THC-SLNs at 60 minutes on Day 5. Animals
were sacrificed at two time points on Day 6 at 60 and 120 minutes (Table 10). THC levels of 12.53
± 3.51 ng/50 mg and 9.87 ± 3.22 ng/50 mg were observed in the IC at 60 and 120 minutes,
respectively.
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Table 10. Tissue concentrations (ng/ 50 mg) of THC on Day 6, post administration of 50 µL of 0.6
% THC-SLN, at 60 minutes (n=3) & 120 minutes (n=3) in Aqueous Humor, Vitreous Humor,
Retina Choroid and Iris Ciliary Bodies. Dose equivalent to 300 µg THC.
ND: below limits of detection
ng / 50 mg THC
Formulation

Tissue Analyzed

Time point
(min)

Mean

Standard Error

Aqueous Humor

60

ND

ND

120

ND

ND

60

ND

ND

120

ND

ND

60

12.5

3.5

120
60

9.9
ND

3.2
ND

120

ND

ND

Vitreous Humor
THC-SLN
Iris Ciliary Bodies

Retina Choroid

Single dose efficacy studies
Pilocarpine HCl (2 %w/v) exhibited a ΔIOPmax of 15.9% at 30 minutes and its IOP lowering effect
lasted for 120 minutes (Fig. 16). The graphs represent %IOP drop from the baseline IOP. Timolol
maleate (0.25 % w/v) resulted in a more intense ΔIOPmax of 23.1% at 60 minutes with duration of
action of 180 minutes for the IOP to reach 90% of the baseline IOP. THC-TOC emulsion or the
placebo-SLNs did not result in any reduction in IOP (Data not shown). The IOP vs Time profiles
of the marketed preparations are compared to that of the THC-VHS-SLNs, THC-VHS-TOC and
THC-SLNs in Figure 16.
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Figure 16. Percent IOP change from baseline vs Time profile for THC-VHS-SLN, THC-VHSTOC and THC-SLN and 2% pilocarpine, 0.25% timolol maleate marketed formulations. A single
drop (50 µL) was instilled. Data represents mean ± SE.

Discussion
In 1977, Green et al. reported a seventeen percent drop in the IOP, sixty minutes post dosing, using
light mineral oil as the vehicle in adult albino rabbits. The tissue concentrations obtained were
extremely low, about one ng of 14C-labelled THC/ mg of wet tissue weight four hours post dosing
in the cornea and IC.
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Hingorani et al. observed that the amount of THC permeating into the

ocular tissues was below levels of detection in rabbit AH, VH, RC and IC, one hour post
administration of THC in light mineral oil (0.1% w/v), emulsion (0.37% w/v) or micellar solutions
(0.125 % w/v THC, 0.5% Cremophor RH 40) in New Zealand White rabbits with detectable levels
only in the cornea and sclera. 131 Such findings suggest that the lipophilic nature of THC prevents
its partitioning from the oily vehicle into the tear film, in turn affecting its overall ocular
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bioavailability. THC has poor aqueous solubility (1–2 µg/mL) and high log P (6.42), which makes
the development of an eye drop for the molecule challenging. The lack of activity through the
topical route of application, as observed in the above-mentioned reports, could be due to the
ineffective delivery of THC to the target ocular tissues rather than absence of local
pharmacological activity. Delivery of a therapeutic agent to the deeper ocular tissues depends on
the type of formulation, physicochemical properties of the molecule and absorption pathway.17
These properties determine the permeation profile of the molecule across alternating lipophilic and
hydrophilic tissue layers and through the corneal tight junctions. For targeting a molecule to the
back-of-the eye, it should possess optimum physicochemical properties and be formulated in
appropriate dosage forms.132
To improve the intrinsic solubility of THC, a prodrug strategy was employed by Hingorani
et al. by using a hemiglutarate (dicarboxylic acid) ester (THC-HG), which, being ionized at
physiological pH would have better aqueous solubility (19 µg/mL).

131, 133

One hour post

instillation of 50 μL of THC-HG, formulated in 0.5% w/v Cremophor RH 40, 35.6 ± 12.5 ng of
THC /50 mg of tissue was observed in the IC and 32.1 ± 12.6 ng of THC / 100 μL was detected in
AH of New Zealand White rabbits, whereas, the THC tissue concentrations obtained post dosing
of 50 μL THC formulated in 0.5% w/v Cremophor RH 40 were below detection levels. This finding
suggested that hydrophilic prodrug derivatization is an efficient method to improve the ocular
bioavailability of THC.131 However, in terms of chemical stability, THC-HG was extremely
unstable and underwent rapid degradation at acidic and alkaline pH conditions, as well as at
physiological pH. 133-134
In subsequent studies, THC-VHS was designed as an amino acid- dicarboxylic acid
prodrug, the amide linkage enhancing its stability. In terms of the physicochemical properties,
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THC-VHS is stable from pH 5 to pH 9.128 Adelli et al. observed the efficacy of THC-VHS in a
soybean oil-based emulsion in an elevated IOP-glaucoma model. THC-VHS demonstrated an IOP
drop comparable to the marketed ophthalmic solution of 2% Pilocarpine HCl.76, 86 However, the
IOP vs time profile indicated that frequent dosing would be necessary. Thus, developing a
formulation strategy that could increase the amount of THC-VHS that could enhance the
bioavailability as well as retention of the therapeutic agent at the ocular surface would be desirable.
Post topical application, a molecule has to overcome significant barriers, such as vascular
and lymphatic drainage in the conjunctiva, sclera and choroid, restricting its passage from the
ocular surface to posterior ocular tissues. 135 SLNs enhance ocular bioavailability of poorly soluble
compounds by acting as unit carriers of the target molecules and prolonging its residence time in
the cul-de-sac and forming a lipid-based drug reservoir that interacts with the ocular mucosa.127,
132, 136-137

SLNs, being solid at room temperature have a modulated drug release profile in

comparison to a liquid based-formulation.138 Punyamurthula et al. demonstrated enhanced delivery
of Δ8 THC-SLNs to all ocular tissues attributed to the probable uptake of the SLNs by the
conjunctival and corneal membranes - resulting in sustained release of the drug.127
However, in order to develop a SLN formulation of THC-VHS, thermal stability of the
prodrug would play an important role during formulation development. Both molecules, THC and
THC-VHS, are amorphous with absence of a definite crystal lattice structure making them
susceptible to atmospheric degradation.134, 139 THC undergoes rapid thermo-oxidative degradation
into its metabolite cannabinol. The use of polymeric stabilizers and cross-linked matrices can be
considered as a way of controlling the oxidative degradation of amorphous molecules such as
THC.139-141 Compritol 888 ATO is a crystalline amphiphilic material with a melting point of about
70°C. The crystalline structure of the bulk lipid can form protective barriers increasing the storage
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stability of the formulation. 142 The high solubility of THC and THC-VHS in Compritol 888 ATO,
along with the stabilizing effect provided by the crystalline lipid make it a good choice of lipid for
development of the SLN formulation. Previous reports show that THC-VHS shows only about 3
% degradation of drug when heated at 120°C for 10 minutes.128 Taking into consideration this
along with the melting point of Compritol® 888 ATO, a temperature of 70°C was chosen to
formulate the SLNs.
The physicochemical data suggests that a structured lipid phase comprising of Compritol®
888 ATO (stabilized by a Poloxamer 188 - Tween 80 surfactant system) resulted in a stable nanoparticulate system. The data obtained from the STEM indicates that the size of the well-rounded
nanoparticles is slightly greater than 200 nm, also consistent with the results obtained from DLS.
In case of multimodal data, particle size may not agree across different measurement techniques,
however, for a monodisperse formulation the particle size data might be comparable.143
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Introduction of any form of energy such as temperature to the nanoparticulate system can lead to
particle growth and subsequent gelation145. The increase in the particle size at the storage condition
of 40°C/60% RH can be attributed to increase in the entropy of the system because of the high
temperature, resulting in coalescence of the SLNs and a corresponding particle size growth. At the
six-month time point, complete gelation of the SLN formulation was observed (Figure 10.).
Histological analysis of the rabbit corneas treated with the SLNs helps understand the
toxicity profile of the SLNs; edema results into separation of structural elements and accumulation
of edematous fluid in the stroma results into empty spaces formed between keratocytes and corneal
collagen fibers.146 Figure 12. (D, E, F), corneas treated with control, portray a more generalized
and widespread edema with detachment of Descemet’s membrane. We also observe structurally
disturbed collagen bonds in areas close to the Descemet membrane invagination. However, taking
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into consideration the exclusivity of this event, the damage to this cornea can be attributed to
mechanical stress during the enucleation and the fixing of the cornea. Figure 12. (A, B, C), for
corneas treated with Placebo-SLNs, the stroma is present as even layers with signs of edema
ranging from slight to none.
Topical THC-VHS-SLNs produced a prolonged and intense drop in the IOP in
normotensive rabbits in comparison to the THC-VHS-TOC as well as THC-SLNs. THC-VHSSLNs lowered the IOP of the treated eye in comparison to the untreated eye and maintained IOP
below baseline until 360 minutes. In comparison, rabbit eyes treated with THC-VHS-TOC
produced a significant drop in IOP in comparison to the untreated eye at 30, 60 and 90 minutes
only. Comparing the p-values for differences in the IOP for treated and untreated eyes, the IOP
drop produced by THC-VHS-TOC was not as significant as THC-VHS-SLN. SLNs, being
colloidal carriers have advantages of better penetration, stability, drug loading and sustained
release of the drug.147 The large surface area provided by the nanoparticulate system increased the
contact area, ensuring close contact with the ocular mucosa after instillation. Lipid based
nanoparticles have an occlusive effect and forms a depot in the cul de sac, slowly releasing the
drug over prolonged duration of time.148-149 The additives present in the formulations, such as
surfactants, also play a role in permeation enhancement via fluidization of the lipid bilayers of the
ocular membranes.150
The THC-SLN treated eyes showed a statistically significant lower IOP in comparison to
the untreated eyes at the 135 minutes time point only. Based on the IOP data, THC-VHS was
effectively delivered to the target tissues within the first 30 minutes from both the SLN and
emulsion-based formulations, whereas the parent molecule required about 2 hours to demonstrate
a pharmacodynamic response.
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The pharmacokinetic data suggests that the SLN formulations deliver an almost 60 times
greater concentration of THC-VHS in the IC in comparison to the emulsion formulation. THC
levels in the ocular tissues from the THC-VHS-SLN formulations were extremely low (below
detection levels in most cases) in comparison to that obtained from the THC-VHS-TOC or THCSLN formulations. However, the duration of IOP drop observed with the THC-VHS-SLNs was
significantly more prolonged. A possible explanation for this disconnect between the
pharmacokinetic and pharmacodynamic observations could be that the site of action might not be
the IC. It could also be possible that the prodrug being more permeable could be distributing deeper
into the tissues better than THC (administered as such or THC generated from THC-VHS). As a
result, a correlation between the prodrug concentration, rather than THC concentration, and IOP
lowering effect is observed. The lack of a pharmacodynamic response even though the ocular
tissues exhibited significant THC concentrations (with the THC-VHS-TOC and THC-SLN
formulations) could be because of THC forming a depot in the ocular tissues, rather than
penetrating and distributing across the ocular tissues (e.g. IC). As a result concentrations at the
site of action maybe low even though the overall tissue concentrations are high..104 The reason
why THC-VHS-TOC is not as effective as THC-VHS-SLN could be because the emulsion
formulation is not protecting the prodrug from bio-reversion (chemical or enzymatic) as a result
of which higher THC tissue concentrations are observed from THC-VHS-TOC, thus decreasing
the concentration deeper in the tissues. On the other hand, the SLN formulation protects against
bioreversion of THC-VHS to THC, as evidenced by the lack of detectable THC concentrations
from the THC-VHS-SLN formulations.
The overall tissue distribution profile indicates a non-corneal route of absorption. With
THC-VHS-SLN, we observe 1466 ± 514.50 ng/50 mg tissue of THC-VHS in the IC at 90 minutes.
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The prodrug concentrations dropped almost 20-fold at 360 minutes, which can be explained by
elimination and slow conversion into THC, which was also detected then. We also observe THCVHS partitioning into the RC, from both THC-VHS-TOC and THC-VHS-SLN formulations,
which is important for neuroprotective action. With THC-SLNs however, we observe THC levels
in the IC at both sacrifice time points, but THC fails to distribute itself across other tissues. The
preferential accumulation of THC in the IC could indicate binding of THC to an IC specific
protein.
The IOP lowering duration with THC-VHS-SLNs lasted almost twice as long as the
marketed formulations, 2.5% w/v pilocarpine or 0.2 % w/v timolol maleate. A combined effect of
prodrug derivatization and the dosage form can be attributed to this effect as the prodrug alone (in
an emulsion formulation) or the parent compound THC in an SLN formulation, were not effective.
The molecule design facilitated easy passage of the parent molecule across the ocular tissues and
the lipid-based nano-carrier system acted as a long acting depot, resulting in a formulation with
better pharmacokinetic and pharmacodynamic profile.
Conclusion
These studies suggest that formulation development efforts along with prodrug
derivatization can effectively improve overall ocular bioavailability. THC-VHS-SLNs were
successfully formulated and tested in a normotensive rabbit model. Results suggested that the
prodrug, THC-VHS has a better permeation profile than THC due to its modified structure. Solid
lipid nanoparticles are efficient in delivery of THC-VHS to the RC, important from the point of
view of neuroprotection. THC-VHS-SLNs, on multiple dosing were able to achieve an intense IOP
drop with its effect lasting for a longer duration than the marketed solutions of 2.5% w/v
pilocarpine HCl and 0.2% timolol maleate. Thus, THC-Val-HS has the potential of bringing forth
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cannabinoids as another line of therapy as anti-glaucoma agents at par with the anti-cholinergic,
beta-blockers and carbonic anhydrase inhibitors, with the added advantage of its neuroprotective
activity
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CHAPTER 4
TRIAMCINOLONE ACETONIDE-NLCS FOR OCULAR DELIVERY:
EFFECT OF CHITOSAN AND CHITOSAN DERIVATIVE
Introduction
Corticosteroids have been used for the treatment of ocular inflammation since the past few
decades. Triamcinolone Acetonide (TA) is a corticosteroid administered intravitreally for the
management of ocular inflammatory conditions such as diabetic retinopathy, cystoid macular
edema, and choroidal neovascularization 151-152. The use of TA has been prevalent in conditions of
posterior uveitis to reduce intraocular inflammation and extravasation of blood vessels. Currently,
the marketed products for ophthalmic use (e.g. Kenalog®, Tricinolon®, Flutex® and Kenacort®) are
intravitreally administered ophthalmic suspensions containing TA

151, 153

. However, intravitreal

injections are often associated with defects such as intraocular pressure elevation, retinal
detachment,

cataract

formation,

subconjunctival

bleeding,

vitreous

hemorrhage

and

endopthalmitis. In addition, repeated administration of corticosteroid intravitreal injections results
in lower patient compliance in comparison to a sustained release device therapy and implants 154155

. Chemically, TA is a lipophilic molecule and has a Log P of 2.5 (Figure 17.), making it an

unfavorable candidate for back of the eye delivery via topical administration. There arises a need
for the development of a novel formulation of TA dosed topically, designed to achieve drug levels
at the back of the eye.

69

Figure.17. Chemical structure of Triamcinolone Acetonide

Bioavailability can be enhanced by modification of physicochemical properties of the drug by
attaching a promoiety, formation of ion-pairs, use of permeation enhancers or by formulation
approaches aiming at increasing the pre-corneal residence time 76, 86, 156-157. In the past few years,
research focus on the use of colloidal nanoparticulate systems as a promising ocular drug delivery
platform has increased 137-138, 158. Lipid based colloidal nanocarriers such as SLNs and NLCs are
nanoparticulate systems efficient in targeted and controlled delivery of lipophilic drugs 159. These
nanoparticulate carriers may demonstrate superior ocular bioavailability of the encapsulated
therapeutic agent because of improved retention in the cul-de-sac resulting in sustained release for
prolonged duration of time. 97
Chitosan (CH) is a biodegradable polymer known to interact with the mucin protein and extend
retention time of the formulation.160-162 It also behaves as mucoadhesive, increasing the contact
time with the membrane and acts as an absorption enhancer across biological membranes. It helps
in opening of the tight junctions between the epithelial cells enhancing transport of molecules.160-
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161, 163-164

The predicted mechanism for this absorption enhancement is interaction of the positively

charged amino groups on the C-2 position of chitosan with the negatively charged sites on the cell
membranes 160-161, 163, 165-166. Protonated chitosan is also known to interact with the glycoproteins
of the mucous membrane covering the cornea and with the lipid bilayer of the corneal cell
membrane resulting in permeability enhancement. The pKa value of chitosan is between 5.5 and
6.5 and thus is insoluble at physiological pH, losing its positive charge

166-167

. Derivatization of

chitosan to its quarternized form, tri-methyl chitosan (TMC) is an effort in solubilizing chitosan at
all pH ranges 168. TMC has been known to interact with the epithelial cell monolayers by the same
mechanism as chitosan 164. The use of permeation enhancers such as TMC and CH as nanoparticle
surface modifiers may further improve the retention of the nanoparticles on the epithelial surface
and increase cellular uptake of the nanoparticles. 162, 166
This research aims at optimizing a colloidal formulation for the topical delivery of TA. The studies
also investigate the effect of CH and TMC on the permeation characteristics of TA. Primarily,
TMC was synthesized using previously reported protocols from deacetylated CH 169. Lipid based
nanoparticles of TA were formulated selecting a combination of solid and liquid lipids. The
rationale behind selection of lipid-based nanoparticles, NLCs, was development of a topically
dosed nano-colloidal based depot system sustaining the release of TA, thus reducing the overall
frequency of administration. Transcorneal permeation of 0.1% TA encapsulated in CH and TMC
nanoparticles was compared to that of the optimized TA-NLC system, 0.1% w/v TA-Randomly
methylated β cyclodextrin (RMβCD) solution (TA-SOL). In addition, the effect of surface
modification of NLCs using polymers CH and TA was evaluated; a 0.25% CH and 0.25% TMC
surface modified TA-NLC system was evaluated for the precorneal retention and overall ocular
bioavailability of TA.
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Materials and methods
Materials
TA and sodium tripolyphosphate (TPP) was procured from Alfa Aesar™, Chitosan chloride (CHCl) < 200 kDa was received from Novamatrix (Philadelphia, PA, USA), Trimethyl Chitosan
Chloride was synthesized using method detailed in the following section. Precirol® 888 ATO
(glyceryl behenate) was obtained as a gift sample from Gattefossé (Paramus, NJ, USA), Glycerin
was purchased from Acros Organics (NJ, USA), Pluronic® F68 (Poloxamer 188) was purchased
from Spectrum Pharmaceuticals (Henderson, NV). Castor oil and Tween® 80 were purchased from
Acros Organics (NJ, USA). HPLC - grade solvents, and other chemicals (analytical grade) were
obtained from Fisher Scientific (Hampton, NH, USA). Amicon® Ultra centrifugal filter devices,
regenerated cellulose membrane (MWCO 100 kDa) were purchased from EMD Millipore
(Billerica, MA). Corneas for the transcorneal studies were purchased from Pel Freez, AK.
Animals
Male New Zealand White rabbits (2-2.5 kg), obtained from Harlan laboratories® (Indianapolis, IN)
were used in all studies. All animal experiments conformed to the Association for Research in
Vision and Ophthalmology statement, “Use of Animals in Ophthalmic and Vision Research” and
followed the University of Mississippi Institutional Animal Care and Use Committee approved
protocols.
Methods
Synthesis of Trimethyl chitosan chloride
To prepare TMC, a two-step synthesis described by Sieval et al. was employed. 169 Initially, 2g of
91% deacetylated chitosan, 4.8 g sodium iodide, 11 mL of 15% aqueous sodium hydroxide
solution and 11.5 mL of methyl iodide was added to 80 mL of 1- methyl-2-pyrrolidinone. This
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mixture was stirred on a water bath at 60°C for 1 hour. The product, N-methyl chitosan iodide,
obtained hereby was precipitated using ethanol and further centrifuged for isolation. To completely
remove the ethanol post centrifugation, the product was subjected to multiple washings with ether.
The substance thus obtained was dissolved in 80 mL of 1-methyl-2-pyrrolidinone and heated to
60°C. 5.4 g of sodium iodide, 11 mL of 15% NaOH solution and 9 mL of methyl iodide was added,
the reaction mixture heated on a water bath with the temperature maintained at 60°C for 30 min.
The product obtained was dissolved in 40 mL of 10% NaCl solution. 1H NMR were measured in
D2O at 400MHz.
The degree of quaternization (DQ) and the degree of dimethylation (DM) were calculated by using
the following equations:
DQ = [(CH3)3]/[H]*1/9] * 100
DM= [(CH3)2]/[H]*1/6] * 100
Saturation solubility studies
Solubility of TA was studied in IPBS at pH 7.4. Effect of addition of solubility enhancers such as
cyclodextrins; 5% HPβCD and 5% RMβCD was also evaluated. The experiment was conducted
by adding excess amount of TA to centrifuge tubes containing 1 mL of the above-mentioned
solutions. To achieve uniform mixing, samples were shaken overnight at 100 rpm, 25°C in a
reciprocating water bath (Fisher Scientiﬁc). After 24hrs, the samples were centrifuged using the
AccuSpin 17R at 13,000 rpm for 30 minutes and the supernatant was analyzed for TA using HPLCUV analytical method.
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Synthesis of TA formulations
TA-SOL solution
TA-SOL solution was prepared by dissolving TA (0.1% w/v) in 2.5% w/v RMβCD solution
prepared in IPBS at pH 7.4. TA was added to the solution and the mixture was vortexed for 2-5
minutes and sonicated until a clear solution was obtained.
TA-NLCs
Lipid excipient screening study
The solubility of TA was observed in solid lipids; Compritol® 888 ATO with a melting point (MP)
of 70°C–72°C, Precirol® 888 ATO (MP: 56°C), Coco butter (MP: 34–38 °C), and Geleol™ Mono
and Diglycerides NF (MP: 54°C–64°C) and Gelucire® 50/13 was studied. Liquid lipids castor oil,
Miglyol 812, Oleic acid and Sesame oil were scanned similarly. The solid and liquid lipids were
heated to 80°C and TA (100 mg) was added to the heated lipids (100 mg) under constant magnetic
stirring at 2000 rpm. The different TA-lipid mixtures were then cooled and observed for
precipitation of the API. The lipids devoid of any precipitation were further selected for synthesis
of the NLCs.
Selection of a binary lipid phase
To determine the best solubilizing potential of the solid-lipid-liquid-lipid mixture, 100 mg of TA
was mixed with three different ratios, (i.e.; 2:3, 1:1, 3:2) of select solid and the liquid lipids, those
showing maximum solubilizing potential for TA in the solubility study. TA was added to the lipid
mixtures under magnetic stirring at 600-800 rpm at 80℃ for 30 minutes. The miscibility of the
binary lipid phase was observed by spreading the mixture on a glass slide followed by visual
observation. Mixtures which presented with least to no bleeding of the oil from the solid lipid were
selected from preparation of the NLCs.
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Preparation of TA-NLCs
TA-NLCs were prepared by an ultrasound sonication method using Vibra-Cell™ Ultrasonic Liquid
Processor, SONICS™. Based on lipid screening studies, Precirol® 888 ATO (glyceryl
palmitostearate) was the choice of solid lipid and castor oil was chosen to be the liquid lipid. The
aqueous phase composed of surfactants such as Poloxamer 188 (0.25% w/v), Tween® 80 (0.75%
w/v) and glycerin (2.25% w/v) in bidistilled water, was heated at 80 ± 2°C and added to the molten
lipid phase under stirring (2000 rpm) to form a coarse emulsion, the temperature during the entire
process maintained at 80 ± 2°C. The premix was then homogenized at 11,600 rpm for 10 mins
using T 25 digital Ultra-Turrax to form a pre-emulsion. This pre-emulsion was further subjected
to probe sonication resulting in further particle size reduction and formation of a hot nanoemulsion.
Further cooling resulted in the formation of TA-NLCs; a lipid based nanocolloidal suspension.
Preparation of TMC/CH surface modified NLCs
For the TMC/CH surface modification of TA-NLCs, TMC synthesized by the previously described
protocols and CH-Cl (mol. wt. < 200 kDa) were used. Accurately weighed amounts of TMC/CH
corresponding to 0.25% w/v were incorporated in the TA-NLC formulation once prepared and
cooled. These surface modified formulations were then stirred at 800-900 rpm for 10-12hrs to
ensure optimum surface interaction of TMC/CH to the NLCs. A pre and post-modification
measurement of the hydrodynamic radius as well as zeta potential could confirm the effectiveness
of the surface modification.
Preparation of TMC/ CH-TA nanoparticles
TMC/ CH nanoparticles (NP) were prepared by cross-linking with TPP by ionotropic gelation
method. Primarily, TMC/CH solution (0.5 % w/v) was prepared by dissolving TMC/ the chloride
salt of CH in bi-distilled water. TA (0.1% w/v) was dissolved in ethanol and added to the TMC/CH
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solution under vigorous stirring. Further, for cross-linking, TPP was added under probe sonication
to form TMC/ CH NPs. The TMC/CH to TPP weight ratio used was 5:1.
Physicochemical characterization
Assay and Entrapment
Methanol was used for the precipitation of lipids in the TA-NLC systems. An accurately measured
volume of the TA-NLC (10 µL) was extracted with methanol (990 µL). For estimating the % Assay
of TA in the CH-NP and TMC-NP formulations, the extracting solvent used was a 1:1 ratio of
methanol: 0.1% Acetic acid for CH-NP and methanol: bidistilled water for TMC-NP. The
supernatant was analyzed after centrifugation (13,000 rpm for 20 min) as such or with further
required dilutions for TA content using a HPLC-UV method described later.
For estimating the % Entrapment Efficiency (%EE), five hundred µL of all the formulations
centrifuged using a 100 kDa centrifugal unit made of regenerated cellulose membrane (Amicon
Ultra) and the sample was centrifuged at 13,000 rpm, for 20 mins, following which the filtrate was
analyzed for free TA content. Percentage EE was calculated using the formula,
% 𝐸𝐸 =

(𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑓𝑟𝑒𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑎𝑞𝑢𝑒𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒) ∗ 100
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡

Chromatography
Samples were analyzed for TA using an HPLC-UV system comprising a Waters 717 plus
Autosampler, Waters 600E pump controller, Waters 2487 dual λ Absorbance detector and an
Agilent 3395 integrator. Stock solutions of TA were prepared in acetonitrile and used immediately.
A mobile phase consisting of 50: 50 Acetonitrile: Water was used on a Phenomenex® C18 (4.6 x
250 mm) column at a flow rate of 1 mL/min. Detection was carried out at 254 nm.
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Dynamic light scattering (DLS)
The hydrodynamic radius and the PDI of the TA-NLCs, TMC/CH coated NLCs and CH/ TMC
NPs was determined by photon correlation spectroscopy using a Zetasizer Nano ZS Zen3600
(Malvern Instruments, Inc.) at 25°C and with 173° backscatter detection in disposable folded
capillary clear cells. The same equipment was used to determine the zeta potential of the
formulations at 25°C in folded capillary cells using the same instrument. To measure the particle
size distribution and zeta potential, the samples were diluted (1:100) with bidistilled water filtered
using 0.2 µ syringe filters.
Scanning transmission electron microscopy (STEM)
TA-NLCs were characterized using a 40-dual beam scanning transmission electron microscope by
Zeiss Auriga®. A negative staining procedure was employed wherein 1% w/v uranyl acetate was
used as a staining agent. A drop of the sample, about 20 µL was placed on a piece of parafilm. A
200-mesh glow discharged copper grid coated with a thin film made of carbon was floated on top
of the sample with the film facing the sample. The contact between the grid and the sample was
maintained for 30 s, after which the grid was displaced and excess sample on the grid was blotted
using a filter paper. The grid was then subjected to washing using ultrapure water; the grid was
placed on a drop of the ultrapure water, after which the excess water was blotted out. The grid then
was placed sample side down on a drop of 1% uranyl acetate for 1 minute. The excess stain was
then removed, and the sample was dried completely. After blotting and drying, the samples were
imaged in a Zeiss Libra operating at 30 kV and in STEM mode. (The STEM studies were
performed at University of Tennessee, Knoxville).
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In vitro drug release of TA from formulations
The in vitro release kinetics of TA from TA-NLCs, TMC/CH coated TA NLCs and TA-SOL were
evaluated across dialysis membranes (10K molecular weight cut-off) using Slide-A-Lyzer® Mini
Dialysis Devices. The dialysis devices were placed in scintillation vials containing 20 milliliters
of the release medium; IPBS at pH 7.4, containing 5% w/v HPβCD, the temperature of which was
maintained at 34°C. The donor chamber was filled with 1 mL of each of the formulations and the
cross-sectional area of diffusion was 0.64 cm2. At regular time intervals up to a total duration of 5
hours, 600-µL of the release medium was aliquoted and replaced with an equal amount of fresh
IPBS solution containing 5% HPβC. The aliquots were analyzed for TA content using a HPLC
UV method.
The in vitro release profile of TA from TA-NLC, TMC/CH coated TA NLCs and TA-SOL was
fitted to different mathematical models to analyze the release kinetics quantitatively. Models such
as zero order, first order, Korsmeyer-Peppas, Higuchi and Hixson- Crowell release model were
evaluated for linear regression of the release data. The best fit model was determined based on the
regression coefficient (r2) and the best fit model was considered the one with the highest r2.
In vitro transcorneal permeability
A vertical Franz diffusion cell setup from PermeGear®, Inc. was used to evaluate trans-corneal
permeability of formulations across isolated rabbit corneas. The corneas were excised from whole
eyes obtained from Pel-Freez Biologicals, AK shipped overnight in Hanks’ balanced salt solution
over wet ice. The corneas were excised so that they had scleral lining of about 2-3 mm thickness
to help secure the membrane between the diffusion cells. The cornea was clamped in between the
two half-cells with the epithelial surface facing upwards toward the donor chamber. A jacketed
circulating water bath helped maintain the temperatures of the diffusion half-cells at 34°C.
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Permeability of TA from formulations TA-NLCs (0.1% w/v), TA-SOL (0.1% w/v), TMC-TANLC (0.1% w/v) and CH-TA-NLC (0.1% w/v) across the excised corneas was studied. The
receiver medium comprised of 5 mL of 2.5% solution of RMβCD in DPBS. The contents of the
receiver chamber were stirred continuously with a magnetic stirrer and aliquots of 600 μL were
withdrawn from the receiver chamber at predetermined time points and replaced with an equal
volume of receiver medium. TA was quantified using the previously mentioned HPLC-UV
chromatography method.
Mucoadhesion study
To study the mucoadhesion of the coated NLCs, the interaction of the coated CH and TMC with
mucin was studied in an in vitro setup. Zeta potential was used as a measure of the interaction
between the surface modified NLCs and different concentrations of mucin solution. A 0.25% w/v
solution of mucin stock solution was prepared by dispersing the mucin in Milli-Q® water. Dilutions
of the stock were prepared at concentrations of 0.025 mg/mL, 0.125 mg/mL, 0.25 mg/mL, 0.5
mg/mL, 1.25 mg/mL, 2.5 mg/mL and 5 mg/mL. A 25 µL aliquot of each of the test formulations
(TA-NLC, TMC-TA-NLC, CH-TA-NLC) was admixed with each of the mucin concentrations
individually. The zeta potential of the resulting mixture was monitored. All the measurements were
performed in triplicates.
Ocular pharmacokinetics
The ocular retention of TA-NLC, TMC-TA-NLC, CH-TA-NLC and TA SOL was determined by
tear sample analysis of male New Zealand white rabbits, weighing between 2 and 2.5 kg. The
experiment was carried out in 12 male rabbits, four groups comprising of three animals per group.
A single instillation of 50 μL of each of the formulations (Dose: 50 µg) was made into the lower
conjunctival sac of the rabbits, after which the test eye was manually closed for 10 s. Tear samples
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were collected using Whatman™ Quantitative filter paper. A dry, pre-weighed triangular piece of
filter paper (11 x 6 x 11mm) was angled using a pair of forceps into the cul-de-sac of the rabbit,
making sure that the filter paper does not poke the eye of the rabbit. Tear samples were collected
at time intervals of 1, 15, 30, 60, 90, 120 minutes after instillation. A pre and post sampling weight
check was recorded for the filter paper in centrifuge tubes to quantify the amount of tear collected.
TA was then extracted from the filter papers by adding 600 μL of acetonitrile to the centrifuge
tube, followed by vortexing the sample for 30 to 45 s and centrifugation at 13,000 rpm for 15 min.
Non-compartmental analysis of the collected tear fluid concentrations was performed to compute
the ocular pharmacokinetic parameters using the software PK Solver 2. TA was quantified from
the supernatant using the HPLC-UV method.
In vivo bioavailability
In vivo bioavailability of TA was determined in male New Zealand white rabbits, weighing
between 2 and 2.5 kg, procured from Charles River Labs. The formulations TA-NLC, TMC-TANLC, CH-TA-NLC, TA-SOL were evaluated in vivo in a conscious rabbit model in triplicates (n
= 3); the ocular penetration of TA was evaluated as a function of the vehicle. Concentration of TA
was determined in the Cornea (Cor), AH, VH, RC, IC and sclera (SC). Fifty microliters of the
above formulations were dosed twice, with a 5-minute gap between the two doses (Dose: 100 μg
TA). The formulations were instilled in the conjunctival sac of the rabbits; the eyelid of the rabbit
was shut manually by the personnel for 10 to 15 seconds post dosing. Three hours after dosing,
the rabbits were anesthetized using a combination of ketamine (35 mg/kg) and xylazine (3.5
mg/kg) injected intramuscularly. The rabbits were euthanized with an overdose of pentobarbital
injected through a marginal ear vein. The eyes of the rabbits were then enucleated and washed

80

thoroughly with IPBS and the intraocular tissues such as Cor, RC, SC, IC, AH and VH were
separated.
Tissue sample preparation and extractions
The amount of TA permeated through the ocular tissues was determined by precipitating the
proteins in the ocular tissues. The solid tissues, namely, Cor (50 mg), Sc (250 mg), IC (50 mg) and
RC (30 mg) were cut into small pieces, whereas, the liquid tissues, AH (100 µL) and VH (500 µL)
were used as is. The calibrators were prepared by spiking the tissues with TA to yield final
concentrations of 0.5, 1, 5, 10, 20, 50, and 100 ng/mL. Fifty ng/mL of internal standard
(Fluocinolone Acetonide) was added to the samples. Volume was made up with ice-cold
acetonitrile, precipitating proteins from individual tissues. Samples were vortexed and kept aside
for 10 minutes. The supernatant was collected after centrifuging for 30 minutes at 13,000 rpm and
analyzed using LC-MS/MS quadrupole.
Quantification of TA from biological matrices
TA quantification post tissue extractions was performed using a Waters Xevo TQ-S triple
quadrupole tandem mass spectrometer with an electrospray ionization (ESI) source, equipped with
the ACQUITY UPLC® I-ClassSystem, was used (Waters Corporation, Milford, MA). A Waters
Xevo TQ-S quantitative analysis TargetLynx software was used for data acquisition which was
processed using the MassLynx mass spectrometry software.
A C18 column (Acquity UPLC®BEH C18 100mm 2.1 m, 1.7-mm particle size) was used for the
chromatographic separations with a gradient elution method. A mobile phase made up of
components (A) Water + 0.1% formic acid and (B) acetonitrile + 0.1% formic acid at a flow rate
of 0.7 mL/min was used. The gradient elution protocol was as follows; at 0 min, a ratio of 98%
A/2% B which was held for 0.2 min, switching over to 100% B in next 2.3 min. This composition
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was held for 1 min and switched over again to 98% A/2% B in the next 0.2 min. The system was
then equilibrated with this composition over the next 2 min for the next injection. The column and
sample temperature were maintained at 50°C and 10°C, respectively. After the chromatographic
separations, the efﬂuent passed into the ESI probe. The ESI source conditions were optimized for
the molecule of interest; source temperature 150°C, desolvation temperature 600°C, capillary
voltage 0.6 kV, cone voltage 26 V, nebulizer pressure 7 bar, and nebulizer gas 1000 Lh-1N2. The
mass spectra were acquired in positive mode and multiple reactions monitoring mode. Instrument
control and data processing were performed by using MassLynx software (version 4.1; Waters,
Milford, MA). The multiple reactions monitoring mode was applied to monitor the transitions
parent to daughter compound; from 435.24 m/z to 339.153 m/z, 357.155 m/z and 397.190 m/z for
TA and from 453.17 m/z to 121.02 m/z, 337.11 m/z and 413.16 m/z for the internal standard,
Fluocinolone Acetonide.
Statistical analysis
Statistical analysis was performed using JMP® 14, SAS. Statistical significance was tested for
using ANOVA followed by Tukey HSD test to analyze for inter-group differences (formulation
dependent). Differences were statistically significant at a level of p ≤ 0.05.
Results and Discussion
Synthesis of TMC
Chitosan was methylated with CH3I to yield TMC. The yield of TMC obtained was 4.5 grams and
the compound was freely soluble in water up to concentrations of 5% w/v. As per the peak
assignments by Sieval et al 169, 1H NMR data (Figure 18.) depicts a tertiary amino N(CH3)2 peak
at 3.13 ppm and a quaternary amino peak at 3.36 ppm. The DQ of the product computed as per the
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previously mentioned formula was 56.76% and the DM was 8.41%. TMC was prepared by a twostep synthesis with a high % DQ as per protocols elucidated by Sieval et al 169.

Figure.18. NMR spectra of the compound synthesized, N-Trimethyl Chitosan Chloride

83

Saturation solubility studies
Cyclodextrins have been known to enhance the solubility of poorly soluble compounds in
ophthalmic and topical products. The solubility of TA was observed in 5% cyclodextrin solutions
of HPβCD and RMβCD (Figure 19.). In HPβCD, the observed solubility of TA was 0.97 ± 0.03
mg/mL whereas in RMβCD saturation solubility of 1.6 ± 0.15 mg/mL was observed. Solubility of
TA was extremely low in IPBS and was found to be 0.029 ± 0.004 mg/mL. The use of
cyclodextrins led to 30-50 times enhancement of solubility of TA at pH 7.4. Based on the solubility
data, RMβCD was selected as the solubility enhancer in the receiver medium for in vitro
transcorneal permeation studies described previously.

Solubility of TA (mg/ml)

2.00
1.60
1.20
0.80
0.40
0.00
5% RMβCD

5% HPβCD

IPBS

Figure 19. Saturation solubility of TA in phosphate buffer, 5% w/v HPβCD in phosphate buffer,
and 5% w/v RMβCD in phosphate buffer (mg/mL). The results are depicted as the mean ± SD
(n=3).
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Lipid excipient screening study
Solubility of TA in both solid and liquid lipids has been illustrated in Figure 20. The lipids
presenting with maximum solubility for TA were chosen to formulate the TA-NLCs. In the solid
lipids tested TA demonstrated superior solubility in Precirol® 888 ATO and Compritol® 888 ATO
whereas amongst the liquid lipids tested, castor oil was the best. At a ratio of 1:1 of TA: individual
solid/liquid lipids, no undissolved drug was observed at an elevated temperature of 80℃.
Furthermore, no precipitation was observed on cooling the lipid melt to room temperature.

Figure 20. Solubility of TA in solid and liquid lipids.
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Selection of a binary lipid phase
Solid lipids, Precirol® 888 ATO and Compritol® 888 ATO were tested individually at three
different ratios for miscibility liquid lipid castor oil. Clear bleeding of castor oil from the solid
phase was observed for both solid lipids at a 2:3 ratio of solid lipid: liquid lipid. However, when
mixed at a 1:1 ratio Precirol® 888 ATO and castor oil demonstrated better stability in comparison
to a combination of Compritol® 888 ATO and castor oil. Presence of higher amounts of liquid lipid
permits for a better drug load and fluidity of the API within the particle. The goal behind
formulation of these NLCs was to allow almost an equal amount of solid and liquid lipid which
would further affect the partition and release characteristics of TA. Keeping this in mind, Precirol®
888 ATO and castor oil were chosen to formulation the NLCs at a ratio of 1:1.
Physicochemical characterization of all the formulations
The % Assay and % EE of TA-NLC, TMC-TA NP and CH-TA NPs was found to be 96.5 ± 8.1%,
85.76 ± 3%, 89.01 ± 0.86% and 99.01 ± 0.69%, 80 ± 0.07% and 88.14 ± 0.02%, respectively. The
NLCs prove to be a superior nano-carrier for TA in terms of % Assay and % EE, which could be
a virtue of the lipophilic nature of TA having increased affinity for the lipids used for the
encapsulation of TA in the TA-NLCs. Table 11. compares the particle size (d. nm), PDI and zeta
potential (mV) of the TA-NLCs and the surface modified NLCs. TA NLCs have a particle size of
192.27 ± 5.05 d. nm and a narrow PDI of 0.23 ± 0.001. On modification of the TA-NLC surface
with different concentrations of TMC, the particle size of the NLC system increased up to 500 d.
nm indicating that TMC had adhered to surface of the NLCs. The negatively charged (-37 mV)
surface of the TA-NLCs provided a favorable setup for this surface modification. This surface
modification can also be backed up by the ZP data, increase in the ZP of the TA-NLCs after surface
modification indicated that TMC has accumulated on the NLC surface. Coating the NLCs with
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concentration of 0.5% TMC or higher could possibly result in particle aggregation and an unstable
formulation. Based on formulation stability, a 0.25% polymeric coating was chosen to coat the
TA-NLCs for in vitro and in vivo evaluation. Table.11. provides a summary of the physicochemical
characterization of the formulations.

Table 11. Particle size (d. nm), PDI and zeta potential (mV) values for each formulation
Particle size (d. nm)

Polydispersity

Zeta Potential

Index

(mV)

Formulation

Mean

Std Err

Mean

Std Err

0.1% TMC COATED NLC

515.90

7.58

0.22

0.02

20.10

0.25% TMC COATED NLC

531.10

11.44

0.24

0.00

26.80

0.5% TMC COATED NLC

325.23

2.82

0.47

0.02

24.10
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Scanning transmission electron microscopy (STEM)

Figure 21. STEM image of the optimized TA-NLC formulation

To visualize the optimized NLCs for morphological characterization, STEM imaging was
employed. (Figure. 21.) An electron beam is passed through a thin layer of prepared sample. The
transmitted beam is then projected on a phosphorescent screen or detector. Figure 21. depicts
spherical NLCs formed with a smooth periphery, the particle size of which is around 100 d.nm.
DLS describes the particles to have a particle size of 192 d. nm, with a PDI of 0.23, and presence
of a slightly polydisperse particle size distribution could be a possible reason for the discrepancy
between the particle sizes reported by DLS and STEM imaging. 143-144
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In vitro drug release of TA from formulations
TA release from the formulations was observed in a simulated ocular tissue environment. The
release curves were obtained by plotting the cumulative % drug release against the time of the
study in minutes, Figure 22. To analyze the drug release rate kinetics, the in vitro drug release
profiles were fit into mathematical models. The model that best fit the release data was determined
by the r2. The r2 values for all the formulations are listed in Table 12. The zero-order model fit the
release profile of TA NLC best, which meant that the nanoparticles did not disintegrate; rather
they released the drug slowly. The release profile of TA from TA-NLCs (Figure.22.) depicts a
slow and gradual increase in release of TA, from 1 to 7% over a period of 5h. Comparing the
release profile of TA from the NLCs to the polymeric coated nanoparticles (Figure. 22.), the
presence of the polymeric coat controlled the release of TA through the duration of the study.
Percent cumulative drug lease from TA NLC was significantly greater than the coated NLCs at
60, 180 and 300 minutes. We observe a burst in release of TA from the TA-NLCs from the 30
minutes to 60-minute time-point. This can be attributed to release of TA from the external surface
of the nanoparticles, following by gradual release from the lipid core. The kinetic model that best
fit the drug release from the coated NLCs was the first order model with a r2 value of 0.96 and
0.99 for TMC-TA-NLC and CH-TA-NLC respectively. Looking at the n values for the KorsmeyerPeppas fit for the coated nanoparticles, CH-TA-NLC and TMC-TA-NLC had n values of 0.73 and
0.54 respectively, which meant that the coated NLCs demonstrated a non-Fickian transport
mechanism, involving swelling of the polymeric coat and diffusion of the drug from the lipidic
core, through the polymer into the release medium.
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***
**
*

Figure.22. In vitro release profile of TA from nano-formulations in phosphate buffer, pH 7.4 over
a period of 5h
*% Drug release from TA-NLC significantly greater than CH-TA-NLC, TMC-TA-NLC and TASOL
** Drug release from TA-NLC significantly greater than CH-TA-NLC, TMC-TA-NLC
*** Drug release from TA-NLC and TA-SOL significantly greater than CH-TA-NLC, TMA-TANLC
Table 12. In vitro release kinetic parameters for TA formulations; r2 is the regression coefficient
r2 value
Model fitted

Equation
TA-NLC TA-SOL CH-TA-NLC TMC-TA-NLC

Zero Order

𝐶𝑡 = 𝐶0 + 𝐾𝑡

0.90

0.93

0.97

0.91

First Order

𝐶𝑡 = 𝐶0 𝑒 −𝐾𝑡

0.73

0.95

0.99

0.96

90

Korsmeyer-Peppas

Higuchi

𝐶𝑡
= 𝐾𝑡 𝑛
𝐶∞

Ct=Kt1/2

0.88

0.97

0.94

0.80

n=0.69

n=0.92

n=0.73

n=0.54

0.86

0.58

0.72

0.75

Mucoadhesion study
Ocular mucus is composed of mucin as one of its many components, protecting the corneal
epithelium from desiccation and bacterial contamination. The mucin is negatively charged due to
the presence of sialic acid residues, which helps the eye repel pathogens

170

. A positively charged

particle would interact with the mucin layer and reside in the cul-de-sac and corneal epithelium for
a longer duration of time. While targeting the delivery of TA to the back of the eye, on topical
application, enhanced ocular retention would in turn increase the overall permeation of the molecule
76, 86

. This mucoadhesion study was conducted to study the electrostatic interaction between the

positively charged coated TA-NLCs and the negatively charged mucin in an in vitro setup. Zeta
Potential of TA-NLC, TMC-TA-NLC, CH-TA-NLC was monitored at increasing concentrations of
mucin to investigate the electrostatic interaction (Figure.23.). On increasing the mucin concentration
from 0.5 mg/mL up to 2.5 mg/mL, there was a sharp drop in the zeta potential of the TMC coated
NLC, from 16.8 ± 4.02 mV to -1.47 ± 3.94 mV, indicating a strong interaction between the polymer
and the mucin. For the CH-NLC, we observe this interaction at a higher concentration of mucin,
with a sharp drop in the zeta potential from 19.3 ± 3.78 mV to 10 ± 5.16 mV at mucin concentrations
of 1.25 mg/mL to 2.5 mg/mL. Increasing the mucin concentration further resulted in a negative zeta
potential of both the coated formulations. Through all the increasing concentrations of mucin, TANLC had a negative zeta potential from about -30 mV to -40 mV, indicating no interaction between
the uncoated particles and mucin. The interaction between the polymer coated NLC and the mucin
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could result in retention of the nanoparticles in the ocular mucosa, improving the overall permeation
profile of the formulation. The fact that TMC interacts with a mucin concentration 5 times lower
than the mucin concentration CH interacts with is indicative that TMC is a better mucoadhesive
agent in comparison to CH.

60
50
40

Zeta Potential (mV)

30
20
10
0
-10
-20
-30
-40
-50
-60
0

0.025

TA-NLC

0.125
0.25
0.5
1.25
Mucin concentration (mg/ml)
0.1% TMC TA NLC

2.5

5

0.1% CH TA NLC

Figure.23. Zeta potential of TA-NLCs, TMC-TA-NLC, CH-TA-NLC formulations at increasing
concentrations of mucin (0.025 to 5 mg/mL)

In vitro transcorneal permeation
The transcorneal permeation profile of TA-NLC, TA-SOL, TMC NP and CH NP solution was
observed over 180 minutes at 34°C across isolated rabbit corneas. The 0.1% TA- SOL
demonstrates an enhanced permeation profile (Figure.24.) with significantly high amounts of
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permeated TA by the 180 min time-point and a permeability of 6.30 ± 0.9 x 10

-6

cm/sec and a

transcorneal flux of 0.378 ± 0.054 µg/min/cm2 (Table 13.). Cyclodextrins have been previously
reported to affect the barrier characteristics of rabbit corneas.171 Cyclodextrins orient
perpendicularly on the surface of the phospholipid monolayer and extract the cholesterol molecule
and result in damage to the corneal membrane, increasing overall transmembrane permeation. CH/
CH derivatives are also known for their ability to interact with the corneal surface; CH/ CH
derivatives interact with the mucin layer increasing the transcellular transport of molecules and
increase the pre-corneal retention time. In terms of flux and permeability, TA-NLC demonstrate a
slightly better permeation profile than the coated nanoparticles (Table.13.). This can be attributed
to the presence of a hydrophilic polymeric barrier on the surface of the NLCs for the coated
nanoparticles. This could possibly hinder the partitioning of the molecule from the lipophilic core
into the external hydrophilic environment. The presence of CH and CH derivatives, along with
mucoadhesion, also affect the dynamic transport mechanisms of molecules. The in vitro
mucoadhesion study provides us with information that both TMC and CH interact with the
negatively charged mucin at different concentrations, indicating that mucoadhesion is one of the
inherent properties of the polymers that would affect the permeation of TA. However, to further
elucidate the effect of polymeric coating on the TA-NLC, a dynamic in vivo environment would
prove to be a better predictor over effect of CH and CH derivatives on overall ocular
bioavailability. The comparable permeation profiles by CH-TA-NLC and TMC-TA-NLC indicate
that despite increased adhesion and retention, the partition of TA from the lipophilic core is
probably hindered and is a vital step that governs the transport mechanisms of TA.
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Figure 24. Transcorneal permeation profile across isolated rabbit cornea from TA-NLC, TA-SOL,
TMC-TA-NLC, CH-TA-NLC at 34ºC. The receiver solution consisted of DPBS containing 2.5%
w/v RMβCD (pH 7.4). The results are depicted as the mean ± S.D (n=3)

Table 13. Permeability (cm/sec) and transcorneal flux (µg/min/cm2) of TA-NLC, TMC-TA-NLC,
CH-TA-NLC and TA-SOL across isolated rabbit cornea. The results are depicted as the mean ±
S.D (n=3)
Formulations

Permeability x 10-6 (cm/sec)

Flux (µg/min/cm2)

TMC-TA-NLC

1.12 ± 0.25

0.067 ± 0.015

CH-TA-NLC

1.29 ± 0.04

0.077 ± 0.002

TA-NLC

1.88 ± 0.07

0.234 ± 0.106

TA-SOL

6.30 ± 0.9

0.378 ± 0.054
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Ocular pharmacokinetics
Tear fluid kinetics of TA-NLCs and polymer coated NLCs in comparison to TA-SOL post single
instillation (Dose: 50 µg) of each of the formulations was studied in NZW rabbits. Achieving
suitable concentrations of the drug in the pre-corneal area and increasing its retention time is the
first limiting step of achieving tissue concentrations at the back of the eye. Ocular barriers such as
blinking, and tear clearance reduce the precorneal residence time of the drug. The concentration
of drug present in the tear fluid is a measure of its availability to further permeate in the tissue
layers. A higher mean residence time (MRT) indicates a longer residence of TA in the pre-corneal
tissues. TMC-TA-NLC demonstrates an MRT of 49.50 minutes (Table 14.), with the MRT of the
all the formulations ordered as TMC-TA-NLC > CH-TA-NLC> TA-NLC> TA-SOL. TMC-TANLC also demonstrated a 1.73, 1.63 and 1.72 times higher AUC0-∞ in comparison to the other
tested formulations, TA-SOL, CH-TA-NLC and TA-NLC respectively. TMC-TA-NLC retain TA
in the precorneal area and show significantly higher concentrations (264.12 ± 59.74 ng/mg tear
weight). Ocular pharmacokinetics of TA-SOL demonstrates quick drainage and minimum
retention of the formulation in the pre-corneal tissues. Figure.25. is a graphical representation of
the tear fluid concentrations; TA-SOL demonstrates a high concentration of TA, 2821.33 ± 78.31
ng/mg tear weight significantly greater than all other formulations at the 0-time point. This
observation can be attributed to the free TA present in solution at the first-time point. However, a
sharp drop in TA concentrations was observed post the 0-minute time point signifying absence of
precorneal retention from this solution formulation; the MRT for TA-SOL is 1.08 minutes. Due to
the colloidal system, TA-NLCs does increase the overall precorneal retention of TA, and the MRT
of the TA-NLCs is 28 times greater than the solution formulation. Presence of a positive charge
on the particles does show a slight improvement in the MRT and AUC0-∞ of the NLCs. Looking
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at the Clearance (Cl) of the TA formulations, TMC-TA-NLC depicts the lowest CL values of
0.0013 mL/min, in comparison to the other formulations. The Cl values of the formulations can be
ordered as TA NLC>TA-SOL>CH-TA-NLC>TMC-TA-NLC. Low Cl values of the coated
nanoparticles can be indicative of the mucoadhesive properties of the positively charged polymers,
CH and TMC and interaction of the same with the negatively charged ocular mucosa. The results
of ocular pharmacokinetics agree with in vitro findings stating that presence of a charged
polymeric coating enhances the residence of TA in the eye. The TMC and CH interact with the
negatively charged corneal surface, impacting the retention of the NLC formulation in the precorneal area.

TA concentration ng/ mg tear weight

*

**

Figure.25. Tear concentration (ng/mg tear weight) vs time (min) profile for TA formulations
*TA-SOL significantly > TA-NLC, CH-TA-NLC, TMC-TA-NLC
**TMC-TA-NLC significantly > TA-SOL
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Table 14. Non-compartmental analysis of tear fluid concentrations post dosing of TA-NLC,
TMC-TA NLC, CH-TA NLC and TA-SOL using software PK Solver 2.0
Formulations

AUC0-∞

t1/2 (min) Cmax (μg/mL) Cl (mL/min) MRT (min)

(μg/mL*min)
TA-NLC

23001.28

43.72

1660.87

0.0043

30.45

CH-TA-NLC

24220.04

67.67

1211.79

0.0021

32.19

TMC-TA-NLC

39466.58

32.59

1635.50

0.0013

49.50

TA-SOL

22763.02

2.93

2821.33

0.0022

1.08

In vivo bioavailability
Male NZW rabbits were dosed consecutively with 50 µg of TA formulations; TA-NLC, TMCTA-NLC, CH-TA-NLC and TA-SOL. The tissues analyzed were Cor, AH, VH, IC, RC and SC.
Looking at Figure.26., TA-SOL was not retained in the pre-corneal area and depicted lower
concentrations (289 ± 99.6 ng/ g of tissue) in the Cor. This result is consistent with the ocular
pharmacokinetics (Figure.8.), with high levels of TA-SOL detected on the 0-time point and quick
drainage from the precorneal region post dosing. The concentrations in the Cor further impacts the
distribution of TA in the ocular tissues and we observe 242 ± 17.5 ng/ mL in the AH, 22.7 ± 7.39
ng/ g of tissue in the IC and 53.4 ± 20.3 ng/ g of tissue in the SC.
With TA-NLC and CH-TA-NLC (Figure.26.), we observe comparable levels of TA, i.e. 533 ± 175
ng/ g of tissue weight and 524 ± 211 ng/ g of tissue weight in the Cor respectively. For TMC-TANLC, TA concentrations were lower than that of CH-TA-NLC and TA-NLC (454 ± 163 ng/ g of
tissue weight). As TA permeates further into the tissues, we observe greater levels of TA delivered
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to the AH via CH-TA-NLC (493 ± 144 ng/ g of tissue weight) in comparison to TA-NLC (377 ±
32.6 ng/ g of tissue weight), indicating that CH enhances permeation of TA across the cornea.
Previous reports of multiple dosing of 0.2% TA liposome formulation demonstrated levels of TA
permeating into the VH and retina 12 h after topical administration. Considering the multiple
dosing regimen and formulation concentration, there was 50-fold difference in the dosing reported
in comparison to our data. Possible reasons for improved penetration could be the presence of
formulation components such as permeability enhancers, which could be another possible
approach employed for increasing TA bioavailability. 172
Looking at the tissue concentrations, we can speculate that the drug permeates the tissues via two
routes, the corneal route into the AH and IC and from the back of the eye, through the SC. A
similar trend as in the AH is observed with the IC, CH-TA-NLC delivers higher levels of TA (146
± 77.1 ng/ g of tissue weight) than TA-NLC (36.4 ± 5.44 ng/ g of tissue weight). We also observe
that the formulations facilitate permeation through non-corneal routes with drug concentrations
detected in the SC; 66 ± 25.6 ng/ g of tissue weight from CH-TA-NLC, 52 ± 9.43 ng/ g of tissue
weight from TA-NLC, 53.4 ± 20.3 ng/ g of tissue weight for TA-SOL and 38.3 ± 7.91 ng/ g of
tissue weight for TMC-TA-NLC. However, TA does not permeate significantly from the SC into
the posterior tissues from any of the formulations.
Comparing the ocular bioavailability to the pre-corneal pharmacokinetic parameters (Table 14.),
we observe that the NLCs reside in the pre-corneal area for a longer duration in comparison to TASOL. This further translates into higher TA concentrations in the anterior segment for the NLCs
in comparison to the SOL. By looking at the overall ocular tissue disposition for TA we can state
that residence time is not the only factor that would govern the ocular bioavailability of a lipophilic
API, inherent molecule characteristics would play a vital role in determining the ADME
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characteristics of the molecule. TA is a lipophilic molecule, and entrapment of TA in lipid based
nanocarriers results into slow release of TA into the hydrophilic tissue microenvironment which
further hindering the overall ocular bioavailability of the molecule.
Reportedly, CH and TMC increase the drug bioavailability by two mechanisms; by increasing the
precorneal residence time and increasing the paracellular transport of the molecule 161. CH and its
derivatives work as permeation enhancers because of an interaction between the positively charged
amino groups on the C-2 position of chitosan with negatively charged sites on the cell membranes
and tight junctions. This alters the integrity of the tight junctions, increasing the overall
paracellular transport of the molecule. 69 TA, being a molecule with some degree of lipophilicity,
would adopt a transcellular pathway for permeation, rather than a paracellular pathway. The lack
in elevation of overall ocular bioavailability could possibly be attributed to the mechanism of
permeation enhancement of TMC, which might not be suitable for a lipophilic molecule such as
TA. Another factor to be taken into consideration is the total positive charge at the site of action,
along with the molecular weight and the DQ which affects the interaction of TMC with the mucin
layer.
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As inferred from the in vitro mucoadhesion study, CH and TMC do interact with the

mucin elements, however, due to the aforementioned reasons, the increase in pre-corneal retention
might not increase the overall permeation profile of the molecule 76. Reportedly, CH also increases
permeation of molecules by endocytosis and transcytosis along with affecting the paracellular
transport, which could be an explanation for increase in bioavailability of TA by surface
modification using CH but not by TMC. 174-175
Another possible explanation could be the drug load of the optimized NLCs, a 0.1% W/V drug
load is not high enough a drug load to create a significant concentration gradient for diffusion of
the molecule from the lipophilic carrier into the tissue micro-environment. Increasing the TA load
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could possibly intensify the differences between the groups enough to make conceivable
conclusions.

Figure.26. Tissue concentrations three hours post dosing of TA formulations (Dose: 100 μg TA)
+ TA-NLC, TMC-TA-NLC, CH-TA-NLC and TA-SOL in New Zealand White rabbits (n=3)

Conclusion
Topical administration is the preferred route for ophthalmic drug delivery, however anatomical
barriers and precorneal factors affect the bioavailability of the formulation. The ocular
bioavailability of any lipophilic molecule post topical dosing is controlled by its solubility in the
hydrophilic tissue environment. Formulation approaches can enhance delivery of the molecule to
the site of application. Lipid based nanoparticles have been previously reported to sustain the
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release of the entrapped moiety by slowly releasing it over a prolonged period. This work
attempted in developing a lipid based nanoparticulate system, NLCs to improve drug load, prolong
the release and reduce dosing frequency of the molecule. Currently, TA is available as an
intravitreal injection and development of a topical route is a desirable alternative. The optimized
TA-NLCs with a 0.1% W/V drug load enhanced the ocular bioavailability of TA in comparison to
a cyclodextrin solution. Furthermore, increasing the drug load would help in delivering sustained
amounts of TA to the site of action. Surface modification of TA-NLCs with TMC increased the
residence time of the formulation, however did not affect the overall ocular bioavailability. CHTA-NLCs on the other hand were able to deliver higher concentrations of TA across the Cor.
Investigations explaining mechanisms of CH on permeation enhancement by non-paracellular
routes would help understand the role of CH and CH derivatives in permeation enhancement for
lipophilic molecules.
Supplementary Data
Table 15. Tear concentration (ng/mg tear weight) post dosing of TA formulations (Dose: 50 µg)
in male New Zealand White rabbits for time points up to 2 hours post dosing (n=3)

Formulation

CH-TA-NLC

TA-NLC

TA-SOL

TA concentrations (ng/mg tear weight)
Time point
Mean
(min)
0
1211.79
15
357.17
30
142.31
60
58.65
90
14.98
120
39.13
0
1660.87
15
158.88
30
99.26
60
76.33
90
61.97
120
21.48
0
2821.33
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Std Err
138.99
255.77
90.41
30.24
4.65
11.11
116.05
130.06
24.38
4.19
14.22
12.75
78.31

TMC-TA-NLC

15
30
60
90
120
0
15
30
60
90
120

105.03
2.34
0.00
0.00
0.00
1635.50
828.99
264.12
147.75
63.95
12.38

37.71
2.34
0.00
0.00
0.00
222.47
282.90
59.74
82.28
18.71
7.30

Table 16. Tissue concentration (ng/g tissue weight) post dosing of TA formulations (Dose: 100 μg
TA) TA-NLC, TMC-TA-NLC, CH-TA-NLC and TA-SOL in New Zealand White rabbits (n=3)

Formulation
CH-TA-NLC

TA-NLC

TA-SOL

TMC-TA-NLC

TA concentration ng/g
Tissue
Mean
AH
493
Cor
524
IC
146
RC
0
SC
66
VH
2.09
AH
377
Cor
533
IC
36.4
RC
0
SC
52
VH
2.36
AH
242
Cor
289
IC
22.7
RC
0
SC
53.4
VH
2.63
AH
253
Cor
454
IC
46.7
RC
0
SC
38.3
VH
2.24
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Std Err
144
211
77.1
0
25.6
0.2
32.6
175
5.44
0
9.43
0.34
17.5
99.6
7.39
0
20.3
0.21
73.3
163
28
0
7.91
0.38

CHAPTER 5
ANTI-FUNGAL & ANTI-BACTERIAL PEGYLATED-NLCS FOR
OCULAR APPLICATIONS: FORMULATION DEVELOPMENT,
CHARACTERIZATION AND IN VITRO EFFICACY TESTING
Introduction
Keratitis or corneal inflammation is commonly associated with bacterial or viral
microorganisms resulting in corneal scarring and even permanent vision loss.176-177 Fungal keratitis
is widespread in tropical and developing countries with an occurrence of over 50%.178 Fungal
keratitis is more challenging to treat and can be more virulent and damaging than bacterial origin.
Primarily an infection of the corneal epithelium, fungal keratitis (keratomycosis) may also affect
the stroma and in more severe cases, the endothelium and the anterior chamber.179 While spreading
through the cornea, into the anterior chamber, fungal organisms often penetrate through the corneal
stroma without rupturing the cornea.179 A molecular target controlling fungal keratitis should
penetrate across the cornea further into the stroma and other sites of infection. The aim of treating
a patient with fungal keratitis is to conserve vision, which can be achieved by a timely diagnosis
and antifungal therapy. Currently, the groups of antifungal agents used for the treatment of fungal
keratitis are polyenes (natamycin, amphotericin B), azoles (voriconazole, posaconazole,
econazole, fluconazole) and echinocandins (caspofungin).178 A 5% Natamycin suspension is
available commercially as a topical ophthalmic preparation, however it is used for superficial
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infections due poor bioavailability on topical application.177-178 Voriconazole (VRC), a second
generation triazole derivative of fluconazole, has emerged as a promising candidate for the
treatment of fungal keratitis because of its wide therapeutic window and high potency.180 VRC
inhibits synthesis of ergosterol in the fungal membranes by binding to the active site of P450dependent enzyme lanosterol 14-demethylase, resulting in depletion of ergosterol, thus affecting
the overall integrity and function of the fungal membrane. VRC has been approved by the US Food
and Drug Administration for the treatment of systemic fungal infections. It is also commercially
available for oral and parenteral use against fungal keratitis.178-180 Studies indicate that VRC is
more potent than amphotericin B against filamentous fungi such as Aspergillus and
Pseudallescheriaboydii.180-182 It is also effective against common pathogens such as C. albicans,
C. parapsilosis, C. tropicalis, A. fumigatus, Aspergillus flavus, and Fusarium solani. The
drawback with using VRC orally for treatment of fungal keratitis is associated side effects and
possible drug interactions.183 An efficient strategy would be delivering VRC locally; minimizing
the drug interactions and side effects. Development of a dosage form of VRC having topical utility,
and enabling VRC to permeate through the ocular tissues, to the desired site of action is necessary.
Developing a topical formulation for VRC would involve overcoming the anatomical and
physiological barriers such as blinking, high tear turnover and drainage and tissue barriers such as
cornea, conjunctiva, blood aqueous barrier, blood-retinal barrier.184 Only about 3-5% of a topically
dosed formulation penetrates into the deeper tissues after crossing the aforementioned barrier
system, which makes development of a topical formulation challenging. VRC, being a lipophilic
molecule unstable in an aqueous environment, needs a carrier system that would provide it with
stability in-solution, along with sustained release by increasing the pre-corneal residence time.
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Antifungal drugs such as VRC have been reported to have a synergistic effect with
fluoroquinolones such as Ciprofloxacin (CIP) via binding to fungal topoisomerase II and inhibiting
DNA replication.185 CIP in itself is devoid of anti-fungal activity, but may demonstrate synergistic
interactions with antifungals such as amphotericin B, voriconazole and caspofungin.185-186
Reportedly, CIP enhances the action of azoles by increasing intracellular concentrations of the
anti-fungal agents due to an overlap of substrate specificity of ATP binding cassette multidrug
transporters.187
Different ocular delivery systems attempting to increase residence time of the formulation
in the cul-de-sac have been investigated.127, 132, 188 NLCs are colloidal nano-carriers synthesized
by blending a mixture of solid and liquid lipids. The resulting formulation is a suspension, particles
which have a melting point lower than that of their counterpart, SLNs but still solid at body
temperature.189 The imperfections in the matrix caused due to the presence of the liquid lipid result
in accommodation of the API and a higher drug load (DL).189-190 NLCs enhance trans-corneal drug
delivery and increase precorneal retention time, thus a favorable system for ocular drug
delivery.132, 191
In these set of studies VRC loaded NLCs were optimized, with the goal of achieving a
stable formulation with an optimum DL which can be delivered topically for the treatment of
fungal keratitis. CIP was loaded along with VRC in this nano-carrier to evaluate the synergism
between anti-bacterial and anti-fungal agents. For efficient excipient selection and methodical
formulation optimization, a statistical DOE methodology was employed. Being an optimization
study, we wanted to look at the curvature in the model and thus a central composite design (CCD),
response surface methodology (RSM) was employed to develop VRC and CIP loaded PEGylated
nanostructured lipid carrier (PEG-NLC) system (VRC-CIP-PEG-NLC). The optimized
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formulation was characterized in an in vitro setup for particle size (d. nm), DL, EE. Also, the
permeation efficacy of the optimized formulation was evaluated across isolated rabbit corneas.
Materials and Methods
Materials
The active molecules, VRC and CIP were purchased from Acros Organics (NJ, USA) along with
glycerin, castor oil and Tween® 80. Pluronic® F68 (Poloxamer 188) was purchased from Spectrum
Pharmaceuticals (Henderson, NV). Lipids, Compritol® 888 ATO, Precirol® 888 ATO (glyceryl
behenate), Geleol Mono and Diglycerides NF and Gelucire 50/13 were obtained as a gift sample
from Gattefossé (Paramus, NJ, USA), mPEG-2K-DSPE sodium salt (PEG) was purchased from
Lipoid®. HPLC - grade solvents, and other chemicals (analytical grade) were obtained from Fisher
Scientific (Hampton, NH, USA). Amicon® Ultra centrifugal filter devices, regenerated cellulose
membrane (MWCO 100 kDa) were purchased from EMD Millipore (Billerica, MA). VRC for
injection, Vfend® and Ciprofloxacin Hydrochloride Ophthalmic Solution 0.3% was obtained from
The University of Mississippi, Health Center. Male albino New Zealand rabbits were procured
from Harlan Labs (Indianapolis, IN, USA).
Formulation optimization for NLCs
Excipient selection
NLCs are lipid-based carriers constituted with both solid and liquid lipids. As a pre-formulation
screening, both solid and liquid lipids were evaluated for solubility of both the APIs. Lipids
demonstrating maximum solubility were further optimized to an optimum binary mixture. Solid
lipids (Compritol® 888 ATO, Precirol® 888 ATO, Stearic Acid, Geleol Mono and Diglycerides
NF) and liquid lipids (castor oil, Oleic acid and Miglyol) were screened to maximize loading of
both VRC and CIP. Primarily, the lipids were heated/melted by maintaining the temperature of the
water bath to 80°C. After attaining the temperature, 100 mg of VRC and CIP were added
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individually to the heated lipids (100 mg) under constant magnetic stirring at 2000 rpm. The API
was allowed to dissolve (in case of VRC) and disperse (in case of CIP) under magnetic stirring for
2-5 minutes. The CIP-lipid and VRC-lipid mixtures were then cooled and evaluated for
precipitation of the API. The basis of lipid selection in this study was optimum solubility and
compatibility with CIP and VRC.
Selection of a binary lipid phase
Presence of a liquid lipid in a lipid based nano-carrier allows for imperfections and accommodation
of a higher load of API. To determine the best solubilizing potential of the solid-lipid-liquid-lipid
mixture, an optimum ratio of the solid and liquid lipid was determined. 100 mg of individual
molecules, CIP and VRC were admixed with the lipids demonstrating maximum solubility in the
excipient selection in three different ratios, i.e.; 2:3, 1:1, 3:2. The API addition took place under
constant magnetic stirring over a period of 30 minutes, with the lipids heated to a temperature of
80℃. The binary lipid phase was then spread on a glass slide and was inspected for bleeding of
the oil from the solid lipid.
Experimental design
After excipient selection, the next step was to optimize the levels of individual ingredients using a
statistical experimental design. A mathematical optimization technique known as RSM was
involved in modeling of the response variables in the dataset. This technique was used in order to
make statistical predictions by fitting a polynomial equation to the set of experimental data. RSM
is generally employed to a multivariate design wherein change in individual independent variables
affects a response or a set of responses.
Keeping in mind the number of trials, the optimization procedure designed experiments with
different levels of the independent variables generating multiple responses. On analysis, these
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responses can be used to determine main effects and the predictions of these responses would help
us design the appropriate formulation with target goals. A CCD of the RSM was employed wherein
the amount of PEG and 1:1 Castor oil and Precirol® 888 ATO each coded as Factors B and C
respectively, was varied at different levels of VRC and CIP loading (Factors A and D respectively).
Each of the factors was studied at 5 levels, the end limits of which were determined based on
screening trials conducted before the optimization study (Table 17.).

Table 17. Independent factors at their five coded levels from the Central Composite Design:
Response Surface Methodology (The amounts (in mg) are per 10 ml of the formulation)
Levels
Independent Factors

-α

-1

0

+1

+α

A: Voriconazole (mg)

0

15

30

45

60

B: mPEG-2K-DSPE sodium salt (mg)

0

75

150

225

300

C: 1:1 Castor oil and Precirol® 888 ATO (Lipid ratio)

360

450

540

630

720

D: Ciprofloxacin

0

15

30

45

60

Once the limits of the input variables were established, a response surface optimization
study was conducted using Design-Expert® software (Version 8.0.7.1, Stat-Ease Inc., MN). The
CCD involved placement of center points (0), factorial points (+1, -1) and augmented axial points
(+α, - α), with the value of α being 1.682, allowing estimation of curvature and to maintain
rotatability. A 30-run design was generated using the software; runs are depicted in Table 18. This
design placed fewer runs on the extremes and focused on the center of the design space, making it

108

a robust predictor design. The dependent variables or the responses evaluated to obtain the optimal
formulations were mean particle size of VRC-CIP-PEG-NLC (d. nm), polydispersity index of the
same (PDI), drug EE and DL for each of VRC and CIP.
Table 18. Runs designed by the Central Composite Design for the optimization study
Run
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

A:
Voriconazole
30
15
45
15
30
15
30
15
45
15
30
60
45
15
30
45
15
30
30
45
45
30
30
0
15
45
45
30
30
30

B: DSPE PEG
150
75
75
225
300
225
150
225
225
75
0
150
75
75
150
225
225
150
150
75
225
150
150
150
75
225
75
150
150
150
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C: Lipid Ratio
540
630
450
450
540
630
540
630
630
630
540
540
630
450
540
450
450
540
360
630
630
540
720
540
450
450
450
540
540
540

D: Ciprofloxacin
0
45
45
45
30
45
30
15
45
15
30
30
15
15
30
45
15
30
30
45
15
30
30
30
45
15
15
60
30
30

Preparation of VRC-CIP-PEG-NLC
The VRC and CIP loaded PEG-NLCs were prepared by an ultra-sonication- cold homogenization
technique. APIs 0.15% VRC and 0.3 % CIP were dispersed in the lipid system and heated at 80°C.
The lipid phase consisted of both the APIs, Precirol® 888 ATO, castor oil and PEG. The aqueous
phase comprised of Poloxamer 188 (0.25% w/v), Tween 80 (0.75% w/v) and Glycerin (2.25%
w/v) was and simultaneously heated in de-ionized water. The hot aqueous phase was added
dropwise to the melted lipid phase to form a premix under constant magnetic stirring at 2000 rpm
for 5 minutes. Further, the premix was homogenized for particle size reduction resulting in the
formation of a pre-emulsion, using T 25 digital Ultra-Turrax™ at 11,000 rpm for 10 min by a cold
homogenization method. The temperature through the second step was maintained at 35 ± 2°C.
The particle size of the pre-emulsion was further reduced using a Vibra-Cell™ Ultrasonic Liquid
Processor, at an amplitude of 40%. A pulse cycle was opted for this step, based on optimizations
cycles run previously, and a 10 sec on and 15 seconds off pulse rate was set for a time duration of
10 minutes. The final formulation obtained post this step was further characterized
morphologically and for its permeation characteristics.
Formulation Characterization
Assay and Entrapment
For the extraction of VRC and CIP, a 1:1 mixture of 0.025M O-Phosphoric acid and acetonitrile
was used. Primarily, a volume of 10 µL was aliquoted from the formulation into centrifuge tubes.
VRC and CIP was extracted from this aliquot using 990 µL of the aforementioned extracting
solvent. This mixture was then sonicated at 30°C in a bath sonicator for 15 minutes to lyse the
nanoparticles and extract both VRC and CIP. Post extraction, the tubes were centrifuged
13,000 rpm for 15 min and the supernatant was analyzed for VRC and CIP content using a HPLCUV method.
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The formulations were analyzed for the %EE for VRC and CIP. Five hundred µL of the
formulation was aliquoted in a 100 kDa centrifugal unit made of regenerated cellulose membrane
(Amicon Ultra). This sample was centrifuged at 13,000 rpm, for 20 mins, following which the
filtrate was analyzed for unentrapped VRC and CIP content. Percentage EE was calculated using
the formula,
% EE = ((Total drug content-Amount of free drug in aqueous phase) *100)/ (Total drug content)
The DL on the other hand was calculated using the following formula,
% DL = (Amount of drug entrapped / Total lipid content) * 100
Chromatography
In vitro quantification took place by using a HPLC-UV method for simultaneously analyzing both
VRC and CIP. The HPLC-UV system comprised of a Waters 717 plus Autosampler, Waters 600E
pump controller, Waters 2487 dual λ Absorbance detector and an Agilent 3395 integrator. A
mobile phase consisting of 65: 35 of 0.025M O-Phosphoric acid and acetonitrile was used on a
Phenomenex® C18 (4.6 x 250 mm) column at a flow rate of 1 mL/min. The stock solution of VRC
was prepared in acetonitrile and that for CIP was prepared in 0.025 M O-Phosphoric acid. A
standard curve ranging from 1 to 100 µg/ml of both VRC and CIP was prepared by spiking required
concentrations from the individual stock solutions, whereas the dilutions were prepared using the
mobile phase. Detection was carried out at 254 nm.
Dynamic light scattering (DLS)
Photon correlation spectroscopy was one of the methods used to determine the particle size and
polydispersity index of the formulations. A Zetasizer Nano ZS Zen3600 (Malvern Instruments,
Inc.) was used to make all the DLS measurements at 25°C and with 173° backscatter detection in
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disposable folded capillary clear cells. A 100 times sample dilution was performed using bidistilled
water filtered using 0.2 µ syringe filters for all the measurements.
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Scanning transmission electron microscopy
Morphological characterization of VRC-CIP-PEG-NLC was carried out using STEM analysis.
This study helped in particle visualization and comparison of the morphology and particle size to
measurements made by DLS. The NLCs were stained using 1% uranyl acetate, using a negative
staining procedure. A 40-dual beam scanning transmission electron microscope by Zeiss Auriga®
was used to characterize the nanoparticles. The sample volume used for the study was 20 µL,
which was placed on a piece of parafilm. A 200-mesh glow discharged copper grid coated with a
thin carbon film was floated on top of the sample for about 30 secs, with the film facing the sample.
The grid was then removed, and the excess sample blotted off using a filter paper. This step was
followed by washing, the grid was placed on a drop of the ultrapure water and excess water was
blotted out. The grid was placed on a drop of 1% uranyl acetate for 1 minute with the sample facing
the stain. After the staining step, the excess stain was then removed, and the sample was dried
completely. After sample preparation, imaging took place using a Zeiss Libra operating at 30 kV
in STEM mode. (The STEM studies were performed at University of Tennessee, Knoxville).
In-vitro trans-corneal permeation
Transmembrane permeability of VRC and CIP from the VRC-CIP-PEG-NLC formulation was
evaluated across isolated rabbit corneas using PermeGear® vertical diffusion apparatus. To
establish the effect of dual drug loading, PEG-NLCs with each of the individual APIs, CIP-PEGNLC & VRC-PEG-NLC were also evaluated for their transcorneal permeability. Bearing in mind
the clinical implications of the optimized formulation, its permeability was compared to marketed
formulations; Ciprofloxacin Hydrochloride Ophthalmic Solution (0.3% as base) and Lyophilized
Voriconazole for Injection (200mg/vial, dose normalized using Dulbecco's phosphate-buffered
saline (DPBS) to 0.1% VRC). Five percent RMβCD in DPBS (5ml) was used in the receiver
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compartment. Aliquots (0.6 ml) were withdrawn from the receiver chamber at predetermined timepoints up to 3 hours and replaced with an equal volume of 5% w/v RMβCD in DPBS. The
concentration of VRC and CIP in the receiver medium was determined using an established HPLCUV method. At the end of 3 hours, the corneas were evaluated for the retention of API.
Results and Discussion
Excipient selection
Based on the excipient solubility screening studies, the lipids that demonstrated the maximum
solubility for both VRC and CIP were selected. Precirol® 888 ATO was chosen as the solid lipid
and castor oil as the liquid lipid.
Selection of a binary lipid phase
With each of the different ratios, we observed CIP finely dispersed and VRC completely
solubilized. However, with higher level of a liquid lipid we observed bleeding of the castor oil
from the Precirol® 888 ATO and API melt. A 1:1 ratio of solid lipid-liquid lipid was chosen to
formulate the NLCs.
Formulation optimization of VRC-CIP-PEG-NLC using RSM-CCD statistical design
Changing parameters or independent variables is the basis of determining the optimum conditions
or a level to a stable and effective formulation. This can be done by using the “one-factor-at-atime” technique, which involves running trials by individually changing singular independent
variables. However, this technique fails to take into consideration complex excipient interactions.
The presence of multiple components in a final formulation leads to the development of a complex
interactive concoction, and in this scenario, it is important to evaluate the independent and
interactive effects of all these variables. Table 19 lists the independent variables that were
evaluated in this design along with the different levels at which they were evaluated. The DOE in
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this case was used for excipient selection and enhancement of the drug loading of CIP and VRC.
The dependent variables, based on which the 30 formulation runs were evaluated were% Assay,
% DL, % EE, particle size (d. nm) and PDI. The run schedule at the different levels of independent
variables is listed in Table 18. Based on the design, 5 levels of each of the independent variables
was selected, with points concentrated around the center of the design, being a response surface
methodology.

Table.19. Effects of Independent Factors on the Response Variables, regression analysis
performed using Design-Expert® software
Response
variable
%EE (VRC)
%EE (CIP)
PDI
% DL (VRC)
% DL (CIP)
%Assay (VRC)

Model

Model Fvalue

Degree of
freedom

Linear
Quadratic
Quadratic
Quadratic
2FI
Linear

14.35
1.95
2.87
10.18
858.52
17.77

1
14
5
9
7
4

R2 values
R2
0.338
0.66
0.374
0.997
0.996
0.747

Adjusted R2
0.315
0.321
0.243
0.996
0.995
0.705

Table 20. Statistical significance using One-way ANOVA for individual response variables
Response
variables
%EE (VRC)
%EE (CIP)
PDI

%DL
(VRC)

Independent factors that
affect the response
variable significantly
A
D
D2
A2
BC
A
B
C
AB
AC

p-value

Model equation

0.0007
EE (VRC) = +81.24 +10.18 A
<0.0001
EE (CIP) = +90.96 + 12.99 D -9.54 D²
<0.0001
0.0057
PDI = +0.4073 -0.0163 A +0.0107 B
+0.0171 C -0.0584 BC - 0.0664 A²
0.0582
<0.0001
DL (VRC) = +3.31 +1.84 A -0.3630
<0.0001
B -0.4632 C -0.2111 AB <0.0001
0.268 AC +0.0938 BC +0.0893 A²
<0.0001
+0.0636 B² +0.0828 C²
<0.0001
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Response
variables

%DL (CIP)

%Assay
(VRC)

Independent factors that
affect the response
variable significantly
BC
A2
B2
C2
A
B
C
D
BC
BD
CD
A

p-value
0.0029
0.0004
0.0066
0.0008
0.00234
<0.0001
<0.0001
<0.0001
0.0149
<0.0001
<0.0001
<0.0001

Model equation

DL (CIP) = +3.62 -0.0641 A -0.3753
B -0.4463 C +1.94 D +0.0852
BC -0.1970 BD -0.2398 CD

Assay (VRC) = 64.56 -16.02 A +
2.75 B + 1.72 C - 3.06 D

The optimum formulation should aim for a maximum DL for both, VRC and CIP without
affecting the overall formulation stability, maintaining particle size and PDI at the minimum.
Figure 27. is a 3D graph representing the effect of PEG and lipid ratio on particle size of the
formulation. The regression analysis for this response variable did not determine any model fitting
the data with a significant p-value (<0.05), however the 3D surface graph enables us to visualize
the trend in the data. We observe a particle size increase at increasing levels of PEG (Figure.27.
A), from 195 mg and above and with an increase with the total lipid concentration. A quadratic
model best fit the PDI data (Table 19.); the variables that significantly affected the PDI values as
per the model equation in Table 20. are VRC concentration (A) and an interaction term (BC),
between the PEG and lipid ratio. Looking at Figure 27.B. which depicts the change in PDI, a
similar trend is followed as the particle size, with higher PDI at high levels of PEG and lipid
content. However, at high levels of both lipid and PEG we observe a drop in the PDI, which
explains the negative sign on the significant BC interaction (Table 20.). Reportedly, PEG forms a
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layer on top of the solidified lipids, stabilizing the colloidal system192. High levels of PEG, with
low lipid content could lead to self-association of the PEG and further aggregation, as seen with
the slight increase in PDI in Figure.27.B. Increasing the overall solid bulk reflects with an increase
in the particle size and for maintaining a particle size of about 200 d. nm, a total lipid ratio below
570 mg and PEG concentration below 195 mg would be desirable.
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Figure.27. 3D Surface plots showing the effect of PEG and 1:1 castor oil and Precirol® 888 ATO
on the Particle Size (d. nm) (A) and PDI (B)
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Figure.28. depicts the effect of PEG and Lipid Ratio on the %DL of VRC. Increasing PEG
concentration resulted in lowering of the %DL of VRC at both low (450 mg) and high (630 mg)
of total lipid content. However, at a lower lipid ratio, the decrease in drug loading on increasing
the PEG was higher than at a higher lipid ratio. From this observation, we can deduce that presence
of PEG affects the loading of VRC; possible reasons for the decrease in DL could be the time of
addition of PEG into the lipid melt during the initial mixing step, which would be a critical
parameter in this situation, allowing VRC to partition into the lipid phase. Presence of high levels
of PEG could possibly hinder the partitioning of VRC into the lipids by displacing the same.

Figure.28. Interaction plots depicting the effect of PEG and 1:1 castor oil and Precirol® 888 ATO
on the % Drug Loading of VRC
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Looking at the equation for %Assay of VRC (Table 20.), both VRC and CIP have a
negative impact on the drug content of VRC, as denoted by the negative signs. From Figure.29. A,
we can see that increasing CIP content in the formulation has a negative effect on the %Assay of
VRC. We also observe an effect of total lipid content on % Assay of VRC; at lower loading levels
of CIP, a high lipid content improves the % Assay. Distribution of CIP in the lipids may saturate
their solubilizing potential for VRC, possibly resulting in leaching of the drug outside the lipid
matrix, or lower amount of drug being encapsulated in the first place. Overall, on increasing the
PEG and total lipid content, the % Assay of VRC increases (Figure.29. B.), indicating that PEG
and the lipids encase the drug and stabilize it, protecting it from degradation.
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Figure.29. Contour plot describing the effect of (A) CIP loading amount and (B) PEG and 1:1
castor oil and Precirol® 888 ATO on the % Assay of VRC.

B
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A

Figure.30. 3D Surface plots showing the effect of PEG and 1:1 castor oil and Precirol® 888 ATO
on the (A) % Assay and (B) % Drug Loading of CIP
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For % Assay of CIP, on the other hand (Figure.30. A), increasing the total lipid content
above 600 mg at lower levels of PEG (75-165 mg) results in a lower % Assay of CIP. A high PEG
content is not favorable for increasing CIP content in the formulation. This observation agrees
with the % DL for CIP, a lower total lipid content and a lower PEG content is favorable for CIP
content.
Based on the models generated for the response variables with the 30 runs, a composite
function was developed by Design-Expert® Software to compute the desirability of a factor
combination. The desirability of a composition can be calculated by incorporating factor
constraints and modifying the factor selection criteria. The aim was to minimize the particle size
and the PDI and maximize the % DL and % EE. Table 21. depicts the composition of the optimized
formulation with a desirability of 0.768. Comparing the model predicted values to the actual values
of the formulated suspension, the values of most responses are close to the predicted values,
indicating that the model is a good predictor for the current formulation (Table 21.). The particle
size of the optimized VRC-CIP-PEG-NLC formulation was 240.67 ± 2.4 d. nm with a PDI of 0.19
± 0.02 and zeta potential of -49 ± 1.28 mV. The drug content was 92.63 ± 0.91 % for VRC and
101.93 ± 0.41 for CIP with an entrapment efficiency of 73.98 ± 1.71 for VRC and 98.86 ± 0.49
for CIP. The formulation was stable for 1 month at both storage conditions of 25°C/75% RH and
4°C (Figure.31.); we observe that the particle size and PDI of the formulation is maintained around
230-240 d. nm and 0.1-0.2 respectively. We do not observe a significant drop in the % Assay and
% EE for both VRC and CIP, pointing towards a stable formulation.
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Figure.31. Changes in (A) Particle size and PDI, (B) % Assay, %EE for VRC in VRC-CIP-PEGNLC, (C) % Assay, %EE for CIP in VRC-CIP-PEG-NLC stored 4°C and 25°C/75% RH over a
period of 1 month

Table 21. Composition of the Most Desirable Formulation Obtained by Design-Expert® Software
with Predicted and Experimental Values
Formulation composition

Predicted values

Experimental values

VRC (15 mg)

%DL (VRC)

2.09

2.38

CIP (30 mg)

%EE (VRC)

71.35

73.98
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PEG (100 mg)

%DL (CIP)

4.44

6.06

Lipid Ratio (450 mg)

% EE (CIP)

90.96

100

% Assay (VRC)

76.59

92.63

PDI

0.29

0.19

Morphological characterization
Figure.32. depicts the morphology of the VRC-CIP-PEG-NLC formulation. The morphology of a
nanoparticulate system is significantly governed by the processing conditions used. A cold
homogenization-ultrasonication method was used for the formulation of the NLCs. During
formulation development attempts, we observed that VRC, at higher processing temperatures,
migrated outside the oily lipid phase and precipitated in the form of shiny crystals. In order to
prevent migration of VRC outside the lipid, during the first processing step, i.e. magnetic stirring,
a high temperature of 80°C was employed, but, post this step, the temperature of the entire process
was maintained below the melting temperature of the lipid mixture. The cold homogenizationultrasonication that followed, was more a fragmentation process to reduce the particle size, which
can be seen in the STEM images in Figure.32. The NLCs have a well-defined periphery, but in
comparison to the well-rounded NLCs as synthesized by a hot homogenization or a high pressure
homogenization process, 192 the spherical particles so formed have an un-even rounded structure.
However, the morphology does not affect the stability of the NLCs; presence of a stable surfactant
system and PEG help in stabilizing this nano-colloidal system. The particle size observed in
Figure.32. is in close agreement with the particle size measurements from DLS as mentioned
previously.
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Figure.32. STEM images for the optimized VRC-CIP-PEG-NLC formulation

In-vitro trans-corneal permeation
Permeation of the VRC-CIP-PEG-NLC formulation across isolated rabbit corneas was observed
(Figure.33.); VRC-CIP-PEG-NLCs, being targeted as an antifungal formulation, the major sites of
action for this formulation would be the cornea and the anterior chamber. To establish effective
comparators, the transcorneal permeation of marketed Ciprofloxacin Hydrochloride Ophthalmic
Solution and Lyophilized Voriconazole for Injection was also evaluated. To establish the effect of
a dual-drug loaded formulation on the in-vitro transcorneal permeation, if any, individual drugs
loaded in the same base formulation were also evaluated in a similar setup.
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Figure.33. Graphical representation of the Permeability (cm/sec) and Flux (µg/min/cm2) across
isolated rabbit corneas of VRC and CIP from CIP-PEG-NLC, VRC-PEG-NLC, VRC-CIP-PEGNLC and CIP and VRC marketed formulations (n=3) over a period of 3 hours

Table 22. Significant p-values enlisted post one-way ANOVA analysis for the ordered between
group differences for CIP-PEG-NLC, VRC-PEG-NLC, VRC-CIP-PEG-NLC and CIP and VRC
marketed formulations (n=3). A p value < 0.05 was significant.
Parameter

Formulations

p-value

Flux

CIP MKTD

VRC-CIP-PEG-NLC (CIP)

0.0034

(µg/min/cm2)

CIP MKTD

CIP-PEG-NLC

0.0036

Permeability

CIP MKTD

VRC-CIP-PEG-NLC (CIP)

0.0032

(cm/sec)

CIP MKTD

CIP-PEG-NLC

0.0034
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Corneal

VRC-CIP-PEG-NLC (VRC)

VRC-MKTD

0.0005

concentrations

VRC-PEG-NLC

VRC-MKTD

0.0084

(µg/ml)

VRC-CIP-PEG-NLC (VRC)

VRC-PEG-NLC

0.0326

The transcorneal flux for CIP from the marketed Ciprofloxacin Hydrochloride Ophthalmic
Solution (0.3% as base) was greater than 10 times (1.52 ± 0.43 µg/min/cm2) that from CIP-PEGNLC (0.14 ± 0.03 µg/min/cm2) and the VRC-CIP-PEG-NLC (0.12 ± 0.04 µg/min/cm2)
(Figure.33.). Table 22. enlists these differences as statistically significant. The transcorneal
permeability of CIP was 506.06 ± 143.65 cm/sec for the marketed Ciprofloxacin Hydrochloride
Ophthalmic Solution, significantly greater than the permeability of CIP from both CIP-PEG-NLC
(39.96 ± 8.02 cm/sec) and VRC-CIP-PEG-NLC (36.77 ± 12.39 cm/sec) (Figure 33., Table 22.).
The concentrations of CIP retained on the isolated corneas post the study were 40.46 ± 2.78 µg/ml,
4.85 ± 1.58 µg/ml, 3.97 ± 0.46 µg/ml for the CIP-MKTD, VRC-CIP-PEG-NLC (CIP) and CIPPEG-NLC formulations respectively (Figure.34.). CIP MKTD being a Ciprofloxacin
Hydrochloride (salt -form) has a high solubility in the pre-corneal area. The formulation is in a
solution form resulting in high transcorneal permeation and corneal retention. CIP being entrapped
in a lipid-based system demonstrates a controlled release and permeation.
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Figure.34. Graphical representation of the concentrations (µg/ml) of CIP and VRC retained in
isolated rabbit corneas 3 hours post dosing of CIP-PEG-NLC, VRC-PEG-NLC, VRC-CIP-PEGNLC and CIP and VRC marketed formulations (n=3) in an in-vitro transcorneal permeation
setup.

The transmembrane permeation of VRC from the PEG-NLCs was better than the marketed
Lyophilized Voriconazole for Injection. The flux for VRC from the marketed formulation was
0.39 ± 0.08 µg/min/cm2 whereas from the VRC-PEG-NLC was 0.48 ± 0.1 µg/min/cm2 and that
from VRC-CIP-PEG-NLC was 0.57 ± 0.21 µg/min/cm2. The permeability of VRC from the VRCPEG-NLC and VRC-CIP-PEG-NLC was 334.46 ± 71.01 cm/sec and 381 ± 138.04 cm/sec and that
from the marketed formulation was 258.25 ± 50.82 cm/sec. The corneal tissue concentrations were
1.14 ± 0.51 µg/ml from VRC-PEG-NLC and 1.97 ± 0.11 µg/ml from the VRC-CIP-PEG-NLC,
whereas no VRC was detected in the corneas treated with the VRC MKTD formulation. Higher
permeation of VRC across the corneas from the lipid based nano-systems could be as a result of
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interaction of this colloidal system with the cornea and possible internalization of the same
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.

However, vehicle-related permeation enhancement of a molecule is also a function of the inherent
molecule properties and the permeation pathway best-fitting the molecule. Lipophilic VRC
entrapped in a PEGylated NLC system demonstrated enhanced permeation, whereas for a highly
water-soluble molecule like CIP, when entrapped in a lipid based nanocarrier failed to demonstrate
a similar effect. From Figure 34. we observe higher amounts of CIP retained in the cornea, but not
permeating across. CIP being a hydrophilic moiety, may be entrapped in the hydrophilic stromal
layers, whereas VRC could be permeating by a different (transcellular) pathway altogether. We
should also keep in mind that the loading of the two APIs is at two different levels, with a 0.15%
w/v load for VRC and a 0.3% w/v loading for CIP, despite which the lipid-based carrier system
enhances the permeation of VRC in comparison to both the VRC-MKTD and the CIP
formulations.
Conclusion
These set of studies successfully used a DOE method to optimize a dual drug loaded
PEGylated lipid nanocarrier. An RSM-CCD was utilized for excipient level optimization,
furthermore, a cold-homogenization- probe sonication process was optimized for the development
of the formulation. The optimized formulation was nano-sized and stable over a period of 1 month
at both 4°C and 25°C/75% RH over a period of 1 month.
The VRC-CIP-PEG-NLC have a comparable permeability and flux to the individual drug
loaded formulations, indicating that each of the APIs are compatible and permeate freely across
isolated corneas. The marketed CIP solution, being in the salt form depicts high transcorneal flux
and permeability as well as high corneal retention. In terms of VRC, however, the PEGylated
NLCs demonstrate a slightly better permeation profile than the marketed formulation and
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improved corneal retention. Thus, a PEGylated nanocarrier system increased the penetration of
VRC across the cornea and controlled the release and permeation of CIP. Further studies
investigating the efficacy of the formulation as an antifungal preparation and exploring the
synergism between CIP and VRC would be a great asset for utilizing this dual drug loaded
formulation as an alternative to conventional therapy.
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CHAPTER 6
OPTIMIZATION OF CAPPING PARAMETERS FOR LOW
TEMPERATURE STORAGE OF A PLASTIC VIAL-RUBBER STOPPER
COMBINATION
Introduction
Most of vaccines and biologic drug products (DP) being thermosensitive, are stored at 2-8°C,
ensuring product quality and potency. However, for some products like Zostavax®, which is an
attenuated varicella virus, a frozen storage state (-80°C) is preferred to ensure sufficient stability
for the required shelf life.194-195 Such products are often shipped in a frozen state using dry ice,
subjecting the product to temperatures lower than -50°C.
Container closure systems (CCS) for drug products usually comprise of a glass vial, elastomeric
stopper and an aluminum crimp cap. The glass transition temperature, (Tg’) of most rubber
stoppers is in the range of –50 to – 65 °C. Aforementioned low storage temperatures might lead to
shrinkage of the rubber and loss of elastomeric properties. In addition, storage temperatures of 80°C can cause condensation of air in the vial headspace resulting in a low-pressure environment.
Loss of stopper elasticity coupled with under pressure in the vial headspace can end up with ingress
of cold dense gas from the immediate environment, implying a potential container closure integrity
(CCI) compromise.196

197

While shipping the DP on dry ice, this CCI breach can lead to carbon

dioxide (CO2) ingress, which may further cause a pH drop affecting DP stability.
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Methods such as dye ingress, vacuum decay and microbial ingress can be used to study CCI at
ambient conditions. However, evaluation of CCI of frozen drug products is a relatively new area
and not much has been spoken about it. In a frozen state, investigative techniques such as Helium
(He) leak detection test and nondestructive gas headspace analysis can be employed.
CCI can be enhanced by selecting CCS components with good compatibility i.e. marriage of the
elastomer and the vial and implementing a tightly sealed vial at all storage conditions. Residual
Seal Force (RSF (Lbs)) is the force exerted by the compressed rubber stopper on the vial-sealing
surface and is a measure of the seal tightness or the seal integrity. A quality seal requires optimal
amount of force in the capping process, which is reflected by a high RSF (Lbs). This can be
measured by the RSF tester, an instrument calculating RSF by a compression stress/distance plot
as it applies a known force over a distance on a capped vial. In addition, visual acceptability is an
important factor to take into consideration in the capping process; the capping parameters have to
be modified to prevent defects such as wrinkling of cap skirt and dimpling rubber stoppers. It is
important to consider visual inspection of crimped vials as a part of any optimization process. 194
This project focuses on enhancing CCI of a particular vial stopper combination by maximizing the
RSF during the capping process whilst generating a visually acceptable seal. We also attempt to
standardize the crimping process across single-station cappers by using RSF as the output variable.
A systematic approach was employed for optimizing the crimping parameters using DOE for a
selected container closure combination (CZ® vial and chlorobutyl rubber stopper) for -80 °C
storage. Two single-station cappers were studied, both the cappers use different techniques to
crimp the vial. The Integra West Capper® uses a spinning roller technique for crimping a stoppered
vial using an aluminum crimp cap. The spinning rollers tuck the skirt of the cap under the vial
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flange to attain a visually acceptable seal. The Bausch and Strobel® capper on the other hand
features a capping station with a plunger and stationary roller blades and a rotating vial holder.
Each capping instrument has a set of input variables (factors) that affect the seal quality. RSM CCD was used to generate a design space for crimping for the Integra West Capper®. Due to the
multiple instrument parameters on the Bausch and Strobel® capper, a D-optimal design was
initially employed to determine the main effects for the design. The D-optimal design was then
augmented into an I-optimal design for capping process optimization on the Bausch and Strobel®
capper. RSF was modelled as the response variable along and the vials were verified for visual
acceptability.
Materials and Methods
Materials
Daikyo (Tokyo, Japan) Crystal Zenith (CZ®) vials with a 20mm vial neck diameter were stoppered
using FluroTec® barrier coated 20mm chlorobutyl rubber stoppers by West (Exton, PA, USA). All
vials were sealed using 20mm aluminum crimp cap by West (Exton, PA, USA) with a flip-off seal.
Equipment
Vials were sealed using two single-station cappers, (a) Integra West Capper® (Genesis Packaging
Technologies, Exton, PA, USA) and (b) Bausch and Strobel® capping equipment HVM4610
(Ilshofen, Germany).
RSF Measurements
All RSF measurements were conducted using the RSF tester by Genesis Packaging Technologies,
Exton, PA, USA.
Statistical Experimental Design
Capping Process Optimization: Integra West Capper®
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The Integra West Capper® is a single station capping machine used on a laboratory scale and has
two modifiable capping process parameters affecting the final seal quality, namely, Precompression force (Lbs) and Pressure Block Reference Height (thousands of an inch). Precompression force is the force applied by the plunger on the aluminum seal with the flip-off cap
(Figure 35. A), whereas Pressure Block Reference Height is the distance between the plunger and
the capping plate (Figure 35. B).

A

B

*Mathaes, R., Impact of Vial Capping on Residual Seal Force and Container Closure Integrity, PDA (copyright pending)

Figure 35. Vial crimping for the Integra West Capper®

A CCD was employed in the capping process optimization experimental design using
JMP® 12 statistical software (SAS Institute, NC, USA) with the independent variables being (A)
Pre-compression force and (B) Pressure Block Reference Height whereas RSF was considered as
the response variable (dependent variable). A CCD uses RSM suitable for investigating the
quadratic response surface and for constructing a second order polynomial model. The limits of
the independent parameters were determined on the basis of random trials conducted before the
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optimization study. In the given study, the above-mentioned two factors were coded as A and B
respectively, each, studied at five levels, A as -α: 10, -1: 13.98, 0: 35, +1: 56.02, +α: 60 and B as
-α: 100, -1: 103.2, 0: 120, +1: 136.8, +α: 140 in 9 different combinations: (0, +α), (-1, +1), (+1,
+1), (-α, 0), (0, 0), (0, +α), (-1,-1), (+1, -1), (0, -α), each combination repeated five times. Table
23. provides the details on the experimental design employed in this study.

Table 23. Design space for the CCD for the vial crimping process on the Integra West Capper®

Run number

Pre-compression Force (Lbs)

Pressure Block Reference Height
(inch*10-3)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

13.98
35.00
10.00
10.00
13.98
56.02
35.00
56.02
35.00
35.00
13.98
60.00
35.00
13.98
56.02
60.00
13.98
56.02
60.00
35.00
35.00
13.98
10.00
60.00
56.02

103.2
120.0
120.0
120.0
136.8
103.2
120.0
103.2
120.0
100.0
103.2
120.0
140.0
103.2
136.8
120.0
136.8
103.2
120.0
120.0
100.0
103.2
120.0
120.0
103.2
136

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

35.00
56.02
56.02
35.00
56.02
10.00
13.98
35.00
13.98
13.98
35.00
60.00
10.00
35.00
13.98
35.00
56.02
35.00
56.02
35.00

100.0
136.8
136.8
120.0
103.2
120.0
103.2
140.0
136.8
136.8
100.0
120.0
120.0
140.0
136.8
140.0
136.8
100.0
136.8
140.0

The general form of the model generated from the design is given below,
Y = β0 + β1A + β2B + β3AB+ β4 A2+ β5 B2 + ε
Where Y is the measured value of the response variable and β0, the intercept, is the arithmetic
average of all quantitative outcomes of 45 experimental runs, β1-β5 are the coefficients computed
from the observed experimental values of Y, and A and B are the coded levels of the independent
factors. The A and B terms indicate the average result of changing one factor at a time from its
low to high value. The interaction term, AB suggests the response changes when these two factors
are changed simultaneously whereas the terms A2 and B2 depict the quadratic terms. The equation
aids in understanding the effect of the independent factor/s on the response variables after
considering the intensity of coefficient and the mathematical sign it carries, that is, positive or
negative. A positive sign indicates additive effect. Statistical validity was established based on
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ANOVA provided in the JMP® 12 statistical software (SAS Institute, NC, USA), with level of
significance considered at p < 0.05.
The model thus generated was then validated by testing multiple points on the design space and
comparing the generated actual results to the values predicted by the model.
Capping Process Optimization: Bausch and Strobel® capper
The Bausch and Strobel® Capper is a single station, hand sensor activated capping machine with
in-built settings allowing to modify the capping recipe. This machine has a greater number of
modifiable crimping parameters in comparison to the Integra West Capper®, namely, Lower
position of crimping tool (in mm) (X1), Crimping tool lift (in mm) (X2), Crimping tool swivel
movement pre--crimping position (in °) (X3), Crimping tool swivel movement crimping position
(in °) (X4), Container rotation revolutions (X5). However, the parameters X3 and X4 denoting
position of the crimping disc before and at the end of the crimping process had to be constant for
a single vial-capper combination in accordance to the manufacturer recommendation.

Figure 36. Capping parameters on the Bausch and Strobel® capper
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The distance (A) in Figure 36. was preset whereas distance (B) corresponding to the factor
X1 and had to be modified physically and measured with the help of Vernier calipers. This value
determined how hard the crimping disc (11) pressed against the container neck (12) from below.
The three major factors or input variable identified that affect the seal quality were Distance B
(mm) X1, Tool lift (mm) X2 and number of rotations X5. A D-optimal design space was generated
to screen the modifications of these parameters. The number of rotations (X5) were studied as a
categorical variable at three levels i.e. 4, 7 and 10. The crimp quality was measured in terms of the
response variable, RSF. D-optimal experimental design was used for creating the experimental
design attesting statistical significance using ANOVA and empirical modelling. This method has
some advantages compared to other designs resulting in smaller number of runs and the ability to
include categorical factors in the DOE. This optimization strategy can be employed to evaluate the
relationship between multiple independent variables and determination the optimum conditions
required to produce a specific desired response. 198
The first step of generating the design space was to estimate the machine as well as acceptability
limits of the input variables, i.e. create the edges of the design space. This was done by conducting
random trials individually modifying the input variables (data not shown). Once the limits of the
input variables were established, a D-optimal screening study was conducted using JMP®
12 statistical software (SAS Institute, NC, USA). A 50-run design was generated using the
software; runs are depicted in Table 24.
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Table. 24 Design space for the D-optimal design on the Bausch and Strobel® capper

Run number

X1: Distance B (mm)

X2: Tool Lift (mm)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

34
35.5
34
34
35.5
34
34
34
34
34
34.75
34
34
34
35.5
35.5
34
35.5
34.75
35.5
35.5
34
34
35.5
35.5
35.5
35.5
34
34.75
34
35.5
35.5
34
35.5
34
34

20
2
2
2
2
20
20
20
20
20
11
2
2
2
2
2
2
2
11
2
20
20
20
20
20
20
2
2
11
2
2
2
2
20
2
2
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X5: (Categorical
variable) Number of
rotations
10
7
4
4
10
10
10
10
7
10
7
10
10
10
10
10
4
4
7
4
10
4
4
10
4
10
4
10
7
10
4
10
4
4
4
4

37
38
39
40
41
42
43
44
45
46
47
48
49
50

34
35.5
35.5
34
35.5
34
35.5
35.5
35.5
35.5
34
35.5
35.5
34

20
2
20
2
20
20
20
20
20
2
20
20
2
20

4
10
7
7
4
4
10
10
4
4
4
4
7
4

The general form of the model generated from the design is given below,
Y = β0 + β1X1 + β2X2 + β3X3 + β1 β2 X1 X2 + β1β3 X1X3 + β2β3 X2 X3 + β1β2 β3 X1X2X3 + ε
D-Optimal designs are appropriate for screening experiments because the optimality
criterion focuses on precise estimates of the coefficients. This design focuses more on the
extremities of the design than in the center and is efficient for determining the extent of a design
space. D-optimal designs, however, are not appropriate for experiments where the primary goal is
prediction. On the other hand, an I-optimal design places fewer runs on the extremes and focuses
on the center of the design space, making them robust predictor designs. Based on the data
generated by the D-optimal design, a response surface screening study was conducted (I-optimal
design). Zones of interest were identified from the D-optimal design, factor constraints and
variable limits were defined accordingly. The I-optimal study allowed us to focus on the
optimization area of interest by tailoring the limits of the design space. (Height B: 34-34.8 mm;
Tool Lift: 12-20 mm; Rotations: 7, 10) The design was augmented with an additional 50 runs as
shown in Table 25.
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Table 25. Design space for the I-optimal design on the Bausch and Strobel® capper

Run number

X1: Distance B
(mm)

X2: Tool Lift
(mm)

X5: (Categorical variable)
Number of rotations

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85

34
34
34.6
34.6
34
34
34
34.6
34
34.6
34.7
34
34
34
34
34
34.7
34.7
34.6
34.6
34.7
34.6
34.7
34
34
34.7
34.6
34.6
34.7
34.6
34.7
34.7
34.7
34
34.6

12.4
12.4
20
20
12.4
12.4
12.4
20
12.4
20
12.4
12.4
20
12.4
12.4
20
12
12
20
20
12
20
12
20
12.4
12
20
20
12
20
12
12
12
20
20

7
7
7
7
7
7
7
7
7
7
7
7
10
7
7
10
7
10
7
7
10
7
10
10
7
10
7
7
7
7
7
10
7
10
7
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86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

34.7
34
34.7
34.7
34.7
34.7
34.7
34.6
34.7
34.7
34
34.6
34.7
34.6
34.7

12
12.8
12
12
12.4
12.4
12
20
12
12
12.4
20
12
20
12

10
7
7
10
7
7
10
7
10
10
7
7
10
7
10

Statistical validity was established based on ANOVA provided in the JMP® 12 statistical software
(SAS Institute, NC, USA), with level of significance considered at p < 0.05.
The model thus generated was then validated by testing multiple points on the design space and
comparing the generated actual results to the values predicted by the model.
Results and Discussion
Capping Process Optimization: Integra West Capper®
Table 26 summarizes the regression analyses evaluating effects of factors on the response variable
(RSF). On the basis of lack-of-fit p-value (0.762) and sequential p-value (<0.0001), a quadratic
model was chosen with a Power (y + k)λ transformation as suggested by the Box-Cox diagnostics.
The positive unstandardized coefficients (β) represent an increase in response variable with a unit
increase in the predictor. The reverse applies to coefficients with negative values (7). The extent
of the effect of the independent factors on RSF was determined using the regression analyses and
plots that provided RSM analyses. Table 27 lists the factors that significantly affect RSF and also
the predictive equation for the quadratic model. It is observed that both factors A and B, which are
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the Pre-compression force (Lbs) and Pressure block reference height (inch*10-3) significantly
affect RSF and they also have a quadratic effect which is evident by the curvature in the Figures
37.A, and 37.B. As the Pressure block reference height is increased up to 120-125 inch*10-3
(Fig.37.A) at a constant Pre-compression force, the RSF value increases.

Table 26. Regression analyses for evaluating the effects of independent factors on the response
variable

Capper
Integra West
Capper®
Bausch and
Strobel®
(D-optimal)
Bausch and
Strobel®
(I-optimal)

R2 values
Adjusted
R2
R2

Model

Model F-value

Degree of
freedom

Quadratic

107.67

5

0.932

2FI

36.104

4

0.762

Quadratic

53.895

5

0.741

0.924

0.741

0.728

Table 27. One-way ANOVA analysis for Quadratic Model on the Integra West Capper®
Response
variables

Independent factors that affect the
response variable significantly

p-value

Model equation

RSF
(Lbs)

A
B
AB
A2
B2

<0.0001
<0.0001
<0.0001
0.0001
<0.0001

RSF = -5.71 + 0.25 A +
0.132 B + 0.011 AB + 0.006
A2 -0.028 B2
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On further increasing the Pressure block reference height, there is an extreme drop in the
RSF. This observation can be explained as Pressure Block reference height determines the length
of the aluminum skirt tucked under the vial flange. As this height is increased, the capping plate
to plunger distance reduces causing the aluminum skirt of the cap to deform and resulting in low
RSF values. However, looking at the effect of the other factor, RSF increases with an increase in
the Pre-compression force at constant Pressure block reference height of 120 inch*10-3. (Fig.37.B)

Design-Expert® Software
Factor Coding: Actual
Original Scale
RSF (lbs)
Design Points
95% CI Bands

One Factor
Warning! Factor involved in AB

25

A.
20

B.

Actual Factor
B: Pressure block reference height = 120.0

15

RSF (lbs)

RSF (lbs)

One Factor
Warning! Factor involved in AB interaction.
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X1 = A: Pre compression force

X1 = B: Pressure block reference height

Actual Factor
A: Pre compression force = 35.00

Design-Expert® Software
Factor Coding: Actual
Original Scale
RSF (lbs)
interaction.
Design Points
95% CI Bands

10

20

15

10

5

5

0

0

103.2

111.6

120.0

128.4

13.98 18.18 22.39 26.59 30.80 35.00 39.20 43.41 47.61 51.82 56.02

136.8

A: Pre compression force (Lbs)

B: Pressure block reference height (thousands of an inch)

Figure 37. A. RSF at increasing values of Pressure block reference height when Pre-compression
force is at a constant of 35 Lbs; B. RSF at increasing values of Pre-compression force when
Pressure block reference height is at a constant of 120 inch*10-3.

The model also presents with a significant AB interaction (Table 27.) represented
graphically in Figure 38. The increase in RSF with Pressure Block reference height is significantly
dependent on the level of Pre-compression force. At a lower level of Pre-compression force (103.2
inch*10-3), increase in the Pressure-block reference height does not lead to a significant change in
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the RSF, however at a higher level of Pre-compression force (136.8 inch*10-3), there is a
significant increase in RSF with an increase in Pressure Block reference height.

Design-Expert® Software
Factor Coding: Actual
Original Scale
RSF (lbs)
Design Points
95% CI Bands

Interaction
25 B:

X1 = A: Pre compression force
X2 = B: Pressure block reference height

Pressure block reference height (thousands of an inch)

20

RSF (lbs)

B- 103.2
B+ 136.8

15
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5

2

3
2

0

Design-Expert® Software
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Design Points
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A: Pre compression force (Lbs)

25 B:

X1 = A: Pre compression force
X2 = B: Pressure block reference height

Pressur

20

Figure 38. Significant interaction between Precompression force and pressure block reference
height for the Quadratic model on the Integra West Capper®

RSF (lbs)

B- 103.2
B+ 136.8

Figure 39. Illustrates a 3D surface profiler, the X1 axis representing increasing levels of

15

10

5

2

Pressure block reference height whereas the X2 axis portraying increasing levels of Precompression force, with a single output (response) variable on the Y axis, RSF (Lbs). Increasing
the Pre-compression force at lower levels of Pressure Block reference height does not significantly
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3

0

13.98 18.1

affect RSF values. However, at Pressure block reference height 120-130 inch*10-3 the predicted
RSF values are above 20 Lbs, making it the optimum working range for this process. The orangered region in the 3D graph are the model predicted zones for process parameters leading to
maximum RSF values.

X2

X1

Figure 39. RSM generated 3D Surface Profiler for Integra West Capper® depicting RSF (Lbs) at
different levels of Independent variables

The robustness of model predictions was verified by crimping vials at different factor
combinations and comparing the actual RSF to the model predicted RSF. Table 28 represents the
factor combinations chosen for the validation study. (n=10) Figure 40. illustrates the results of this
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validation. Mean RSF (Lbs.) (red bar) and Mean RSF predicted (blue bar) are plotted on the Yaxis against increasing levels of Pressure Block reference height divided by Pre-compression force
on the Y2-axis. There is no statistically significant difference amongst the actual vs the predicted
RSF values at any level of Pre-compression force or Pressure Block reference height.

Table 28. Model Validation parameters for Integra West Capper®
Pre-compression Force
(Lbs)

Pressure Block Reference Height
(inch*10-3)

Predicted RSF
(Lbs)

25
32
37
40
60

125
128
128
130
110

15.2
17.1
18.8
19.1
14.7

Figure 40. Design validation, Actual vs Predicted RSF (LBS) varying Pre-compression force and
pressure block reference height.
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Capping Process Optimization: Bausch and Strobel® Capper
The Bausch and Strobel® capper had a greater number of factors affecting the RSF in comparison
to the Integra West Capper® including a categorical variable. A D-optimal design was chosen as a
screening study to initially study the design space and observe the effect of single factors/
interactions on the response variable. Table 29. summarizes the regression analyses evaluating
effects of factors on the response variable (RSF). A 2FI (2 Factor Interaction) model was selected
for this analyses on the basis of favorable R- Squared value (0.762) and the Lack of Fit test p-value
(0.915). Table 29 lists the factors that significantly affect RSF and the predictive equation for the
2FI model. According to this model, factors Distance B (mm), Tool lift (mm) and Number of
rotations significantly affect RSF of the final crimp.

Table 29. ANOVA for 2FI model and Quadratic model for D-optimal and I-optimal design
respectively
Experimental
design
D-optimal
design
(Screening)
I-optimal
design
(Optimization)

Independent factors that affect
the response variable
significantly
X1
X2
X5
X1X2
X1
X2
X5
X1X2
X12

p-value

Model equation in terms
of Coded Factors

<0.0001
<0.0001
0.0161
<0.0001
<0.0001
<0.0001
0.0161
<0.0001
0.0026

RSF = 9.29 -5.24 * X1 +
3.40* X2 + 1.72 * X5 [1]
-0.12* X5 [2] -4.46 * X1X2

RSF = 16.82+ -2.756 * X1
+ 2.39* X2 + 1.298 * X5 +
{X1 X2* -1.021} + {X12*
-0.763}

We also observe a significant two factor interaction between Distance B and the Tool lift (Figure
41.). From Figure 41 we can conclude that RSF is not significantly dependent on the Distance B
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at low levels of the Tool lift (2mm), however, at a higher level of Tool lift (20 mm), RSF decreases
with an increase in Distance B.
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Figure 41. 2FI for the D-optimal screening design, Factors Distance B and Tool lift.

Distance B corresponds to the height of the container with a loosely positioned cap and lesser this
distance, snugger is the fit of the cap. The crimping tool protrudes (lifts) during the time of
crimping. Tool lift is the lift of the crimping tool during the crimping process, and thus at higher
value of tool lift the vial is sealed more tightly and corresponds to high RSF value. The D-optimal
screening study provides us with a general idea about the acceptable factor limits for the model.
Figure 42. depicts the prediction profiler for the D-optimal design helping us determine factor
constraints for further augmenting this design. It is not desirable (desirability factor below 0.5) to
increase the distance B above 34.8 mm or to reduce the Tool lift below 12 mm. Taking into
consideration the data from both of the output variables, the factors were further tailored for the
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34

augmentation, Distance B was studied from 34-34.8 mm, Tool lift was studied from 12-20 mm
and number of rotations were restricted to 7 and 10.

Distance B

Figure 42. Prediction profiler for the D-optimal screening design: Output variable RSF, Input
variables: Distance B, Tool lift and Number of rotations and the predicted Desirability

Table 29 enlists the significance testing for the I-optimal design; a quadratic model was chosen for
this data based on the model R- Squared value and the Lack of Fit (p-value 0.9926) (Table 26.).
The individual factors that significantly affect RSF include all the three independent variables;
Distance B (mm), Tool lift (mm) and number of rotations. Also, Distance B has a slight quadratic
effect on the observed RSF values, observed in Figure 43. Figure 43 is the 3D surface profiler for
the I-optimal design and it plots Tool Lift and Distance B on the X1 and X2 axes respectively,
while RSF as the response on the Y axis. According to the model predictions, the red zone as
shown in Figure 43 are the areas of maximum RSF predicted. To achieve values of RSF 20 Lbs
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and above, it is advisable to operate with Tool lift maintained above 15mm and Distance B
maintained below 34.4mm. The rotations have been maintained at number 10, however there is no
major difference in RSF by changing the number of rotations from 7 to 10.

Figure 43. Surface profiler for the I-optimal screening design: Output variable RSF, Input
variables: Height C, Tool lift Number of Rotations set at 10

The robustness of the I-optimal design model was verified by crimping vials at different factor
combinations and comparing the actual RSF to the model predicted RSF. Table 30 represents the
factor combinations chosen for the validation study. (n=10) In terms of percentage, there is about
4%, 22%, 8%, 6%, 4% for factor combinations 1, 2, 3, 4, 5 (Sr.no.) respectively. The model has
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very good predictability with % error less than 10% for all combinations except Sr.no 2, which has
a 21.8% deviation from the predicted value. This explains that the model has good predictability
for factors near the center of the model, but its prediction efficacy reduces at the edges of the
design.

Table 30. Design validation, Actual vs Predicted RSF (LBS) varying factors Distance B, Tool
Lift and Number of rotations

Sr. no.

Distance B
mm

Tool Lift
mm

Number of
rotations

Predicted
RSF (Lbs)

Actual RSF
(Lbs)

1
2
3
4
5

34.4
35.2
34.6
34
34

12
12
22
20
22

7
10
7
7
10

14.83
8.7
18.29
22.84
25.21

14.2 ± 1.2
6.8 ± 1.3
16.8 ± 1.0
21.4 ± 1.5
26.4 ± 1.9

Conclusion
Using a statistical Design of Experiment technique, capping parameters were optimized for
single station cappers, Integra West Capper® and Bausch and Strobel® capper to increase CCI
of crimped vials in all storage and transport conditions. On the basis of these generated models
CCI can be studied as a function of unit processes, such as capping. This study also helped us
co-relate the crimping mechanisms for lab-scale single station cappers in turn helping us
standardize the capping process for a vial-stopper combination across lab-scale equipment. For
the Integra West Capper®, in order to maintain CCI and obtain a high RSF value, Precompression force of 35 Lbs and above and Pressure Block reference height of 120 to 130
inch*10-3 are instrumental. For the Bausch and Strobel® capper, lower position of crimping
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tool (Distance B) of 34-34.4 mm and Tool lift of 15mm and above are important. Increasing
the number of rotations during crimping from 7 to 10 did not play a significant role in
optimizing the RSF values.

154

BIBLIOGRAPHY

155

1.

Walters, W. P., Going further than Lipinski's rule in drug design. Expert Opinion on Drug

Discovery 2012, 7 (2), 99-107.
2.

Lipinski, C. A., Lead- and drug-like compounds: the rule-of-five revolution. Drug

Discovery Today: Technologies 2004, 1 (4), 337-341.
3.

Choy, Y. B.; Prausnitz, M. R., The Rule of Five for Non-Oral Routes of Drug Delivery:

Ophthalmic, Inhalation and Transdermal. Pharmaceutical Research 2011, 28 (5), 943-948.
4.

Lee, V., Mechanisms and facilitation of corneal drug penetration. J Control Release 1990,

11 (1–3), 79–90.
5.

Hussain, A.; Truelove, J. E., Prodrug approaches to enhancement of physicochemical

properties of drugs IV: novel epinephrine prodrug. Journal of Pharmaceutical Sciences 1976, 65
(10), 1510-1512.
6.

Hussain, A.; Truelove, J. E., Prodrug approaches to enhancement of physicochemical

properties of drugs IV: novel epinephrine prodrug. J Pharm Sci 1976, 65 (10), 1510-1512.
7.

Attar, M.; Schiffman, R.; Borbridge, L.; Farnes, Q.; Welty, D., Ocular pharmacokinetics

of 0.45% ketorolac tromethamine. Clin Ophthalmol 2010, 4, 1403-1408.
8.

Rácz, P.; Ruzsonyi, M. R.; Nagy, Z. T.; Bito, L. Z., Maintained intraocular pressure

reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An
in-hospital, placebo-controlled study. Arch. Ophthalmol. 1993, 111 (5), 657-661.
9.

Gerald, W. B.; Carl, B. C., Commercially available prostaglandin analogs for the reduction

of intraocular pressure: similarities and differences. Survey of Ophthalmology 2008, 53 (6).
10.

Kikuchi, H.; Carlsson, A.; Yachi, K.; Hirota, S., Possibility of heat sterilization of

liposomes. Chem Pharm Bull (Tokyo) 1991, 39 (4), 1018-1022.

156

11.

Sharma, A.; Sharma, U. S., Liposomes in drug delivery: progress and limitations.

International Journal of Pharmaceutics 1997, 154 (2), 123-140.
12.

Puglia, C.; Offerta, A.; Carbone, C.; Bonina, F.; Pignatello, R.; Puglisi, G., Lipid

nanocarriers (LNC) and their applications in ocular drug delivery. Curr. Med. Chem. 2015, 22
(13), 1589-1602.
13.

Hippalgaonkar, K.; Adelli, G. R.; Hippalgaonkar, K.; Repka, M. A.; Majumdar, S.,

Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization,
and in vitro evaluation. J Ocul Pharmacol Ther 2013, 29 (2), 216-228.
14.

Urtti, A., Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv

Drug Deliv Rev 2006, 58 (11), 1131–1135.
15.

Lee, V. H.; Robinson, J. R., Topical ocular drug delivery: recent developments and future

challenges. Journal of ocular pharmacology 1986, 2 (1), 67-108.
16.

Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V., Recent advances in ocular drug

delivery. Drug Dev Ind Pharm 2013, 39 (11), 1599-1617.
17.

Maurice, D. M.; Mishima, S., Ocular Pharmacokinetics. In Pharmacology of the Eye,

Sears, M. L., Ed. Springer: Berlin Heidelberg, 1984; pp 19-116.
18.

Khurana, Ophthalmology. New Age International: New Delhi, 2003; p 576.

19.

Fangueiro, J. F.; Veiga, F.; Silva, A. M.; Souto, E. B., Ocular drug delivery - new strategies

for targeting anterior and posterior segments of the eye. Current pharmaceutical design 2015, 22
(9), 1135-46.
20.

Goel, M.; Picciani, R. G.; Lee, R. K.; Bhattacharya, S. K., Aqueous Humor Dynamics: A

Review. Open Ophthalmol J 2010, 4, 52-9.

157

21.

Järvinen, K.; Järvinen, T.; Urtti, A., Ocular absorption following topical delivery. Adv

Drug Deliv Rev 1995, 16 (1), 3-19.
22.

Becker, B., Chemical composition of human aqueous humor: effects of acetazoleamide.

AMA Arch Ophthalmol 1957, 57 (6), 793-800.
23.

Lee, V. H.; Li, V. H., Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev

1989, 3 (1), 1-38.
24.

Lund‐Andersen, H.; Sebag, J.; Sander, B.; La Cour, M., The vitreous. Adv Organ Biol

2005, 10, 181–194.
25.

Lee, V. H.-L.; Robinson, J. R., Mechanistic and quantitative evaluation of precorneal

pilocarpine disposition in albino rabbits. J. Pharm. Sci. 1979, 68 (6), 673-684.
26.

Dartt, D.; Hodges, R.; Zoukhri, D., Tears and their secretion. Adv Organ Biol 2005, 10,

21–82.
27.

Cunha-Vaz, J., The blood-ocular barriers. Survey of Ophthalmology 1979, 23 (5), 279-296.

28.

Barar, J.; Javadzadeh, A. R.; Omidi, Y., Ocular novel drug delivery: impacts of membranes

and barriers. Expert Opin Drug Deliv 2008, 5 (5), 567-581.
29.

Komarova, Y.; Malik, A. B., Regulation of endothelial permeability via paracellular and

transcellular transport pathways. Annu Rev Physiol 2010, 72 (1), 463-493.
30.

Klyce, S. D.; Crosson, C. E., Transport processes across the rabbit corneal epithelium: a

review. Curr Eye Res 1985, 4 (4), 323-331.
31.

Ehlers, N.; Hjortdal, J., The cornea: epithelium and stroma. Adv Organ Biol 2005, 10, 83–

111.

158

32.

Wang, W.; Sasaki, H.; Chien, D. S.; Lee, V. H., Lipophilicity influence on conjunctival

drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr Eye Res
1991, 10 (6), 571-9.
33.

Ahmed, I.; Gokhale, R. D.; Shah, M. V.; Patton, T. F., Physicochemical determinants of

drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 1987, 76 (8), 583-6.
34.

Huang, H.-S.; Schoenwald, R. D.; Lach, J. L., Corneal penetration behavior of β-blocking

agents II: assessment of barrier contributions. J. Pharm. Sci. 1983, 72 (11), 1272-1279.
35.

Saha, P.; Yang, J. J.; Lee, V. H., Existence of a p-glycoprotein drug efflux pump in cultured

rabbit conjunctival epithelial cells. Investigative ophthalmology & visual science 1998, 39 (7),
1221-6.
36.

Mannermaa, E.; Vellonen, K.-S.; Urtti, A., Drug transport in corneal epithelium and blood–

retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006,
58 (11), 1136-1163.
37.

Rautio, J., Prodrugs and Targeted Delivery: Towards Better ADME Properties. John

Wiley & Sons: Weinheim, Germany, 2011; p 523.
38.

Hosoya, K.-i.; Tomi, M., Advances in the cell biology of transport via the inner blood-

retinal barrier: establishment of cell lines and transport functions. Biol Pharm Bull 2005, 28 (1),
1-8.
39.

Ahmed, T.; Patton, I., Importance of the noncorneal absorption route in topical ophthalmic

drug delivery. Investigative ophthalmology & visual science 1985, 584-7.
40.

Rizzolo, L. J., Polarity and the development of the outer blood-retinal barrier. Histology

and histopathology 1997, 12 (4), 1057-67.

159

41.

Ban, Y.; Rizzolo, L. J., Differential regulation of tight junction permeability during

development of the retinal pigment epithelium. American journal of physiology. Cell physiology
2000, 279 (3), C744-50.
42.

Bauer, H. C.; Krizbai, I. A.; Bauer, H.; Traweger, A., “You Shall Not Pass”—tight

junctions of the blood brain barrier. Front Neurosci 2014, 8, 392.
43.

Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Maag, H.; Tilley, J., Prodrugs:

Challenges and Rewards. Springer Science + Business Media: New York, NY, 2007.
44.

Teżyk, M.; Jakubowska, E.; Milanowski, B.; Lulek, J., Implementation of quality by design

approach in manufacturing process optimization of dry granulated, immediate release, coated
tablets – a case study. Drug Development and Industrial Pharmacy 2017, 43 (10), 1626-1636.
45.

Huerva, V.; #xed; Ascaso, F. J.; Grzybowski, A., Ocular Inflammation. Mediators of

Inflammation 2015, 2015, 2.
46.

Cheung, N.; Mitchell, P.; Wong, T. Y., Diabetic retinopathy. The Lancet 2010, 376 (9735),

124-136.
47.

Bourne, R. R. A.; Stevens, G. A.; White, R. A.; Smith, J. L.; Flaxman, S. R.; Price, H.;

Jonas, J. B.; Keeffe, J.; Leasher, J.; Naidoo, K.; Pesudovs, K.; Resnikoff, S.; Taylor, H. R., Causes
of vision loss worldwide, 1990&#x2013;2010: a systematic analysis. The Lancet Global Health
2013, 1 (6), e339-e349.
48.

Yau, J. W. Y.; Rogers, S. L.; Kawasaki, R.; Lamoureux, E. L.; Kowalski, J. W.; Bek, T.;

Chen, S.-J.; Dekker, J. M.; Fletcher, A.; Grauslund, J.; Haffner, S.; Hamman, R. F.; Ikram, M. K.;
Kayama, T.; Klein, B. E. K.; Klein, R.; Krishnaiah, S.; Mayurasakorn, K.; O’Hare, J. P.; Orchard,
T. J.; Porta, M.; Rema, M.; Roy, M. S.; Sharma, T.; Shaw, J.; Taylor, H.; Tielsch, J. M.; Varma,
R.; Wang, J. J.; Wang, N.; West, S.; Xu, L.; Yasuda, M.; Zhang, X.; Mitchell, P.; Wong, T. Y.,

160

Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care 2012, 35 (3),
556.
49.

Neely, K. A.; Gardner, T. W., Ocular Neovascularization : Clarifying Complex

Interactions. The American Journal of Pathology 1998, 153 (3), 665-670.
50.

El-Remessy, A. B.; Al-Shabrawey, M.; Khalifa, Y.; Tsai, N.-T.; Caldwell, R. B.; Liou, G.

I., Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental
Diabetes. The American Journal of Pathology 2006, 168 (1), 235-244.
51.

El-Remessy, A. B.; Behzadian, M. A.; Abou-Mohamed, G.; Franklin, T.; Caldwell, R. W.;

Caldwell, R. B., Experimental Diabetes Causes Breakdown of the Blood-Retina Barrier by a
Mechanism Involving Tyrosine Nitration and Increases in Expression of Vascular Endothelial
Growth Factor and Urokinase Plasminogen Activator Receptor. The American Journal of
Pathology 2003, 162 (6), 1995-2004.
52.

Qaum, T.; Xu, Q.; Joussen, A. M.; Clemens, M. W.; Qin, W.; Miyamoto, K.; Hassessian,

H.; Wiegand, S. J.; Rudge, J.; Yancopoulos, G. D.; Adamis, A. P., VEGF-initiated Blood–Retinal
Barrier Breakdown in Early Diabetes. Investigative ophthalmology & visual science 2001, 42 (10),
2408-2413.
53.

JOUSSEN, A. M.; POULAKI, V.; MITSIADES, N.; KIRCHHOF, B.; KOIZUMI, K.;

DÖHMEN, S.; ADAMIS, A. P., Nonsteroidal anti-inflammatory drugs prevent early diabetic
retinopathy via TNF-α suppression. The FASEB Journal 2002, 16 (3), 438-440.
54.

Nakagami, H.; Morishita, R.; Yamamoto, K.; Yoshimura, S.-i.; Taniyama, Y.; Aoki, M.;

Matsubara, H.; Kim, S.; Kaneda, Y.; Ogihara, T., Phosphorylation of p38 Mitogen-Activated
Protein Kinase Downstream of Bax-Caspase-3 Pathway Leads to Cell Death Induced by High

161

&lt;span class=&quot;sc&quot;&gt;d&lt;/span&gt;-Glucose in Human Endothelial Cells.
Diabetes 2001, 50 (6), 1472.
55.

Liou, G. I.; El-Remessy, A. B.; Ibrahim, A. S.; Caldwell, R. B.; Khalifa, Y. M.; Gunes, A.;

Nussbaum, J. J., Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated
Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development. Current
pharmacogenomics and personalized medicine 2009, 7 (3), 215-222.
56.

Butcher, J. M.; Austin, M.; McGalliard, J.; Bourke, R. D., Bilateral cataracts and glaucoma

induced by long term use of steroid eye drops. BMJ : British Medical Journal 1994, 309 (6946),
43-43.
57.

Buchman, A. L., Side Effects of Corticosteroid Therapy. Journal of Clinical

Gastroenterology 2001, 33 (4), 289-294.
58.

Richard H. Roe, M. M.; H. Richard McDonald, M. D., Complications of Vitreoretinal

Surgery. Review of Ophthalmology 2008.
59.

M, T. D.; Cairns Elizabeth, A.; Szczesniak, A.-M.; Toguri James, T.; Caldwell Meggie, D.;

Kelly Melanie, E., The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to
Reduce Corneal Pain and Inflammation. https://home.liebertpub.com/can 2018.
60.

Toguri, J. T.; Caldwell, M.; Kelly, M. E. M., Turning Down the Thermostat: Modulating

the Endocannabinoid System in Ocular Inflammation and Pain. Frontiers in Pharmacology 2016,
7 (304).
61.

Pertwee, R. G., The diverse CB1 and CB2 receptor pharmacology of three plant

cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. British
Journal of Pharmacology 2009, 153 (2), 199-215.

162

62.

Porcella, A.; Casellas, P.; Gessa, G. L.; Pani, L., Cannabinoid receptor CB1 mRNA is

highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.
Brain Res Mol Brain Res 1998, 58 (1-2), 240-5.
63.

Porcella, A.; Maxia, C.; Gessa, G. L.; Pani, L., The human eye expresses high levels of

CB1 cannabinoid receptor mRNA and protein. The European journal of neuroscience 2000, 12
(3), 1123-7.
64.

Hall, W.; Solowij, N., Adverse effects of cannabis. The Lancet 1998, 352 (9140), 1611-

1616.
65.

Straiker, A. J.; Maguire, G.; Mackie, K.; Lindsey, J., Localization of cannabinoid CB1

receptors in the human anterior eye and retina. Investigative ophthalmology & visual science 1999,
40 (10), 2442-8.
66.

Gérard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M., Molecular cloning of a human

cannabinoid receptor which is also expressed in testis. Biochemical Journal 1991, 279 (Pt 1), 129134.
67.

Reggio, P. H., Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known

and What Remains Unknown. Current medicinal chemistry 2010, 17 (14), 1468-1486.
68.

Grotenhermen, F.; Müller-Vahl, K., The Therapeutic Potential of Cannabis and

Cannabinoids. Dtsch Arztebl Int 2012, 109 (29-30), 495-501.
69.

Kowapradit, J.; Opanasopit, P.; Ngawhiranpat, T.; Apirakaramwong, A.; Rojanarata, T.;

Ruktanonchai, U.; Sajomsang, W., Methylated N-(4-N,N-Dimethylaminobenzyl) Chitosan, a
Novel Chitosan Derivative, Enhances Paracellular Permeability Across Intestinal Epithelial Cells
(Caco-2). AAPS PharmSciTech 2008, 9 (4), 1143-1152.

163

70.

Liou, G. I.; Auchampach, J. A.; Hillard, C. J.; Zhu, G.; Yousufzai, B.; Mian, S.; Khan, S.;

Khalifa, Y., Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside
transporter and A2A adenosine receptor. Investigative ophthalmology & visual science 2008, 49
(12), 5526-31.
71.

Cunha-Vaz, J., The blood-ocular barriers. Survey of Ophthalmology 1979, 23 (5), 279-296.

72.

Han, H. K.; Oh, D. M.; Amidon, G. L., Cellular uptake mechanism of amino acid ester

prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res 1998,
15 (9), 1382-6.
73.

Nelson, W. L.; Walker, R. B., The structure of propranolol hemisuccinate. Research

communications in chemical pathology and pharmacology 1978, 22 (3), 435-45.
74.

Ambrose, P. J., Clinical pharmacokinetics of chloramphenicol and chloramphenicol

succinate. Clinical pharmacokinetics 1984, 9 (3), 222-38.
75.

Zhang, X.; Mehvar, R., Dextran-methylprednisolone succinate as a prodrug of

methylprednisolone: dose-dependent pharmacokinetics in rats. Int J Pharm 2001, 229 (1-2), 17382.
76.

Taskar, P.; Tatke, A.; Majumdar, S., Advances in the use of prodrugs for drug delivery to

the eye. Expert Opinion on Drug Delivery 2017, 14 (1), 49-63.
77.

Mississippi, M. A. E.; Soumyajit, M.; Waseem, G.; Mohammad Khalid, A.; Kenneth

Joseph, S.; Hannah Marie, H.; University, O., Biologically active cannabidiol analogs. 2017.
78.

Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities

of protein utilizing the principle of protein-dye binding. Analytical biochemistry 1976, 72, 248-54.
79.

Design of Amino Acid Prodrugs of Acyclovir for Improved Bioavailability and Therapeutic

Activity: Utility in Treating Ocular, Oral and Genital Herpes Infections. ProQuest: 2007; p 182.

164

80.

Atluri, H.; Anand, B. S.; Patel, J.; Mitra, A. K., Mechanism of a model dipeptide transport

across blood-ocular barriers following systemic administration. Exp. Eye Res. 2004, 78 (4), 815822.
81.

Beauchamp, L. M.; Orr, G. F.; de Miranda, d. P.; Bumette, T.; Krenitsky, T. A., Amino

acid ester prodrugs of acyclovir. Antiviral Chemistry and Chemotherapy 1992, 3 (3), 157-164.
82.

Vig, B. S.; Huttunen, K. M.; Laine, K.; Rautio, J., Amino acids as promoieties in prodrug

design and development. Advanced Drug Delivery Reviews 2013, 65 (10), 1370-1385.
83.

Quigley, H. A.; Addicks, E. M.; Green, W.; Maumenee, A. E., Optic nerve damage in

human glaucoma: Ii. the site of injury and susceptibility to damage. Archives of Ophthalmology
1981, 99 (4), 635-649.
84.

Abe, R. Y.; Diniz-Filho, A.; Costa, V. P.; Gracitelli, C. P. B.; Baig, S.; Medeiros, F. A.,

The Impact of Location of Progressive Visual Field Loss on Longitudinal Changes in Quality of
Life of Patients with Glaucoma. Ophthalmology 2016, 123 (3), 552-557.
85.

Cook, C.; Foster, P., Epidemiology of glaucoma: what's new? Canadian journal of

ophthalmology. Journal canadien d'ophtalmologie 2012, 47 (3), 223-6.
86.

Adelli, G. R.; Bhagav, P.; Taskar, P.; Hingorani, T.; Pettaway, S.; Gul, W.; ElSohly, M.

A.; Repka, M. A.; Majumdar, S., Development of a Delta9-Tetrahydrocannabinol Amino AcidDicarboxylate Prodrug With Improved Ocular Bioavailability. Investigative ophthalmology &
visual science 2017, 58 (4), 2167-2179.
87.

Quigley, H. A.; Broman, A. T., The number of people with glaucoma worldwide in 2010

and 2020. The British Journal of Ophthalmology 2006, 90 (3), 262-267.
88.

(NEI), N. E. I. Glaucoma, Open-angle

https://nei.nih.gov/eyedata/glaucoma.

165

89.

Grüb, M.; Mielke, J., [Aqueous humor dynamics]. Ophthalmologe 2004, 101 (4), 357-365.

90.

Macri, F. J.; Cevario, S. J., The formation and inhibition of aqueous humor production: A

proposed mechanism of action. Archives of Ophthalmology 1978, 96 (9), 1664-1667.
91.

Brubaker, R. F., Goldmann's equation and clinical measures of aqueous dynamics. Exp.

Eye Res. 2004, 78 (3), 633-637.
92.

Goel, M.; Picciani, R. G.; Lee, R. K.; Bhattacharya, S. K., Aqueous Humor Dynamics: A

Review. The Open Ophthalmology Journal 2010, 4, 52-59.
93.

Gabelt, B. A. T.; Kaufman, P. L., Changes in aqueous humor dynamics with age and

glaucoma. Progress in Retinal and Eye Research 2005, 24 (5), 612-637.
94.

Yablonski, M. E.; Zimmerman, T. J.; Waltman, S. R.; Becker, B., A fluorophotometric

study of the effect of topical timolol on aqueous humor dynamics. Exp. Eye Res. 1978, 27 (2), 135142.
95.

Tătaru, C. P.; Purcărea, V. L., Antiglaucoma pharmacotherapy. Journal of Medicine and

Life 2012, 5 (3), 247-251.
96.

Toris, C. B., Pharmacology of Aqueous Humor Formation A2 - Dartt, Darlene A. In

Encyclopedia of the Eye, Academic Press: Oxford, 2010; pp 312-315.
97.

Patil, A.; Singh, S.; Opere, C.; Dash, A., Sustained-Release Delivery System of a Slow

Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma. AAPS PharmSciTech
2017, 18 (6), 2291-2302.
98.

New Medical Therapies for Glaucoma. https://www.glaucoma.org/treatment/new-

medical-therapies-for-glaucoma.php.
99.

Schehlein, E. M.; Novack, G.; Robin, A. L., New pharmacotherapy for the treatment of

glaucoma. Expert Opinion on Pharmacotherapy 2017, 18 (18), 1939-1946.

166

100.

Twitchell, W.; Brown, S.; Mackie, K., Cannabinoids Inhibit N- and P/Q-Type Calcium

Channels in Cultured Rat Hippocampal Neurons. Journal of Neurophysiology 1997, 78 (1), 43-50.
101.

Malinowska, B.; Godlewski, G.; Bucher, B.; Schlicker, E., Cannabinoid CB1 receptor-

mediated inhibition of the neurogenic vasopressor response in the pithed rat. NaunynSchmiedeberg's Archives of Pharmacology 1997, 356 (2), 197-202.
102.

Sugrue, M. F., New Approaches to Antiglaucoma Therapy. Journal of Medicinal

Chemistry 1997, 40 (18), 2793-2809.
103.

Allingham, R. R.; de Kater, A. W.; Ethier, R. C., Schlemm 's Canal and Primary Open

Angle Glaucoma: Correlation Between Schlemm 's Canal Dimensions and Outflow Facility. Exp.
Eye Res. 1996, 62 (1), 101-110.
104.

Tomida, I.; Pertwee, R. G.; Azuara-Blanco, A., Cannabinoids and glaucoma. The British

Journal of Ophthalmology 2004, 88 (5), 708-713.
105.

Panahi, Y.; Manayi, A.; Nikan, M.; Vazirian, M., The arguments for and against

cannabinoids application in glaucomatous retinopathy. Biomedicine & pharmacotherapy =
Biomedecine & pharmacotherapie 2016, 86, 620-627.
106.

Porcella, A.; Maxia, C.; Gessa, G. L.; Pani, L., The synthetic cannabinoid WIN55212-2

decreases the intraocular pressure in human glaucoma resistant to conventional therapies. The
European journal of neuroscience 2001, 13 (2), 409-12.
107.

Morgan-Davies, J.; Taylor, N.; Hill, A. R.; Aspinall, P.; O’Brien, C. J.; Azuara-Blanco, A.,

Three dimensional analysis of the lamina cribrosa in glaucoma. The British Journal of
Ophthalmology 2004, 88 (10), 1299-1304.
108.

Agarwal, R.; Gupta, S. K.; Agarwal, P.; Saxena, R.; Agrawal, S. S., Current concepts in

the pathophysiology of glaucoma. Indian Journal of Ophthalmology 2009, 57 (4), 257-266.

167

109.

Abe, R. Y.; Gracitelli, C. P. B.; Diniz-Filho, A.; Tatham, A. J.; Medeiros, F. A., Lamina

Cribrosa in Glaucoma: Diagnosis and Monitoring. Current ophthalmology reports 2015, 3 (2), 7484.
110.

Almasieh, M.; Wilson, A. M.; Morquette, B.; Cueva Vargas, J. L.; Di Polo, A., The

molecular basis of retinal ganglion cell death in glaucoma. Progress in Retinal and Eye Research
2012, 31 (2), 152-181.
111.

El-Remessy, A. B.; Khalil, I. E.; Matragoon, S.; Abou-Mohamed, G.; Tsai, N. J.; Roon, P.;

Caldwell, R. B.; Caldwell, R. W.; Green, K.; Liou, G. I., Neuroprotective Effect of(−)Δ9Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity :
Involvement of Peroxynitrite. In Am J Pathol, 2003; Vol. 163, pp 1997-2008.
112.

Ko, M. L.; Hu, D. N.; Ritch, R.; Sharma, S. C., The Combined Effect of Brain-Derived

Neurotrophic Factor and a Free Radical Scavenger in Experimental Glaucoma. Investigative
ophthalmology & visual science 2000, 41 (10), 2967-2971.
113.

Naveh, N.; Weissman, C.; Muchtar, S.; Benita, S.; Mechoulam, R., A submicron emulsion

of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefe's archive for
clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und
experimentelle Ophthalmologie 2000, 238 (4), 334-8.
114.

Shohami, E.; Gallily, R.; Mechoulam, R.; Bass, R.; Ben-Hur, T., Cytokine production in

the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an
effective neuroprotectant. Journal of Neuroimmunology 1997, 72 (2), 169-177.
115.

Crandall, J.; Matragoon, S.; Khalifa, Y. M.; Borlongan, C.; Tsai, N. T.; Caldwell, R. B.;

Liou, G. I., Neuroprotective and Intraocular Pressure-Lowering Effects of (–)Δ<sup>9</sup>Tetrahydrocannabinol in a Rat Model of Glaucoma. Ophthalmic Research 2007, 39 (2), 69-75.

168

116.

Crandall, J.; Matragoon, S.; Khalifa, Y. M.; Borlongan, C.; Tsai, N. T.; Caldwell, R. B.;

Liou, G. I., Neuroprotective and intraocular pressure-lowering effects of (-)Delta9tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res 2007, 39 (2), 69-75.
117.

Grotenhermen, F.; Russo, E., Cannabis and Cannabinoids: Pharmacology, Toxicology,

and Therapeutic Potential. Haworth Integrative Healing Press: 2002.
118.

Hepler, R. S.; Frank, I. R., Marihuana smoking and intraocular pressure. Jama 1971, 217

(10), 1392.
119.

Green, K., Marijuana smoking vs cannabinoids for glaucoma therapy. Archives of

Ophthalmology 1998, 116 (11), 1433-1437.
120.

Crawford, W. J.; Merritt, J. C., Effects of tetrahydrocannabinol on arterial and intraocular

hypertension. International journal of clinical pharmacology and biopharmacy 1979, 17 (5), 1916.
121.

Merritt, J. C.; Perry, D. D.; Russell, D. N.; Jones, B. F., Topical Δ9-Tetrahydrocannabinol

and Aqueous Dynamics in Glaucoma. The Journal of Clinical Pharmacology 1981, 21 (S1), 467S471S.
122.

Elsohly, M. A.; Harland, E.; Murphy, J. C.; Wirth, P.; Waller, C. W., Cannabinoids in

Glaucoma: A Primary Screening Procedure. The Journal of Clinical Pharmacology 1981, 21 (S1),
472S-478S.
123.

Jay, W. M.; Green, K., Multiple-drop study of topically applied 1% δ9-

tetrahydrocannabinol in human eyes. Arch Ophthalmol 1983, 101 (4), 591-593.
124.

Muchtar, S.; Almog, S.; Torracca, M. T.; Saettone, M. F.; Benita, S., A Submicron

Emulsion as Ocular Vehicle for Delta-8-Tetrahydrocannabinol: Effect on Intraocular Pressure in
Rabbits. Ophthalmic Research 1992, 24 (3), 142-149.

169

125.

Song, Z.-H.; Slowey, C.-A., Involvement of Cannabinoid Receptors in the Intraocular

Pressure-Lowering Effects of WIN55212-2. Journal of Pharmacology and Experimental
Therapeutics 2000, 292 (1), 136-139.
126.

Elsohly, M. A.; Gul, W.; Repka, M. A.; Majumdar, S., Compositions containing delta-9-

thc-amino acid esters and process of preparation. Google Patents.
127.

Punyamurthula, N. S.; Adelli, G. R.; Gul, W.; Repka, M. A.; ElSohly, M. A.; Majumdar,

S., Ocular Disposition of 8-Tetrahydrocannabinol from Various Topical Ophthalmic
Formulations. AAPS PharmSciTech 2016, 18 (6), 1936-1945.
128.

Elsohly, M. A.; Gul, W.; Repka, M. A.; Majumdar, S., Compositions containing delta-9-

thc-amino acid esters and process of preparation. Google Patents: 2011.
129.

Schubert, M. A.; Müller-Goymann, C. C., Characterisation of surface-modified solid lipid

nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. European Journal of
Pharmaceutics and Biopharmaceutics 2005, 61 (1), 77-86.
130.

Green, K.; Bigger, J. F.; Kim, K.; Bowman, K., Cannabinoid penetration and chronic

effects in the eye. Exp. Eye Res. 1977, 24 (2), 197-205.
131.

Hingorani, T.; Adelli, G. R.; Punyamurthula, N.; Gul, W.; ElSohly, M. A.; Repka, M. A.;

Majumdar, S., Ocular Disposition of the Hemiglutarate Ester Prodrug of ∆9-Tetrahydrocannabinol
from Various Ophthalmic Formulations. Pharm Res 2013, 30 (8).
132.

Balguri, S. P.; Adelli, G. R.; Majumdar, S., Topical ophthalmic lipid nanoparticle

formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.
European Journal of Pharmaceutics and Biopharmaceutics 2016, 109 (Supplement C), 224-235.

170

133.

Hingorani, T.; Gul, W.; Elsohly, M.; Repka, M. A.; Majumdar, S., Effect of ion pairing on

in vitro transcorneal permeability of a Delta(9) -tetrahydrocannabinol prodrug: potential in
glaucoma therapy. J. Pharm. Sci. 2011, 101 (2), 616-26.
134.

Thumma, S.; Majumdar, S.; ElSohly, M. A.; Gul, W.; Repka, M. A., Preformulation

Studies of a Prodrug of Δ9-Tetrahydrocannabinol. In AAPS PharmSciTech, 2008; Vol. 9, pp 98290.
135.

Duvvuri, S.; Majumdar, S.; Mitra, A. K., Drug delivery to the retina: challenges and

opportunities. Expert Opinion on Biological Therapy 2003, 3 (1), 45-56.
136.

Kaur, I. P.; Kakkar, S., Nanotherapy for posterior eye diseases. Journal of Controlled

Release 2014, 193 (Supplement C), 100-112.
137.

Patil, A.; Lakhani, P.; Taskar, P.; Wu, K.-W.; Sweeney, C.; Avula, B.; Wang, Y.-H.; Khan,

I. A.; Majumdar, S., Formulation Development, Optimization, and In-Vitro Characterization of
Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications. Journal of
Pharmaceutical Sciences 2018, 107 (8), 2160-2171.
138.

Lakhani, P.; Patil, A.; Taskar, P.; Ashour, E.; Majumdar, S., Curcumin-loaded

Nanostructured Lipid Carriers for ocular drug delivery: Design optimization and characterization.
Journal of Drug Delivery Science and Technology 2018, 47, 159-166.
139.

Thumma, S.; ElSohly, M. A.; Zhang, S. Q.; Gul, W.; Repka, M. A., Influence of plasticizers

on the stability and release of a prodrug of Delta(9)-tetrahydrocannabinol incorporated in poly
(ethylene oxide) matrices. European journal of pharmaceutics and biopharmaceutics : official
journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2008, 70 (2), 605-14.

171

140.

Munjal, M.; ElSohly, M. A.; Repka, M. A., Chemical stabilization of a Delta9-

tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: Role
of microenvironment pH. AAPS PharmSciTech 2006, 7 (3), E114-e125.
141.

Munjal, M.; Elsohly, M. A.; Repka, M. A., Polymeric Systems for Amorphous Δ9-

Tetrahydrocannabinol Produced by a Hot-Melt Method. Part II: Effect of Oxidation Mechanisms
and Chemical Interactions on Stability. J. Pharm. Sci. 2006, 95 (11), 2473-85.
142.

Punyamurthula, N. S.; Hingorani, T.; Adelli, G.; Gul, W.; ElSohly, M. A.; Repka, M. A.;

Majumdar,

S.,

Controlled

release

tablet

formulation

containing

natural

Delta(9)-

tetrahydrocannabinol. Drug Dev Ind Pharm 2015, 42 (7), 1158-64.
143.

Lizunova, A. A.; Loshkarev, A. A.; Tokunov, Y. M.; Ivanov, V. V., Comparison of the

Results of Measurements of the Sizes of Nanoparticles in Stable Colloidal Solutions by the
Methods of Acoustic Spectroscopy, Dynamic Light Scattering, and Transmission Electron
Microscopy. Measurement Techniques 2017, 59 (11), 1151-1155.
144.

Anderson, W.; Kozak, D.; Coleman, V. A.; Jämting, Å. K.; Trau, M., A comparative study

of submicron particle sizing platforms: Accuracy, precision and resolution analysis of polydisperse
particle size distributions. Journal of Colloid and Interface Science 2013, 405 (Supplement C),
322-330.
145.

Freitas, C.; Müller, R. H., Effect of light and temperature on zeta potential and physical

stability in solid lipid nanoparticle (SLN™) dispersions. International Journal of Pharmaceutics
1998, 168 (2), 221-229.
146.

Goldman, J. N.; Kuwabara, T., Histopathology of corneal edema. International

ophthalmology clinics 1968, 8 (3), 561-79.

172

147.

Wang, J.; Xia, Q., Alpha-lipoic acid-loaded nanostructured lipid carrier: sustained release

and biocompatibility to HaCaT cells in vitro. Drug Delivery 2014, 21 (5), 328-341.
148.

Montenegro, L.; Parenti, C.; Turnaturi, R.; Pasquinucci, L., Resveratrol-Loaded Lipid

Nanocarriers: Correlation between In Vitro Occlusion Factor and In Vivo Skin Hydrating Effect.
Pharmaceutics 2017, 9 (4).
149.

Wang, J.; Zhao, F.; Liu, R.; Chen, J.; Zhang, Q.; Lao, R.; Wang, Z.; Jin, X.; Liu, C., Novel

cationic lipid nanoparticles as an ophthalmic delivery system for multicomponent drugs:
development, characterization, in vitro permeation, in vivo pharmacokinetic, and molecular
dynamics studies. International Journal of Nanomedicine 2017, 12, 8115-8127.
150.

Sarpotdar, P. p.; Zatz, J. L., Percutaneous Absorption Enhancement by Nonionic

Surfactants. Drug Development and Industrial Pharmacy 1986, 12 (11-13), 1625-1647.
151.

Araújo, J.; Gonzalez-Mira, E.; Egea, M. A.; Garcia, M. L.; Souto, E. B., Optimization and

physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular
antiangiogenic applications. International Journal of Pharmaceutics 2010, 393 (1), 168-176.
152.

Jermak, C. M.; Tulane University Health Sciences Center, N. O. L.; Retina Consultants of

Western New York, B. N. Y. U. S. A.; Dellacroce, J. T.; Tulane University Health Sciences Center,
N. O. L.; Heffez, J.; Tulane University Health Sciences Center, N. O. L.; Peyman, G. A.; Tulane
University Health Sciences Center, N. O. L., Triamcinolone Acetonide in Ocular Therapeutics.
Survey of Ophthalmology 2007, 52 (5), 503-522.
153.

Chen, H.; Sun, S.; Li, J.; Du, W.; Zhao, C.; Hou, J.; Xu, Y.; Cheng, L., Different Intravitreal

Properties of Three Triamcinolone Formulations and Their Possible Impact on Retina Practice.
Investigative ophthalmology & visual science 2013, 54 (3), 2178-2185.

173

154.

Erkiliç, A. Ö.; aozkiris@erciyes.edu.tr; Kuddusi, Complications of intravitreal injection of

triamcinolone acetonide. Canadian Journal of Ophthalmology 2005, 40 (1), 63-68.
155.

Reichel, C. A. P.; Pravin, U. D.; Scott, W. C.; Kirk, H. P.; Alexander, M. E.; Richard, K.

P.; Szilárd, K.; Elias, Improving Outcomes for Patients With Diabetic Macular Edema. Ophthalmic
Surgery, Lasers and Imaging Retina 2015, 46 (10).
156.

Gaudana, R.; Ananthula, H. K.; Parenky, A.; Mitra, A. K., Ocular drug delivery. AAPS J

2010, 12 (3), 348-60.
157.

Morrison, P. W.; Khutoryanskiy, V. V., Advances in ophthalmic drug delivery. Ther Deliv

2014, 5 (12), 1297-315.
158.

Sultana, Y.; Jain, R.; Aqil, M.; Ali, A., Review of ocular drug delivery. Curr Drug Deliv

2006, 3 (2), 207-17.
159.

Hippalgaonkar, K.; Adelli, G. R.; Hippalgaonkar, K.; Repka, M. A.; Majumdar, S.,

Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization,
and in vitro evaluation. J Ocul Pharmacol Ther 2013, 29 (2), 216-228.
160.

Bonferoni, M. C.; Sandri, G.; Rossi, S.; Ferrari, F.; Caramella, C., Chitosan and its salts

for mucosal and transmucosal delivery. Expert Opin Drug Deliv 2009, 6 (9), 923-39.
161.

Caramella, C.; Ferrari, F.; Bonferoni, M. C.; Rossi, S.; Sandri, G., Chitosan and its

derivatives as drug penetration enhancers. Journal of Drug Delivery Science and Technology 2010,
20 (1), 5-13.
162.

Liu, D.; Li, J.; Pan, H.; He, F.; Liu, Z.; Wu, Q.; Bai, C.; Yu, S.; Yang, X., Potential

advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on
the performance of ophthalmic delivery of curcumin. Sci Rep 2016, 6, 28796.

174

163.

da Silva, S. B.; Ferreira, D.; Pintado, M.; Sarmento, B., Chitosan-based nanoparticles for

rosmarinic acid ocular delivery—In vitro tests. International Journal of Biological
Macromolecules 2016, 84, 112-120.
164.

Mourya, V. K.; Inamdar, N. N., Trimethyl chitosan and its applications in drug delivery.

Journal of materials science. Materials in medicine 2008, 20 (5), 1057-79.
165.

Ranaldi, G.; Marigliano, I.; Vespignani, I.; Perozzi, G.; Sambuy, Y., The effect of chitosan

and other polycations on tight junction permeability in the human intestinal Caco-2 cell line(1). J
Nutr Biochem 2002, 13 (3), 157-167.
166.

Murugan, K.; Choonara, Y. E.; Kumar, P.; Bijukumar, D.; du Toit, L. C.; Pillay, V.,

Parameters and characteristics governing cellular internalization and trans-barrier trafficking of
nanostructures. Int J Nanomedicine 2015, 10, 2191-206.
167.

M. N. V. Ravi Kumar; R. A. A. Muzzarelli; C. Muzzarelli; H. Sashiwa, a.; Domb‖, A. J.,

Chitosan Chemistry and Pharmaceutical Perspectives. 2004.
168.

van der Merwe, S. M.; Verhoef, J. C.; Kotzé, A. F.; Junginger, H. E., N-Trimethyl chitosan

chloride as absorption enhancer in oral peptide drug delivery. Development and characterization
of

minitablet and

granule formulations.

European Journal of

Pharmaceutics and

Biopharmaceutics 2004, 57 (1), 85-91.
169.

Sieval, A. B.; Thanou, M.; Kotze´, A. F.; Verhoef, J. C.; Brussee, J.; Junginger, H. E.,

Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride.
Carbohydrate Polymers 1998, 36 (2), 157-165.
170.

Davidson, H. J.; Kuonen, V. J., The tear film and ocular mucins. Veterinary Ophthalmology

2004, 7 (2), 71-77.

175

171.

Adelli, G. R.; Balguri, S. P.; Majumdar, S., Effect of Cyclodextrins on Morphology and

Barrier Characteristics of Isolated Rabbit Corneas. AAPS PharmSciTech 2015, 16 (5), 1220-1226.
172.

C., A.-V. J.; Jose, N.-P.; Alejandro, G.-D. l. R.; H., H. J.; S., O.-G. J.; C., G.-V. A.; C., K.

B.; Lourdes, B.-L.; Arturo, S., Characterization and Pharmacokinetics of Triamcinolone
Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery. Journal of
Ocular Pharmacology and Therapeutics 2018, 34 (5), 416-425.
173.

Sadeghi, A. M. M.; Dorkoosh, F. A.; Avadi, M. R.; Weinhold, M.; Bayat, A.; Delie, F.;

Gurny, R.; Larijani, B.; Rafiee-Tehrani, M.; Junginger, H. E., Permeation enhancer effect of
chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and
nanoparticulate systems on insulin absorption in Caco-2 cells. European Journal of Pharmaceutics
and Biopharmaceutics 2008, 70 (1), 270-278.
174.

Sandri, G.; Bonferoni, M. C.; Rossi, S.; Ferrari, F.; Boselli, C.; Caramella, C., Insulin-

Loaded Nanoparticles Based on N-Trimethyl Chitosan: In Vitro (Caco-2 Model) and Ex Vivo
(Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties.
AAPS PharmSciTech 2010, 11 (1), 362-371.
175.

Rosenthal, R.; Günzel, D.; Finger, C.; Krug, S. M.; Richter, J. F.; Schulzke, J.-D.; Fromm,

M.; Amasheh, S., The effect of chitosan on transcellular and paracellular mechanisms in the
intestinal epithelial barrier. Biomaterials 2012, 33 (9), 2791-2800.
176.

McClintic, S. M.; Srinivasan, M.; Mascarenhas, J.; Greninger, D. A.; Acharya, N. R.;

Lietman, T. M.; Keenan, J. D., Improvement in corneal scarring following bacterial keratitis. Eye
2012, 27, 443.
177.

Ansari, Z.; Miller, D.; Galor, A., Current Thoughts in Fungal Keratitis: Diagnosis and

Treatment. Current fungal infection reports 2013, 7 (3), 209-218.

176

178.

Al-Badriyeh, D.; Neoh, C. F.; Stewart, K.; Kong, D. C. M., Clinical utility of voriconazole

eye drops in ophthalmic fungal keratitis. Clinical Ophthalmology (Auckland, N.Z.) 2010, 4, 391405.
179.

Tuli, S. S., Fungal keratitis. Clinical Ophthalmology (Auckland, N.Z.) 2011, 5, 275-279.

180.

Gao, H.; Pennesi, M. E.; Shah, K.; et al., Intravitreal voriconazole: An electroretinographic

and histopathologic study. Archives of Ophthalmology 2004, 122 (11), 1687-1692.
181.

Maesaki, S.; Iwakawa, J.; Higashiyama, Y.; Miyazaki, Y.; Yanagihara, K.; Tomono, K.;

Tashiro, T.; Kohno, S., Antifungal activity of a new triazole, voriconazole (UK-109496), against
clinical isolates of Aspergillus spp. Journal of Infection and Chemotherapy 2000, 6 (2), 101-103.
182.

Espinel-Ingroff, A.; Boyle, K.; Sheehan, D. J., In vitro antifungal activities of voriconazole

and reference agents as determined by NCCLS methods: Review of the literature. Mycopathologia
2001, 150 (3), 101-115.
183.

Jurkunas, U. V.; Langston, D. P.; Colby, K., Use of Voriconazole in the Treatment of

Fungal Keratitis. International ophthalmology clinics 2007, 47 (2), 47-59.
184.

Sánchez-López, E.; Espina, M.; Doktorovova, S.; Souto, E. B.; García, M. L., Lipid

nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye –
Part I – Barriers and determining factors in ocular delivery. European Journal of Pharmaceutics
and Biopharmaceutics 2017, 110, 70-75.
185.

Stergiopoulou, T.; Meletiadis, J.; Sein, T.; Papaioannidou, P.; Tsiouris, I.; Roilides, E.;

Walsh, T. J., Isobolographic Analysis of Pharmacodynamic Interactions between Antifungal
Agents and Ciprofloxacin against Candida albicans and Aspergillus fumigatus. Antimicrobial
Agents and Chemotherapy 2008, 52 (6), 2196-2204.

177

186.

Brilhante, R. S. N.; Caetano, E. P.; Sidrim, J. J. C.; Cordeiro, R. A.; Camargo, Z. P.;

Fechine, M. A. B.; Lima, R. A. C.; Castelo Branco, D. S. C. M.; Marques, F. J. F.; Mesquita, J. R.
L.; Lima, D. T.; Monteiro, A. J.; Rocha, M. F. G., Ciprofloxacin shows synergism with classical
antifungals against Histoplasma capsulatum var. capsulatum and Coccidioides posadasii. Mycoses
2013, 56 (3), 397-401.
187.

White, T. C.; Marr, K. A.; Bowden, R. A., Clinical, Cellular, and Molecular Factors That

Contribute to Antifungal Drug Resistance. Clinical Microbiology Reviews 1998, 11 (2), 382-402.
188.

Adelli, G. R.; Hingorani, T.; Punyamurthula, N.; Balguri, S. P.; Majumdar, S., Evaluation

of topical hesperetin matrix film for back-of-the-eye delivery. European Journal of Pharmaceutics
and Biopharmaceutics 2015, 92, 74-82.
189.

Müller, R. H.; Radtke, M.; Wissing, S. A., Solid lipid nanoparticles (SLN) and

nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Advanced Drug
Delivery Reviews 2002, 54, S131-S155.
190.

Müller, R. H.; Petersen, R. D.; Hommoss, A.; Pardeike, J., Nanostructured lipid carriers

(NLC) in cosmetic dermal products. Advanced Drug Delivery Reviews 2007, 59 (6), 522-530.
191.

Mo, Z.; Ban, J.; Zhang, Y.; Du, Y.; Wen, Y.; Huang, X.; Xie, Q.; Shen, L.; Zhang, S.;

Deng, H.; Hou, D.; Chen, Y.; Lu, Z., Nanostructured lipid carriers-based thermosensitive eye drops
for enhanced, sustained delivery of dexamethasone. Nanomedicine 2018, 13 (11), 1239-1253.
192.

Patil, A.; Lakhani, P.; Taskar, P.; Wu, K.-W.; Sweeney, C.; Avula, B.; Wang, Y.-H.; Khan,

I. A.; Majumdar, S., Formulation Development, Optimization, and In Vitro–In Vivo
Characterization of Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications.
Journal of Pharmaceutical Sciences 2018, 107 (8), 2160-2171.

178

193.

Gong, Q.; Huntsman, C.; Ma, D., Clathrin-independent internalization and recycling.

Journal of Cellular and Molecular Medicine 2008, 12 (1), 126-144.
194.

Mathaes, R.; Mahler, H. C.; Roggo, Y.; Ovadia, R.; Lam, P.; Stauch, O.; Vogt, M.; Roehl,

H.; Huwyler, J.; Mohl, S.; Streubel, A., Impact of Vial Capping on Residual Seal Force and
Container Closure Integrity. PDA J Pharm Sci Technol 2016, 70 (1), 12-29.
195.

Morton, D. K.; Lordi, N. G., Residual seal force measurement of parenteral vials. I.

Methodology. J Parenter Sci Technol 1988, 42 (1), 23-9.
196.

Victor, K. G.; Levac, L.; Timmins, M.; Veale, J., Method Development for Container

Closure Integrity Evaluation via Headspace Gas Ingress by Using Frequency Modulation
Spectroscopy. PDA J Pharm Sci Technol 2017, 71 (6), 429-453.
197.

Nieto, A.; Roehl, H.; Brown, H.; Nikoloff, J.; Adler, M.; Mahler, H. C., Evaluation of

Container Closure System Integrity for Frozen Storage Drug Products. PDA J Pharm Sci Technol
2016, 70 (2), 120-33.
198.

Hao, J.; Wang, F.; Wang, X.; Zhang, D.; Bi, Y.; Gao, Y.; Zhao, X.; Zhang, Q.,

Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by
coacervation method using central composite design. Eur J Pharm Sci 2012, 47 (2), 497-505.

179

VITA
Pranjal Sameer Taskar
Education

Ph.D., Pharmaceutics and Drug Delivery

Joined August 2014

University of Mississippi, University

Bachelor of Pharmacy

April 2013

Institute of Chemical Technology, Mumbai, India

Work Experience

Plough Center for Sterile Drug Delivery Solutions, UTHSC
Research Scientist
BioMarin Pharmaceutical Inc.

May 2017-December 2017

Intern-Formulations Associate
Unilever Ltd.

May 2012-July 2012

Intern

180

Certifications

•

Hands-on course in tablet technology, University of
Mississippi, March 2015

•

Comprehensive Pharmaceutical Aseptic Course, University
of Tennessee Health Science Center, August 2018

•

Aseptic manufacturing technique BSL 2, BioMarin
Pharmaceutical Inc. May 2017

•

Assistant Laboratory Animal Technician (ALAT) 19: Rats
(2009), ALAT 23: Rabbits (2009) & Laboratory Animal
Allergy on AALAS learning library

Publications

•

Taskar P, Tatke A, Majumdar S. Advances in the use of
prodrugs for drug delivery to the eye. Expert Opin Drug
Deliv. 2016;14(1):49-63.

•

Adelli GR, Bhagav P, Taskar P, Hingorani T, Pettaway S,
Gul W, ElSohly MA, Repka MA, Majumdar S. Development
of a Delta9-Tetrahydrocannabinol Amino AcidDicarboxylate Prodrug With Improved Ocular
Bioavailability. Invest Ophthalmol Vis Sci.
2017;58(4):2167-79.

•

Patil A, Lakhani P, Taskar P, Majumdar S. “Formulation
Development, Optimization, and In vitro – In vivo
Characterization of Natamycin Loaded PEGylated Nano-

181

lipid Carriers for Ocular Applications” April 2018, Journal
of Pharmaceutical Sciences 10.1016/j.xphs.2018.04.014
•

Lakhani P, Patil A, Taskar P, Majumdar S. “Curcuminloaded Nanostructured Lipid Carriers for Ocular Drug
Delivery: Design Optimization and Characterization” Journal
of Drug Delivery Science and Technology, Volume 47,
2018, Pages 159-166, ISSN 1773-2247

Achievements

•

Inducted in Rho Chi Pharmacy’s Academic Honor Society

•

Associate editor, Journal of Advanced Drug Delivery
Research, MedCrave publications

•

Multiple publications in international peer-reviewed journals

•

Over 10 posters in national and international conferences, 3
intra-school podium presentations/ talks

•

Participated in three-minute thesis competitions

182

